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ABSTRACT 
 
This dissertation focuses on the design of novel strategies for the prevention and 
treatment of neglected tropical and infectious diseases using polyanhydride nanoparticles 
as a drug delivery platform. The overall goal of this research is to design efficacious drug 
delivery vehicles that are effective against the filarial nematode Brugia malayi and B. pa-
hangi and intracellular bacteria Mycobacterium tuberculosis, M. paratuberculosis, and 
M. marinum. The primary goal is to use the polyanhydride nanoparticles to deliver high 
enough microenvironmental concentrations to cause the death of the organism, thereby 
reducing the mortality, morbidity, and transmission of the disease. While a wide array of 
vaccine delivery vehicles have been investigated the majority of the research has focused 
on the use of polyesters and polyanhydride. This research presented shows the benefits of 
biodegradable polyanhydride as an effective drug delivery platform using the polymers 
and copolymers of various chemistries.   
We demonstrate the use of a polyanhydride nanoparticle-based platform for the 
co-delivery of the antibiotic doxycycline with multiple antiparasitic drugs, (ivermectin, 
diethylcarbamazine, and albendazole) to reduce microfilariae burden and to rapidly kill 
adult worms. By encapsulating two of these drugs, ivermectin, and doxycycline, into bio-
degradable polyanhydride nanoparticles, we report the ability to effectively kill adult B. 
malayi and B. pahangi worms with up to a 4,000-fold reduction in the amount of drug 
used. Additionally, we significantly reduced the average time to death of the macrofilaria 
(five-fold) when the anti-filarial drug cocktail was delivered within polyanhydride nano-
particles.  
xiii 
 
Knowledge gained from filarial studies was then applied to kill the intracellular 
bacteria Mycobacterium, we sought to examine the effectiveness of the first line an-
tituberculous rifampicin, isoniazid, pyrazinamide, and ethambutol, encapsulated into vari-
ous polymer and copolymer combinations in vitro. Initial experiments focused on particle 
internalization, co-localization, and reduced macrophage bacterial population. Subse-
quently, gained knowledge from the in vitro effectiveness was then applied to systemic 
acute M. tuberculosis in vivo infection focusing on multi-drug resistance and extensively 
drug-resistant strains. We observed through short course chemotherapy utilizing the na-
noparticle-based drug delivery platform 20:80 CPTEG:CPH, we were able to reduce the 
prevalence of a persister bacterial population significantly. In summary, the studies de-
scribed herein support the rational design and use of a polyanhydride nanoparticle drug 
delivery platform to reduce both the course of treatment and the amount of drug needed 
to treat neglected infectious disease effectively.  
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CHAPTER 1 . INTRODUCTION 
 
From the first discovery of penicillin in 1928 to the first successful therapeutic 
use in 1941, antibiotics have had a profound impact on survival and reducing the overall 
microbial burden on humans and animals. Despite their success, overuse and misinfor-
mation have led to the development of antimicrobial resistance. Our early understanding 
of the interactions of antibiotics with microorganisms and how they effectively overcome 
our most potent chemotherapy was, in fact, rudimentary at best.  Because of our 
overconfidence in the abilities of these chemotherapies, without understanding the patho-
genesis and specific virulence mechanism of these microorganisms, we are faced with 
substantial infectious disease challenges. 
This dissertation is presented in two major sections: The first is actionable 
research that focuses on overcoming the challenges associated with neglected tropical 
diseases such as Lymphatic Filariasis. The research will focus on strategies for the 
development of a biodegradable polyanhydride nanoparticle-based platform for the co-
delivery of small molecules, to reduce the microfilariae burden and rapidly kill adult 
worms. The second section will focus on the development of a polyanhydride 
nanoparticle platform for the delivery of a four-drug cocktail against multi-drug resistant 
Mycobacterium species through reducing the bacterial burden in vivo. 
Antimicrobial therapies directed against M. tuberculosis must overcome numer-
ous difficulties to be successful at reducing morbidity and mortality of the infection. The 
difficulties challenging M. tuberculosis infections results from the layered seclusion of 
the organism within 1) a walled structure (granuloma) within the lungs 2) within the 
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intracellular microenvironment of monocytes and macrophages 3) a thick hydrophobic 
mycolic acid protective outer layer which reduces permeability to antibiotics. Within the 
monocyte and macrophage host cells, the bacteria are not destroyed and establish an in-
tracellular niche that further impedes antibiotic delivery. The studies presented will out-
line a methodical experimental approach that addresses these challenges in the treatment 
of mycobacteria.  We will review and address the challenges the current chemotherapies 
possess, with a strategic approach in developing a novel antimicrobial drug delivery plat-
form utilizing polyanhydride nanoparticle to address the presences of multi-drug resistant 
M. tuberculosis. It is anticipated that these studies will help guide the next decade of anti-
microbial research and development. 
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CHAPTER 2 . LITERATURE REVIEW 
 
Drug delivery systems 
 
Over the last ten years, new and innovative technologies have spurred the devel-
opment of biodegradable nanoparticles for use as a drug delivery platform. There are cur-
rently four classifications of delivery systems [1]. These new and FDA approved plat-
forms includes various particle technologies and vary in size from 10-1000 nm.  As a 
technology, nanoparticles are capable of delivering a variety of payloads by implement-
ing heterogeneity in materials and methods [2]. The payloads can be both hydrophilic and 
hydrophobic, and the specific application is primary in the development. Examples of 
payloads include small molecules, proteins, peptides, and nucleic acids. Because of the 
volatile nature of these payloads, the particle system must provide increased encapsula-
tion efficiency, controlled release mechanisms, tissue-specific active targeting and im-
provement of therapeutic indexes. There is a need to develop better characterization tech-
niques for quality control, consistency in synthesis, reduction in development and manu-
facturing costs to facilitate the successful translation of theoretic applications of nano-
technologies into approved clinical therapies. A critical benefit of nanoparticle-based 
therapies is their ability to be internalized through phagocytosis, which presents a particu-
lar advantage in situations where standard internalization mechanisims would be chal-
lenging for a given molecule [3]. 
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Solid Lipid Nanoparticles and Microparticles 
 
Lipid nanoparticles are a new generation of colloidal drug carrier systems that are 
solid at basal and room temperature. Solid lipid nanoparticles are comprised of up to 
2.5% of physiological lipids and have not shown toxicity issues to date. They typically 
contain a hydrophobic core with a phospholipid coating which provides increased drug 
loading and the ability to encapsulate bioactive and hydrophilic compounds [4]. These 
nanoparticles, in general, possess adequate stability for periods of more than a year and 
are highly stable. However, due to the homogenization processes which requires excess 
heat and excessive handling, degradation occurs on the active components during the en-
capsulation process [5]. The administration is primarily through the dermal route alt-
hough, intravenous injection has been attempted consistency in particle size is a chal-
lenge [3]. 
Emulsion-based delivery systems 
 
Emulsion-based delivery systems are becoming increasingly prevalent in encapsu-
lating lipophilic components. The emulsion delivery system comes in three different 
forms and is composed of an oil and water phase[6].  Homogination of the aqueous phase 
with the oil phase solubilizes the lipophilic component and requires thermodynamic sta-
bilization through combinations of surfactant [7, 8], resulting emulsions of micro >100 
nm or nano <100 nm. Emulsions systems protect enzymatic hydrolysis [9] and stabilize 
the bioavailability of the lyophilic components [10]. As a drug delivery system, they 
enhance the therapeutic efficacy of the drug, minimize the adverse effect and toxic reac-
tions, a larger surface area providing greater absorption and can be formulated into 
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foams, creams, liquids, and sprays[11]. Use of the emulsion systems allows for a variety 
of administration applications and it is one of a most 
promising delivery system for poorly soluble drugs 
[12].  
Polymeric nanoparticles 
 
Polyesters 
 
Individual Polyester, or in combination with 
other polymers are the most investigated biodegradable 
polymer and have been widely adapted for the use as 
drug carrier NPs. Poly (lactic acid) (PLA) and poly(lactic-co-glycolic acids) are the most 
versatile of the polyesters with an array of different 
MWs, compositions and variable degradation rate [13].  
Polyesters are among the most popular choices due to 
their high biocompatibility and biodegrade property despite generation of acidic by-prod-
ucts which directly interferes with encapsulation stability.  PLGA polymer formulations 
are compatible with injectable delivery of peptides, therapeutic proteins, hormones, and 
antibiotics.[14] 
Polyanhydride 
Polyanhydride nanoparticles have been studied extensively as carriers for drugs and 
vaccines for over 30 years [15-19]. These NPs are FDA approved, as evidenced by the 
Glidal polyanhydride wafer consisting of 1,3-bis(p-carboxyphenoxy)propane (CPP) and 
sebacic acid (SA) [20]. These biodegradable materials degrade into dicarboxylic acids 
upon scission of the anhydride bond, rendering them highly biocompatible. These materials 
Poly(CPTEG) 
Poly(CPH) 
Figure 2-1 Structures of 
poly(CPH) and poly(CPTEG). 
Also shown is a scanning photo-
micrograph of drug-loaded 
CPTEG:CPH NPs. Scale: 1 µm. 
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are hydrophobic, and this confers a surface erosion mechanism to devices made of polyan-
hydrides [21, 22]. The advantage of such a surface erosion mechanism is that payloads can 
be released in a sustained and predictable manner, providing a so-called zero order release 
profile, in which the release rate of the payload is constant. Such release profiles enable 
single-dose therapies, maximize the time over which the in vivo drug concentration is 
maintained within the therapeutic window, and enhance patient compliance. 
Infectious diseases targeted for nanotherapeutic development 
 
Lymphatic filariasis 
 
Filarial parasites belonging to the family Onchocercidae remain a significant 
global burden, endemic in over 80 countries worldwide, particularly India and sub-Sa-
haran Africa [23]. Currently, there are upwards of 120 million individuals at risk [23-25] 
with an average of 38.5 million people disfigured and incapacitated by the disease.  The 
primary human diseases caused by filariae are Lymphatic Filariasis (LF), River Blindness 
(RB), and Loiasis. The parasitic helminth Wuchereria bancrofti, Brugia malayi, and B. 
timori are the causative agents of Lymphatic Filariasis (LF). Of the Onchocercidae, On-
chocerca volvulus causes RB. While efforts to mitigate the effect of these diseases have 
been successful in some regions, current medications are insufficient to reach elimination 
by 2020 [26-28]. Most cases of the disease have little to no symptom presentation. Some 
individuals, however, develop a syndrome called elephantiasis, which is characterized by 
fever, lymphangitis, hydrocele, and lymphoedema, and is one of the most common causes 
of arthropod mediated disability [28, 29].   
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Table 2-1 Lymphedema Stage and Its Characteristics 
Lymphedema Stage and Its Characteristics (Dreyer et al., 2002). 
Lymphedema Stage  Characteristics  
 
Stage 1.  
 
Swelling goes away overnight 
Stage 2  Swelling does not go away overnight 
 
Stage 3  Shallow skin folds 
 
Stage 4  Knobs 
 
Stage 5  Deep skins folds 
 
Stage 6.  
 
Mossy lesions 
Stage 7  Unable to care for self or perform daily activities 
 
 
Morbidity associated with infection stems from both the persistence of the worm in the 
skin and the lymphatics that creates scarring and fluid accumulation and the larval form 
of LF microfilariae (MF) causing debilitating chronic dermatitis due to irritation of MF 
antigen [30]. 
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Lifecycle  
 
The unique parasitic life cycle begins (Figure 1) when the larval microfilariae 
(MF) are picked up during a blood meal from an infected host by the insect vector and re-
main in the thoracic muscles of the mosquitoes. The principal mosquito vectors include 
Mansonia, Anopheles, and Aedes mosquitoes. The microfilariae (L1) undergoes two lar-
val molting’s stages L2, and the infective L3 stage, this takes around 10-14 days [31]. 
When the infected mosquito feeds on another human host, the infective larvae (L3) are 
deposited within host tissue at the bite site and migrate to the lymphatics. 
 
Figure 2-2 Schematic representation of the life cycle of lymphatic filariasis, showing parasite de-
velopment in the human host and vector. 
 
One of the unique characteristics of the L3 stage is its ability to modulate and sup-
press the host immune response via secretion of proteins and microRNAs [32, 33]. These 
proteins and microRNAs allow for the initial suppression of the innate immune response 
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which gives the opportunity for the L3 stage to mature into the adult worms (macrofi-
laria). The host’s immune response to the microfilariae involves many different cell pop-
ulations, which include granulocytes such as eosinophils, mast cells and polymorphonu-
clear leukocytes (PMNs), as well as monocytes. These immune cell populations can rec-
ognize, trap and kill the blood circulation microfilaria (L1)  stage in the human filarial 
parasitic nematode Brugia malayi [34, 35].  For the majority of the day, microfilariae se-
quester within the lungs of the host and only appear in the peripheral blood circulation for 
a few hours each night, which coincides with maximal mosquito feeding [36].  
Endosymbiotic bacteria 
 
Resident within W. bancrofti and B. malayi parasites at all stages of life are the 
endosymbiotic bacteria, Wolbachia. These obligate intracellular bacteria are members of 
the Rickettsialaes order of α-proteobacteria [37] that also contain the mammalian patho-
gens in the genera Rickettsia, Brucella, Bartonella, Ehrlichia and Anaplasma [38]. Typi-
cally, Wolbachia is present within hypodermal cells of the lateral cords of both sexes. 
However, vertical transmission of the bacteria to MF is facilitated by the presence of 
bacteria in the ovaries, oocytes, and embryos during development in females [39]. 
Wolbachia, are a vital component of larval development and adult-worm fertility and via-
bility.   
Host response 
 
A single female macrofilaria can produce over a billion MF during this time [40, 
41]. The host’s immune response to the microfilariae involves many different cell popu-
lations, which include granulocytes such as eosinophils, mast cells and polymorphonu-
10 
 
clear leukocytes (PMNs), as well as monocytes. These immune cell populations can rec-
ognize, trap and kill the blood circulation microfilaria (L1)  stage in the human filarial 
parasitic nematode Brugia malayi [34, 35].  For the majority of the day, microfilariae se-
quester within the lungs of the host and only appear in the peripheral blood circulation for 
a few hours each night, which coincides with maximal mosquito feeding [36].  
Treatment 
 
No vaccine is currently available; filariases are controlled through chemotherapy, 
although vector control and bed-nets are important. Current treatment protocols primarily 
focused on interrupting the spread of LF by targeting the microfilariae larvae with combi-
nations of anti-helminthic medications. The drugs most frequently used to manage LF 
include albendazole (ABZ), a benzimidazole derivative; diethylcarbamazine (DEC), a 
derivative of piperazine; which is involved in modulation of the host immune response to 
be effective [42] and Ivermectin (IVM), which is believed to be a broad-spectrum 
antiparasitic agent [43-47]. Ivermectin has been shown in animal parasites to modulate 
the activity of PMNs as well as monocytes [35, 48].  
 
Table 2-2 Recommended dosage of Antifilarial 
Recommended doses of antifilarial for adults. 
 
Drug  Daily administration Administration 
Standard dose  
(mg/kg)  
Maximal dose 
(mg)  
Standard dose  
(mg/kg)  
Total maximal doses 
Ivermectin 
(IVM)  
200  150-200mg/kg 1-2 
11 
 
 
Table 2-2 continued 
Diethylcarbam-
azin (DEC) 
100 6 mg/kg 12 
Albendazole 
(ABZ) 
400 400 mg 1 
Doxycycline 
(DOX) 
600 100-200 mg/kg 
for 42 - 
42 
 
These drug combinations are used primarily for long-term, community-directed 
treatments aimed at interrupting transmission. Some of the possible side effects of these 
drugs include fever, itching, oedema, arthritis, and lymphadenopathy [49]. These side 
effects are primarily due to the extensive paralysis and killing of the microfilariae. These 
medications have minimal activity against the causative organism, adult Wuchereria 
bancrofti, Brugia malayi and B. timori worms, and have thus far, failed to deliver a radi-
cal curative treatment. This failure is due to the unique composition of the outer cuticle 
and the specificity of infected tissue limits, and the permeability of these compounds   
Research has highlighted the use of the above drugs with macrofilaricidal activity 
as a single therapy or combinations could improve the probability of a curative treatment. 
This approach has reduced the reoccurrence in some countries by 46% over the last 13 
years [25, 50]. These antimicrobials have been shown to reduce the number of resident 
Wolbachia, although the exact symbiotic role within the nematode is not directly known. 
Research has shown that the use of DOX can cause long-term sterilization and death of 
adult female worms in 6 to 12 months with a 3-6 week treatment course [51-54]. 
However, limitations associated with the use of the above drugs is four-fold: specific 
restrictions on patient age and health status due to cytotoxicity; the inability to reach 
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broad tissues where the adult filarial nematodes reside; as well as counter-indications in 
areas endemic for the Loa loa parasite; and poor patient compliance. 
  An alternative antibiotic which has been tested and has shown effectiveness 
against Rickettsiae is rifampicin, which is better tolerated in children and pregnant 
patients and has been shown to be effective against Wolbachia in Onchocerca parasites in 
vitro [55]. However, rifampicin is less effective than doxycycline in vivo [56, 57]. Addi-
tional therapeutic options for doxycycline could be useful when combined with current 
antiparasitic drugs; however, combination therapies present difficulties for drugs that 
have different systemic half-lives, similar toxicity profiles, low aqueous solubility and re-
duced shelf life properties. These equilibrium solubility issues can be exasperated by the 
differing comprehensive drug administration programs that already suffer from poor pa-
tient compliance, and multi-year therapy regimes [58]. 
Ivermectin 
 
Ivermectin, is a broadly used macrocyclic lactone endectocid used in veterinary 
medicine for the treatment or prevention of nematode infections. In humans, IVM is one 
of the three mainstay drugs in the LF global elimination program [59].  IVM is primarily 
a microfilaricidal, due to the fast MF clearance that is observed. The killing effectiveness 
against the adults is moderate and requires repeated treatment cycles over several years. 
Despite the effectiveness, the exact mode of action remains elusive. We do understand 
that ivermectin binds to the nematodes glutamate-gated chloride channels (GluCls),  in-
terrupting the neurotransmission processes that regulates [60] pharyngeal muscle move-
ments [61, 62]. This interruption leads to the channeling irreversibility opening; leading 
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to hyperpolarization and depolarization of the neuron [63, 64]. Leading to muscular pa-
ralysis and inhibition of pharyngeal pumping, which do not directly kill the worm [65]. 
Doxycycline 
 
Doxycycline (α-6-deoxy-5-oxytetracycline), is a broad spectrum semi-synthetic 
isomer antibacterial derived from tetracycline [66]. The primary mode of action is to 
inhibit protein synthesis by binding to the 30S or 50S ribosomal RNA subunits thereby 
preventing access of aminoacyl tRNA to the acceptor site on the mRNA-ribosome com-
plex. Because inhibition of the tRNA requires active transport through adenosine triphos-
phate (ATP) the doxycycline effectively penetrates the cytoplasmic membrane[67]. Re-
search done by [68, 69] showed a < 80% effectiveness against long-term sterilizing activ-
ities of adult worms render it as a “disease-curing “. This disease curie is believed to be a 
direct result of doxycycline inducing growth retardation, embryostasis, and inhibition of 
MF shedding [70, 71].  
Albendazole 
 
 Albendazole, is a heterocyclic aromatic organic compound derived from benzim-
idazole. Albendazole selectively binds to the nematodes β-tubulin and inhibits the micro-
tubule polymerization in a two-step process [61, 72, 73] resulting in the destruction of 
cell structure and death of the worm [74]. 
Diethlycarbamazine 
 
Diethlycarbamazine, is a piperazine derivative, which has been shown to kill at all 
stages of the parasite life-cycle [75]. Like ivermectin the exact mechanism by which kill-
ing occurs remains to be elucidated, DEC is thought to sensitize them to phagocytosis 
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through targeting of the arachadonic acid, 5-lipoxygenase, and cyclooxygenase-1 path-
ways. Studies have suggested that DEC indirect, host-mediated mode of action along 
with anti-inflammatory effects during treatments [76, 77]. Such studies suggested that use 
of DEC inhibits inducible nitric oxide synthase (iNOS), nuclear transcription factor kappa 
B (NF-kB) activation, a regulator of the proinflammatory genes such as TNF-α, and  IL-1 
[78].  In addition DEC has also been shown too inferred with the host arachidonic acid 
and nitric oxide metabolic pathways [78, 79]. 
 Mycobacterium  
 
Mycobacterium marinum 
 
Mycobacterium marinum is a “slow-growing” nontuberculosis mycobacterium 
(NTM) that is most commonly a waterborne pathogen responsible for tuberculosis-like 
infections in ectotherms and is an occasional opportunistic human pathogen. Marinum is 
the closest genetic relative of the M. tuberculosis complex and as such is the most reliable 
in testing for drug susceptibility. Nontuberculous mycobacteria are responsible for a mul-
tiplicity of different types of infections, including respiratory, cutaneous, and systemic 
[80], of which many of the species of NTM are multidrug-resistant [81], including M. 
marinum. M. marinum is an atypical bacilli’s that are reported to be resistant to the anti-
tuberculosis medications isoniazid, pyrazinamide, and para-aminosalicylic acid and 
shows intermediate sensitivity to streptomycin [82, 83].  Unlike M. tuberculosis slow 
growth rate of 3-6 weeks, M. marinum grows within 1-2 weeks. This faster growth rate 
allows for a model that can be correlated to effective drug susceptibility in vitro. 
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Mycobacterium avium subspecies paratuberculosis  
 
Mycobacterium avium subspecies paratuberculosis (MAP) is the causative agent 
of chronic granulomatous enteritis in ruminants called Johne's disease (JD) [84] as well 
as suspected in the human inflammatory bowel diseases Crohn’s (CD) and Ulcerative Co-
litis (UC) [85-89]. MAP is a nontuberculosis mycobacterium, of the Mycobacterium 
avium complex (MAC) most often associated with the small intestinal lamina propria of 
ruminants that is eventually fatal in many cases [90, 91]. The infection in ruminants is 
most commonly transmitted through the fecal-oral route due to contaminated closed con-
finement, pasture, soil, and water, as well as vertical intrauterine transfer [92]. The effects 
of JD on the U .S. dairy industry accounts for upwards of $220 million per year, with 2 
out of every three farms being seropositive [93]. Like most mycobacterium infection 
symptomology does not occur until many months after initial expose and treatment in ru-
minates is not suggested. 
Source of human contamination is believed to be a direct result of bacterial shed-
ding into drinking water, milk and in even meat [94-96]. A significant characteristic 
found in Mycobacterium spp. is the lipid-rich cell wall which in MAP is believed to 
provide needed protection during pasteurization [97].The occurrences of  MAP being 
found in individual testing positive for CD has been shown to exceed 59% [88, 89] but 
testing is limited and can be unreliable [94]. Individuals testing seropositive for the MAP 
may undergo extensive extended drug therapy (<5 weeks) [98] using the standard 
antituberculous rifampicin, isoniazid, ethambutol, and pyrazinamide [99] as well as 
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clythromycin [100].  Treatment of infected individuals caused by MAC remains a chal-
lenge since these organisms are resistant to the majority of antituberculous drugs [99, 
101].  
Mycobacterium tuberculosis 
 
The world health organization (WHO) has reported that in 2016, 6.3 million new 
cases of M. tuberculosis were reported and nearly 1.3 million individuals died as a result 
[28]. M. tuberculosis is the ninth leading cause of death worldwide and the leading cause 
of death from a single infectious agent [28, 102]. Mycobacterium tuberculosis (MTB) is a 
non-spore forming, acid fast, non-motile rod shaped bacilli which is highly resistant to 
solvents. In human medicine the most significant group of mycobacteria are the members 
of the Mycobacterium tuberculosis complex (consisting of M. tuberculosis, M. bovis, M. 
africanum, M. microti, M. pinipendi and M. canettii. Human MTB is a highly contagious 
infectious disease predominantly caused by M. tuberculosis. It is a weak Gram-positive 
rod-shaped bacterium that has no flagellum, does not form spores nor produces toxins 
and has no capsule. Mycobacterium’s size varies from 1 to 4 μm in length, respectively. It 
has been found to affect nearly all organs within the human body, but the lung is of 
particular high incidence. It is a intracellular pathogen that establishes its infection prefer-
entially to macrophages of the respiratory system where it can be contained and enters 
into a dormancy state [103, 104]. 
 The primary means of transmission occurs by infective particles (Figure 1-3) of 
as little as 1 to 10 bacilli are required for infection. Inhaled bacilli are phagocytised by 
primary alveolar macrophages where they avoid fusion with lysosomes and posterior di-
gestion in the protective intracellular environment [105]. The first evidence of infection 
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usually occurs within six to eight weeks, followed by the development of cellular immun-
ity and subsequent lymphocyte and activated macrophage to the site of infection. Where 
the primary population of bacilli are eliminated without manifestation of symptoms.  The 
infected phagocytic macrophages and lung parenchymal cells are also killed, which pro-
duces a characteristic solid caseous necrosis consisting of macrophages and giant cells, T 
cells, B cells, and fibroblasts, and these granulomas can prevail not only in the lung, but 
in other organs as well. When host immunity predominates, the granuloma type lesion 
can be contained, resulting in residual damage to the lungs. The sustained necrotic lesion 
expands collapsing into the bronchus, where a exsentive lung lesion can be formed, result 
in systemic bacterial dissemination into the blood stream and airway. However, more 
commonly, mycobacteria can remain dormant or develop into a latent form of infection 
within the host, which establishes a bacterial reservoir [99]. Around 20% of individuals 
infected present extra-pulonary MTB, which is caused by development and evolution of 
baccili disseminating into the blood vessels.  Miliary tuberculosis is widespread 
dissemination through the blood stream, where it cn be found within lymph nodes, liver, 
spleen, bones and joints, heart, brain, genital-urinary system, meninges, peritoneum and 
skin [104]. Mycobacterium’s pathogenesis and virulence factors produces typical symp-
toms such as weakness, fever, weight loss, night sweat, chest pain, respiratory insuffi-
ciency and excessive cough, whereas advanced pathology may also cause bleeding, 
which leads to haemoptysis. Many symptoms including tissue destruction are mediated as 
a result of the host´s immune response and not directly as a result of the bacteria itself. 
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Figure 2-3 Route of infection and development of primary disease by MTB 
  
Latent tuberculosis infection is defined as an infection with M. tuberculosis in 
combination with a positive tuberculin skin test or an interferon- γ (INF- γ) release assay 
results concurrently without indication of active TB symptoms, progressive radiographic 
changes or microbiological evidence of replicating organisms [106, 107]. The terms dor-
mancy, persistence and latency have been used interchangeably generally to refer to the 
non-replicating state of mycobacteria, tolerance to antituberculotics or an infection with-
out active disease. Dormancy is a physiological state of arrested growth, persistence con-
sists in the phenotypic transient tolerance to the antibacterial effects of drugs [108-110]. 
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Latent tuberculosis is recognized as a result of the interaction of the host’s immunity with 
M. tuberculosis infection, forcing it into a dormant state in the infected alveolar tissue. 
Bacteria do not undergo any metabolic process in response to the host immune response. 
During this dormancy period latent TB is in a state of non-infectious disease and, there-
fore, does not represent a public health threat. The bacterial intracellular survival depends 
on the phagosome acidification in infected macrophages thus preventing the phagosome-
lysosome fusion.  
Drug resistance 
 
The prevalence of resistance within individuals infected with MTB currently ex-
ceed 10% of the newly reported cases were found to be resistance to the first line drugs, 
rifampicin and an additional 5% of these cases reported multi-drug resistance (MDR-TB) 
strains. These strains are reported to be resistant to at least rifampicin (RIF) and isoniazid 
(INH) [111-113]. Individuals that succumb to this disease could be prevented with appro-
priate treatment and diagnosis. The clinical features of tuberculosis (TB) infection in-
clude multistage processes of primary infection, latency, and reactivation. Years of ef-
forts have been made to reduce the adverse treatment and develop an understanding of 
the pathogenesis of the organism [114-116] 
Frequent failures of the treatment of tuberculosis (TB) are due to the insufficient 
dosing, incomplete treatment regimens caused by poor patient compliance, and latency 
profile of the bacilli [117, 118]. Initial treatment requires a two-step process; the first 
involves an “intensive phase” of a four-drug high dose cocktail containing the antibiotics 
rifampicin (RIF), isoniazid (INH), pyrazinamide (PZA) and ethambutol (EMB). The 
“intensive phase” can only last for to two-month due to high toxicity issues with the 
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antibiotic therapy. Immediately following the “intensive phase” a longer “continuation 
phase” occurs with RIF and INH for up to two years [28, 119, 120]. This secondary treat-
ment is necessary to eradicate the remaining Mycobacterium that has entered a dormant 
or latent phase. The need for such lengthy treatment reflects the unique nature of the 
latent population of mycobacterium that remains in a non-replicating persistent state 
within caseous lung granulomas [121]. These “persister” bacilli are genetically drug-
susceptible but exhibit a phenotypic tolerance to currently available first-line drugs [122, 
123].  
Table 2-3 The classification of the drugs used for the treatment of drug-resistant tubercu-
losis 
The classification of the drugs used for the treatment of drug-resistant tuberculosis.  
The groups of drugs used for the treatment of drug-resistant tuberculosis 
Group/drug  Recommendation/drug  
First-line oral antituberculosis agents  (use all possible drugs)  
isoniazid  Ethambutol 
rifampicin  pyrazinamide  
rifabutin  
Injectable agents  (use one because of similar targets)  
capreomycin  streptomycin  
kanamycin  (viomycin)  
amikacin  (enviomycin)  
Fluoroquinolones  (use one because of the same target)  
ofloxacin  moxifloxacin  
levofloxacin  (gatifloxacin)  
Second-line oral antituberculosis agents  (use all possible drugs if necessary)  
ethionamide  cycloserine  
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Table 2-3 continued  
prothionamide  terizidone 
p-aminosalicylic acid  
Antibiotics with an unclear role in the 
treatment of MDR-TB  
(use all necessary drugs to complete four-
combination of antituberculotics)  
clofazimine  clarithromycin 
amoxicillin/clavulanate  high-dosed isoniazid  
linezolid  thioacetazone  
imipenem/cilastatin  
 
Although the incidence and mortality rates of TB have significantly declined over the 
last ten years, the current advances in TB control remain hindered by the increase in re-
ports of drug-resistance [123, 124]. Multidrug-resistant TB (MDR-TB), is defined as re-
sistant to at least two antibiotics such as rifampicin and isoniazid [112, 113]. Extensively 
drug-resistant TB (XDR-TB) is a phenotypically adapted MDR which shows resistant to 
isoniazid and rifampin, plus fluoroquinolones and at least one of the injectable second-
line drugs [111, 125]. Furthermore, cases of totally drug-resistant tuberculosis (TDR-TB) 
have originated in Asia, Africa, India and Europe. In TDR-TB, the Mycobacterium is re-
sistant to all available drug chemotherapy’s [102].  
There are two types of mycobacterial resistance; acquired resistance (i.e., environ-
mental) or by infection with a drug-resistant strain (i.e., primary resistance) [126]. 
Resistance is defined as an infection of a naïve patient with an already resistant tubercu-
losis strain 
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 Primary resistance is defined as an infection of a naive (i.e. previously untreated) 
patient with an already resistant tuberculosis strain, 
 Acquired resistance develops in patients originally infected with a drug-suscepti-
ble strain that during the treatment becomes resistant to multiple medications. 
Therapeutic failures are primarily due to inadequate, inappropriate or irregular 
treatment, non-adherence to treatment protocols and prescribed therapy or non-
compliance 
These intrinsic resistance mechanisms of MTB are thought to be the crucial link 
between a therapeutic cure and persistent infection [119, 127]. Because virtually all clas-
ses of antibiotics require metabolically active bacteria for their primary mode of action, 
the non-replicating state of MTB within the host is thought to render MTB resistant to 
otherwise bactericidal antibiotics. This unique nature of the disease, specificity of loca-
tion, and development of closed granulomas that contain persister bacilli [128, 129] in-
creases the need for an antimicrobial treatment that provides continuous intracellular drug 
concentrations within the phagocyte and granuloma to be effective.  
Intrinsic resistance mechanisms 
 
The cellular wall of mycobacteria is an effective barrier against penetration of an-
tibiotics. The cellular wall is extremely lipid-rich, multi-layered and has varied hydropho-
bicity. The two hydrophilic layers of Mycobacterium’s cellular wall consist of the arabi-
nogalactan and peptidoglycan layer which both are essential in the selection and transport 
of hydrophobic molecules [130, 131]. Also, the waxy outer mycolic acid layer is 
covalently linked to the peptidoglycan and arabinogalactan layers. Together these form, 
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long chain fatty acids barrier which act as a impenetrable, non-fluidic barrier restricting 
the active and passive diffusion of  hydrophobic and hydrophilic molecules [132, 133]  
Extrinsic antibiotic resistance  
 
Pathogenic bacteria acquire drug resistance through horizontal gene transfer 
through plasmids and transposons. However, in M. tuberculosis drug resistance is caused 
primarily by spontaneous single nucleotide polymorphism mutations in chromosomal 
genes producing a select strain during a suboptimal chemotherapeutic treatment [134, 
135]. To date, no single pleiotropic mutation [136] has been found in Multi-drug (MDR-
TB) or Extensively drug-resistant (XDR-TB) M. tuberculosis.  
M. tuberculosis mutations in the gyrA and gyrB genes are [134] phenotypically 
resistant but genotypically sensitive to chemotherapy [137]. This sensitivity induces 
spontaneous mutations within the rpoB, rrs, tlyA, katG, and embB genes and eis, inhA 
promoter region [134, 135, 138, 139] occurs at a rate of 10,218 mutations per cell divi-
sion [140] in the presence of a single antibiotic. Like most organisms, the fitness cost as-
sociated with that of resistance is very high, but we do not observe that phenomena in 
Mycobacterium [141, 142]. This high rate of genetic mutations and low fitness cost are 
the primary reason that a multi-drug therapy is recommended in treating tuberculosis.  
 
Internalization  
 
Many intracellular pathogens gain initial entry through the host mucosal surfaces, 
especially those of the respiratory tracts. Transmission can be primarily a result of 
person-to-person contact and or aerosolization of droplets containing bacteria [143], 
through broken skin in an aquatic environment [83] or contaminated food products [88, 
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89, 144].  Mycobacterium uses both complement and non-complement receptors to in-
crease uptake by phagocytic cells [145, 146], where it can persist by inhibiting 
phagosome-lysosome maturation [147-149]. The cellular wall of Mycobacterium consists 
of highly lipid-rich components also perform an active role in the inhibition of endosomal 
maturation, and acidification of the phagolysosome. 
Environmental niche and host response 
 
Phagocytosis of M. tuberculosis by phagocytic-macrophages undergoes a series of 
membrane invagination, and fusion events, resulting in the formation of the phagosome. 
Internalization can occur through direct surface interaction or through surface attachment 
through acquisition of serum opsonions to the bacterial surface. The specific route by 
which phagocytic entry occurs has a large impact on the survivability of M. tuberculosis 
once internalization occurs. The two primary routes of internalization are zipper phagocy-
tosis [150] and tripper phagocytosis[151]. The routes by which macrophages are activate 
occur at varying degrees based on the specific receptor, such as mannose, scavenger, Fcγ 
receptors and complement. Opsonized M. tuberculosis has been shown to activate the al-
ternative pathway of complement, resulting in opsonization with C3b molecule [152].  
Complement mediated 
 
Unlike other intracellular bacteria, mycobacteria, actively recruited complement 
molecules such as, C2a to form a C3 convertase and generate C3b, as well as the den-
dritic cell-specific intercellular adhesion molecule “(ICAM)-3-grabbing nonintegrin (DC-
SIGN)” [153, 154]. It has been suggested that internalization via the CR3 receptors pre-
vents the activation of the macrophages [155]. CR3 mediated internalization requires the 
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presence of host plasma membrane cholesterol [156]  Mycobacterium sequester the cho-
lesterol to prevent the rearrangement of the membrane-cytoskeleton network to prevent 
fusion of the bacteria-containing vesicle with lysosomes [156, 157]. 
The active recruitment and sequestering of the host cytoskeleton-associated mole-
cule coronin 1(P57) [158, 159] by mycobacteria provides another means by which inhibi-
tion of acidification of the lysosome occurs. This molecule links the cytoskeleton with the 
plasma membrane in leukocytes, and is equally distributed throughout non-infected mac-
rophage. In macrophages infected with live bacilli, the mycobacteria phagolysosomes 
have been found to contain high levels of coronin 1 in contrast to dead bacteria found ex-
clusively in lysosomes [160].  
Interferon (IFN)-inducible GTPases proteins are involved in the regulation of the 
phagolysosome maturation by mycobacterium is IRGM1 (formerly called LRG-47) 
[161].  This small GTPase protein provides pathogen specific protection [162] against in-
tracellular infections. They primary function is in cell-autonomous resistance[163], there 
exact mechanism is dependent on the specific structure or organelles that the proteins in-
teraction occurred [161, 163]. IRGM1 promotes the maturation and acidification of my-
cobacteria phagolysosomes [164] and regulation of cellular autophagy  [165]. Autophagy 
can eliminate intracellular Mycobacterium in a process akin to the sequestration and deg-
radation of large particles and dysfunctional intracellular organelles [166]. If M. tubercu-
losis phagosome is not appropriately acidified the cell will resort to autophagy in an at-
tempt to induce an effective host response against mycobacteria [167]. 
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Receptor mediated cellular components 
 
Mannosylated lipoarabinomannan, lipoarabinomannan, trehalose dimycolate, and 
acyltrehalose containing glycolipids have all been shown to interact with several different 
receptors of the immune system [168-170]. Lipoarabinomannan has been associated with 
Toll-like receptor signaling, Mannosylated lipoarabinomannan C-type lectins and man-
nose receptors of macrophages [149, 168, 169]. The microbial tyrosine phosphatase PtpA 
(Rv2234) inhibits the acidification through modulation of binding of the V-ATPase with 
Mycobacterium containing vacuoles [145, 168, 171-173].  
Granuloma formation 
 
During the early stage of infection, Mycobacterium replicate within macrophages 
and dendritic cells. While most bacteria prefer to remain within the protective confines of 
a macrophage Mycobacterium does not. The nature of the infectious process by which 
mycobacteria are spreads from host to host relies on the presence of live bacilli found 
within lung tissue, are vital for continual infection through aerosolization.  
Alveolar infected macrophages internalize the bacilli and transport them across the lung 
epithelium. When an infected alveolar macrophage is recognized by CD4+ lymphocytes 
activation and recruitment occurs. The activated T-cells and macrophages responds by se-
cretion of interferon-γ (INF-γ) and tumor necrosis factor-α (TNF-α) [174, 175]. This ini-
tial signaling event recruits mononuclear cells from the surrounding tissue to form the 
first start of the granuloma. As the localized chemokine gradient is upregulated the 
signaling process results in recruitment of multiple immune cell phenotypes in different 
states of activation [176]. This cellular recruitment is accompanied (Figure 1-4) by the 
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differentiation and activation of multinucleated giant cells, foamy macrophages, and epi-
thelioid cells [177].   
 
 
Figure 2-4 Granuloma comprised of aggregate immune cells [177]. 
 
The initial stages of the granuloma formation are highly vascularized, and the re-
cruitment has little effect on Mycobacterium. As Mycobacterium replicates inflammation 
develops, and loss of vascularization occurs leading to necrosis of tissue with the accu-
mulation of a caseum granuloma core[178]. It is during this stage that most mycobacteria 
are in the persistent state of which some remain intracellularly or within the caseum core 
(Figure 1-4). Eventually, the granuloma collapses and aerosolized infectious Mycobacte-
rium are expelled into the environment through coughing [179]. 
 
 
28 
 
Treatments 
 
The primary drugs used in the treatment of mycobacterial infections are unique 
between species. Because the focus of this research is on M. tuberculosis, the primary fo-
cus of antituberculous will consist of rifampicin (RIF), isoniazid (INH), pyrazinamide 
(PZA) and ethambutol (EMB). 
 Isoniazid  
 
Isoniazid, pyridine-4-carbohydrazide was introduced in 1952 under the name 
Rimifon SV (Table 1-4) [180] [181]. It was deemed a miracle a cure for “consumption,” 
but the incidence of resistance began within the first six months of use [182] [183]. INH 
requires activation by the mycobacterial enzyme KatG. These enzymes are responsible 
for the generation of reactive oxygen species that are inhibitors of lipid and nucleic acid 
biosynthetic enzymes [184, 185].  Intrinsic resistance occurs primarily from mutations 
within a katG gene which encodes for the mycobacterial catalase-peroxidase enzyme that 
is responsible for drug activation.[186].  
 
Table 2-4 Recommended dosage of first-line antituberculous drugs 
The recommended dosage of antituberculous first-line medicines. 
Recommended doses of first-line antituberculotics for adults. The mechanisms of the action 
of a range of antimycobacterial agents are briefly summarized within the context.  
Drug  Daily administration Administration three times per 
week  
Standard dose  
(mg/kg)  
Maximal dose 
(mg)  
Standard dose  
(mg/kg)  
Daily maximal dose (mg) 
Isoniazid (INH)  5 300 10 900 
29 
 
Table 2-4 continued 
Rifampicin 
(RIF)  
10 600 10 600 
Pyrazinamide 
(PZA)  
25 - 35 - 
Ethambutol 
(EMB)  
15 - 30 - 
 
Rifampicin 
 
Rifampicin, 3-(4-methyl-1-piperazinyl)-iminomethyl derivative of rifamycin SV 
(Table 1-4). It was first introduced as a TB therapy in 1972. Its effective antimicrobial ac-
tion, it is considered, together with isoniazid, to be the foundation of the “intensive 
phase”treatment regimen for TB. Rifampicin targets Mycobacterium b-subunit of RNA 
polymerase, where it binds and inhibits the elongation of messenger RNA [187]. Rifam-
picin is active against actively growing and latent bacilli [188-190].  
Pyrazinamide 
 
Pyrazinamide, pyrazine-2-carboxamide was chemically synthesized in 1936 and 
not discovered as a (Figure 1-4) treatment towards tuberculosis until 1952. In its earlier 
use, it was considered too toxic, and the required dose was reduced to overcome this. Ad-
dition of pyrazinamide to use of rifampicin and isoniazid reduced the treatment times 
from 9 to 6 months. Pyrazinamide is a prodrug which requires metabolic activation 
through conversion of its nicotinamide and its active form, pyrazinoic acid, by the en-
zyme pyrazinamidase/nicotinamidase (PZase) [191]. The inactive form, PZA enters My-
cobacterium through passive diffusion where it is converted into the active state whereby 
targeting and disrupting the bacterial membrane energetics and inhibiting membrane 
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transport. In areas of high acid conditions protonated pyrazinioc acid accumulates inside 
the cell [131].  
Ethambutol 
 
Ethambutol, 2,2′-(1,2-ethanediyldiimino)bis-1-butanol, (Figure 1-4) was intro-
duced in 1966 as an alternative to PZA. EMB’s activity against TB was not directly 
known until most recently. Together with isoniazid, rifampicin, and pyrazinamide, make 
up the first-line drugs currently use in the treatment of tuberculosis The use of the bacte-
riostatic antitubercular ethambutol (EMB), as part of the antitubercular regime was intro-
duced in 1960 as an alternative to PZA [192]. Resistance occurs as a direct result of its 
overuse and poor patient compliance [193]. EMB inhibits arabinosyl transferases, en-
coded on the embCAB operon, thereby inhibiting biosynthesis of the cellular wall mecha-
nisms of arabinogalactan and lipoarabinomannan [194].  
Vaccine 
 
Bacille Calmette-Guerin (BCG) vaccine is currently the only available vaccine 
against MTB. Many foreign-born individuals have been BCG-vaccinated and have been 
administered to over three billion people without serious complications. In countries 
where tuberculosis or leprosy are endemic a single dose is administered to children 
shortly after birth [195, 196] The vaccine has been shown to provide up to 80% protec-
tion to TB meningitis[197]. Although it displays some advantages (i.e., administration, 
conferred immunity, and low cost), recent analysis have revealed that genetic modifica-
tions have selected for a subpopulation of resistant bacteria as a direct result of the vac-
cine. Additionally, there can be a gradual loss of T-memory cell population during in the 
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course of time [198]. Regrettably, BCG vaccination has had limited impact on the global 
burden of MTB.  
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Abstract 
 
Filarial diseases represent a significant social and economic burden to over 120 
million people worldwide and are caused by endoparasites that require the presence of 
symbiotic bacteria of the genus Wolbachia for fertility and viability of the host parasite. 
Targeting Wolbachia for elimination is a therapeutic approach that shows promise in the 
treatment of onchocerciasis and lymphatic filariasis. Here we demonstrate the use of a 
biodegradable polyanhydride nanoparticle-based platform for the co-delivery of the 
antibiotic doxycycline with the antiparasitic drug, ivermectin, to reduce microfilarial 
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burden and rapidly kill adult worms. When doxycycline and ivermectin were co-
delivered within polyanhydride nanoparticles, effective killing of adult female Brugia 
malayi filarial worms was achieved with approximately 4,000-fold reduction in the 
amount of drug used. Additionally the time to death of the macrofilaria was also 
significantly reduced (five-fold) when the anti-filarial drug cocktail was delivered within 
polyanhydride nanoparticles. We hypothesize that the mechanism behind this 
dramatically enhanced killing of the macrofilaria is the ability of the polyanhydride 
nanoparticles to behave as a Trojan horse and penetrate the cuticle, bypassing excretory 
pumps of B. malayi, and effectively deliver drug directly to both the worm and 
Wolbachia at high enough microenvironmental concentrations to cause death. These 
provocative findings may have significant consequences for the reduction in the amount 
of drug and the length of treatment required for filarial infections in terms of patient 
compliance and reduced cost of treatment. 
 
 
Author Summary 
Infection with the filarial endoparasites Brugia malayi and its symbiotic bacteria 
Wolbachia represent a significant burden to both humans and animals. Current treatment 
protocols include use of multiple drugs over a course of months to years, resulting in high 
costs, undesirable side effects, and poor patient compliance. By encapsulating two of 
these drugs, ivermectin and doxycycline, into biodegradable polyanhydride nanoparticles, 
we report the ability to effectively kill adult B. malayi with up to a 4,000-fold reduction 
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in the amount of drug used. These results demonstrate a promising role for the use of 
nanoscale drug carriers to reduce both the course of treatment and the amount of drug 
needed to increase affordability of lymphatic filariasis treatment and enhance patient 
compliance. 
Introduction 
 
Filarial parasites belonging to the family Onchocercidae remain a significant 
global burden, endemic in over 80 countries worldwide, particularly India and sub-
Saharan Africa [1] , and infecting up to 120 million individuals [2]. The major human 
diseases caused by filaria are Lymphatic Filariasis (LF), River Blindness (RB), and 
Loiasis. Of the Onchocercidae, Onchocerca volvulus causes RB while LF results from the 
infections of Wuchereria bancrofti and Brugia malayi. Infection is initiated through 
arthropod transmission of larvae into the skin of a vertebrate host where they feed, 
mature into fertile adults and reproduce. Adult worms survive within these tissues for 
several years shedding thousands of microfilariae (MF) that migrate through the skin and 
lymphatics and distribute throughout the body. Morbidity associated with infection stems 
from both the persistence of the worm in the skin and the lymphatics that creates scarring 
and fluid accumulation and the MF causing debilitating chronic dermatitis due to 
irritation of MF antigen [3]. Resident within W. bancrofti and B. malayi parasites at all 
stages of life are the endosymbiotic bacteria, Wolbachia. These obligate intracellular 
bacteria are members of the Rickettsialaes order of α-proteobacteria [4] that also contain 
the mammalian pathogens in the genera Rickettsia, Brucella, Bartonella, Ehrlichia and 
Anaplasma [5]. Typically, Wolbachia are present within hypodermal cells of the lateral 
cords of both sexes, however, vertical transmission of the bacteria to MF is facilitated by 
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the presence of bacteria in the ovaries, oocytes and embryos during development in 
females [6].  
Within the last decade increasing concerns have arisen regarding the ability to 
effectively control and eradicate current infections of the filarial endoparasitic worms that 
cause onchocerciasis and LF [7]. It is estimated that 120 million people are currently 
suffering from LF and more than one billion individuals in 73 countries are at risk of 
developing LF [8]. In 2000, the WHO initiated a call to eliminate LF as a public-health 
problem by 2020 [9]. Significant steps have been taken towards this eradication effort but 
have been mainly limited to the use of mass drug administration of a microfilaricide to 
interrupt transmission and diminish morbidity. This approach has reduced the 
reoccurrence in some countries by 46% over the last 13 years [2, 9]. Drugs with the 
greatest efficacy toward LF have been limited to trials of annual, bi-annual, single-dose, 
multiple dose, and combinations of either ivermectin or diethylcarbamazine with 
albendazole [7, 10]. Recently, antimicrobial treatments such as doxycycline have been 
added to antifilarial regimens to target the symbiotic intracellular bacteria Wolbachia [11-
13]. Anti-Wolbachia drugs have been shown to reduce the pathogenicity and reproductive 
capacity of adult filarial worms [14]. The limitations associated with the use of the above 
drugs are four-fold: specific restrictions on patient age and health status due to 
cytotoxicity; the inability to reach the deep tissues where the adult filarial nematodes 
reside; counter-indications in areas endemic for the Loa loa parasite; and poor patient 
compliance [15]. These limitations have created an urgent need to seek new technologies 
that can be used to dramatically improve therapy protocols.  
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 In the parasite, Wolbachia are vertically transferred from the ovaries of the adult 
into embryos that gestate and are shed as MF into the surrounding tissue [16]. In the adult 
female, the bacteria contribute to reproduction and embryo development. Treating adult 
worms in vitro and in vivo with tetracyclines, including doxycycline, to eliminate 
Wolbachia has been shown to halt embryogenesis, reduce the amount and viability of MF 
shed [14, 17, 18] in tissues, and lead to death of the adult worm in 6 to 12 months [12, 
19]. Loss of viability in the adult worm through anti-Wolbachia therapy is precipitated by 
loss of the endosymbiont, triggering apoptosis and tissue disruption [20]. Another 
antibiotic that is effective against Rickettsiae is rifampicin, which is better tolerated in 
children and pregnant patients, is able to kill Wolbachia in Onchocerca parasites in vitro 
[21]. However, rifampicin is less effective than doxycycline in vivo [18, 22]. Additional 
therapeutic options for doxycycline are to combine it with other current antiparasitic 
drugs; however combination therapies present difficulties for drugs that have different 
half-lives, for widespread drug administration programs that suffer from poor patient 
compliance, and for long treatment regimens that require multiple years of therapy [23]. 
Amphiphilic polyanhydride nanoparticles have been studied extensively as carri-
ers for drugs and vaccines [24-28]. These biodegradable materials degrade into 
dicarboxylic acids upon scission of the anhydride bond, rendering them highly 
biocompatible. These materials are generally hydrophobic and this confers a surface 
erosion mechanism to devices made of polyanhydrides [29, 30]. The advantage of such a 
surface erosion mechanism is that payloads can be released in a sustained and predictable 
manner, providing a so-called zero order release profile, in which the release rate of the 
payload is constant. Such release profiles enable single dose therapies, maximize the time 
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over which the in vivo drug concentration is maintained within the therapeutic window, 
and enhance patient compliance. This nanoscale platform also has the capability to be a 
delivery system for combination therapies that carry payloads to hard to reach tissues, 
thereby offering the potential to increase the efficacy of the drug-nematode interaction. 
The ability of the polyanhydride nanoparticles to slowly erode and release the cargo 
molecule in a controlled manner can also allow for specificity against both the adult 
nematode and Wolbachia [11]. In this work, we demonstrate that co-delivery of 
doxycycline and ivermectin through encapsulation into polyanhydride nanoparticles 
effectively kills adult B. malayi filarial worms 8-fold faster with up to a 4,000-fold 
reduction in the amount of drug used. We hypothesize that the mechanism behind this 
enhanced killing of the macrofilaria is the ability of the nanoparticles to penetrate the 
outer membrane of the B. malayi worm and effectively deliver drug directly to the worm 
and its symbiotic bacteria Wolbachia at high enough microenvironment concentrations to 
cause death. The approach described herein holds great promise to interrupt the life cycle 
of the nematode not only by reducing the number of MF, but also by improving 
macrofilaricidal activity. These findings have the potential to dramatically enhance the 
treatment of patients suffering from debilitating filarial diseases such as LF and RB. 
Materials and methods 
 
Acquisition and storage of B. malayi and microfilariae 
 
Live adult B. malayi females, males, and microfilariae were acquired from the 
NIH/NIAID Infectious Disease Filariasis Research Reagent Repository Center (FR3) at 
the University of Georgia (Athens, GA). Adult worms were maintained in non-phenol red 
Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 10% heat-
54 
 
 
inactivated fetal bovine serum (FBS) and 1% penicillin-streptomycin. The B. malayi were 
held in an incubator at a temperature of 37˚C supplemented with 5% carbon dioxide 
(CO2). Female and male worms were stored individually in 48 well microtiter plates 
containing 1 mL of RPMI-1640. Previously shed microfilariae were housed in 50 mL 
conical tubes containing 25 mL of RPMI-1640. Upon arrival of the filarial worms they 
were separated and placed into individual 48 well microtiter plates that contained the 
previously described media. 
Motility scoring 
 
The motility of the adult worms treated with various formulations was observed 
for 30 seconds by utilizing a 2X objective on a Nikon Microscope and scored utilizing 
the following 0-5 scoring system: zero percent motility reduction, head and tail 
uninhibited as well as mid-section unaffected = 5; 1 to 25% motility reduction, ability to 
visualize both the head and tail movements easily as well as midsection = 4; 26 to 49% 
motility reduction, showing a partial mid-section paralysis = 3; 50 to 74% motility 
reduction, showing full mid-section paralysis followed by a substantial reduced 
movement in the head and tail = 2; 75 to 99% motility reduction, showing full mid-
section paralysis followed by either head and or tail paralysis but not limited to 
occasional movement over a 30 second time period = 1; and a score of 0 represented 
100% death (i.e., non-motile). The loss of motility of the adult worms was compared with 
that of respective untreated controls. 
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Synthesis of ivermectin and doxycycline-loaded polyanhydride nanoparticles 
Materials 
For the synthesis of the 1,6-bis(p-carboxyphenoxy)hexane (CPH) and 1,8-bis(p-
carboxyphenoxy)-3,6-dioxaoctane (CPTEG) monomers and the corresponding 20:80 
CPTEG:CPH copolymer, and the ivermectin and doxycycline-loaded nanoparticles, ace-
tic acid, acetic anhydride, acetone, acetonitrile, chloroform, dimethyl formamide, ethyl 
ether, hexane, methylene chloride, pentane, petroleum ether, potassium carbonate, so-
dium hydroxide, sulfuric acid, and toluene were purchased from Fisher Scientific (Fair-
lawn, NJ). The chemicals 1,6-dibromohexane, 1-methyl-2-pyrrolidinone, hydroxybenzoic 
acid, N,N-dimethylacetamide, sebacic acid, and tri-ethylene glycol were obtained from 
Sigma Aldrich (St. Louis, MO). The chemical 4-p-fluorobenzonitrile was purchased from 
Apollo Scientific (Cheshire, UK). For 1H NMR analysis deuterated chloroform and deu-
terated dimethyl sulfoxide were purchased from Cambridge Isotope Laboratories (Ando-
ver, MA). Rhodamine B, a fluorescent dye, and the drugs, ivermectin and doxycycline, 
were purchased from Sigma Life Science (St. Louis, MO).   
Polymer synthesis 
 
Synthesis of the CPH and CPTEG monomers was performed as described 
elsewhere [34]. Copolymers containing 20:80 molar ratios of CPTEG and CPH were 
synthesized through melt condensation, as previously described [28, 29]. Molecular 
weight and copolymer composition were confirmed using 1H NMR. 
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Nanoparticle synthesis 
 
Doxycycline- and ivermectin-loaded 20:80 CPTEG:CPH nanoparticles were syn-
thesized using solid/oil/oil nanoprecipitation, as previously described [25, 31, 32]. 
Briefly, ivermectin and doxycycline, each at 5% (w/w), and rhodamine B at 2% (w/w) of 
the total weight of the polymer were dissolved in methylene chloride at a concentration of 
20 mg/mL followed by rapid precipitation into the anti-solvent, pentane. The polyanhy-
dride nanoparticles were then collected using vacuum filtration. The drug-loaded parti-
cles were characterized for size and morphology by scanning electron microscopy (SEM, 
FEI Quanta SEM, Hillsboro, OR). So, every 100 mg of the final nanoparticle preparation 
would contain 5 mg of IVM, 5 mg of doxycycline and 2 mg of rhodamine. 
Drug release kinetics 
The in vitro release kinetics of ivermectin and doxycycline from 20:80 
CPTEG:CPH nanoparticles was determined using high performance liquid chromatog-
raphy (HPLC). Nanoparticles were suspended in 1 mL of phosphate buffered saline 
(PBS, pH 7.2), followed by thorough sonication to suspend the particles and incubated at 
37°C under constant shaking. At each time point, the tubes were centrifuged at 10,000 rcf 
for 10 min. The supernatant was removed and replaced with fresh PBS and returned to 
incubation. 
The ivermectin was separated using a Zorbax C8 4.6 x 250 cm chromatography 
column using a mobile phase of tetrahydrofuran, acetonitrile, and water in a 40:40:20 
volume ratio, respectively. The flow rate was set at 1 mL/min and ivermectin eluted at a 
retention time of 5.3 min. The ivermectin was quantified with fluorescent detection using 
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an excitation wavelength of 365 nm and an emission wavelength of 475 nm with a gain 
of 10 and attenuation of 64 [33]. The doxycycline was quantified using a Varian Pursuit 
XRs 3 C18 150 x 2 mm column. The mobile phase consisted of water with 0.1% formic 
acid and acetonitrile at a 98:2 volume ratio and at a flow rate of 0.2 mL/min. After one 
minute the mobile phase was ramped to 100% acetonitrile over 4 min. Doxycycline was 
quantified with tandem mass spectroscopy (MS/MS) using the following conditions: Q1 
to Q3 transitions of 445 to 154 at 30 V collision energy and 445 to 427.9 at 16 V collision 
energy [34]. The encapsulation efficiency of the particles was determined as described 
previously [35] and found to be approx. 100% for both drugs and for the rhodamine. 
Drug treatments of B. malayi  
Ivermectin (22,23-dihydroavermectin B1) and doxycycline hyclate (C22H24N2O8 · 
HCl · 0.5H2O · 0.5C2H6O) were dissolved in DMSO at a final concentration of 0.02 % 
v/v. RPMI-1640 medium was prepared such that the final concentrations of each drug in 
nanoparticles were 195, 49, 10, 5, 1.95, 0.049, 0.01, 0.005, and 0.001 µM, respectively. 
Control medium contained 0.02% DMSO and rhodamine B, but no drug. Individual 
worms that were previously placed into 48 well flat bottom culture plates upon arrival 
had new fresh media that contained 1 mL of RPMI-1640, 0.01% streptomycin and 
penicillin and 10% heat-inactivated fetal calf serum. B. malayi were incubated at 37̊ C 
and 5% CO2 for 1-2 hours for acclimatization to evaluate base line motility before the 
experiment began. The nanoparticle-encapsulated drugs and standard antifilarials (i.e., 
free drug with no nanoparticle encapsulation) were added as previously described above. 
For example, 2 mg of the 195 µM drug concentration nanoparticles were added to each 
well and correspondingly lower amounts of nanoparticles were added as the drug 
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concentrations decreased. Controls received equal amounts of media but lacked the 
nanoparticles and standard antifilarials. B. malayi were incubated at 37̊C and 5% CO2 and 
monitored for 14 days post treatment. 
Viability assessment  
Reversibility assays where conducted 24 h following a 9 day course of treatment 
and or after the final individual within the soluble group reached a motility score of 0. 
Individual worms where transferred to a new 48 well microtiter plate that contained 1 mL 
of the previously described media and were placed into an incubator at a temperature of 
37˚C supplemented with 5% carbon dioxide (CO2). After 24 h a motility score was 
recorded.  Upon completion of reversibility adult female worm viability was assessed 
utilizing a standard 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
(MTT)-formazan colorimetric assay. The same female worms used in the motility assay 
were gently blotted and transferred to a 96 well microtiter plate that contained 0.2 mL of 
1mg/mL MTT in phosphate-buffered saline (pH 7.2) and incubated for 2 h at 37°C. The 
formazan formed was extracted in 0.15 mL of DMSO for 4 h at 23°C and the absorbance 
was measured at 570 nm using a spectrophotometer (FLUOstar Omega version 1.01). 
The mean absorbance of the formazan from the treated worms was compared with that of 
the controls. The viability of the treated worms was assessed by calculating the percent 
inhibition in motility and MTT reduction over the DMSO-treated control worms. 
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MF shedding and motility 
The effect of treatments on MF shedding and subsequent motility was assessed 
using two experimental approaches. The direct effect on MF was performed by collecting 
MF from the spent media of healthy untreated female worms. Spent media was 
centrifuged for 10 min at 200 rcf, the MF were re-suspended in fresh media and 
enumerated by counting using a 14.80 mm² grid plate. Aliquots containing at least 250 
MF were dispensed into wells of a 96 well plate and treated in triplicate with either 
soluble drug, blank nanoparticles or nanoparticles containing drugs as indicated. Wells 
were then monitored and scored daily for MF movement. Motility of MF scoring was 
carried out using a 10X Nikon microscope and individual scores from five separate fields 
of view (FOV) were averaged to yield a motility score for each well. Scoring was adapted 
from a previously reported method by observing the movements of the anterior and 
posterior body over one min [36]. Data were analyzed by ANOVA and graphs were 
assembled using GraphPad Prism (v6.05). In separate experiments, the effect of treating 
adult female Brugia and their ability to release MF was monitored and recorded for 14 
days. The motility of the shed MF was also recorded. Each experiment, the various 
treatment groups, and the different doses of the drugs were repeated for a minimum of 
three times. 
Nanoparticle uptake by B. malayi 
To understand the interaction between the nanoparticles and the filarial worms, 
recently deceased adult worms (motility score of “0”) from treated and untreated 
experimental groups were fixed and prepared for confocal microscopy. Worms were 
removed from treatment wells, washed twice in pH 7.4 PBS and fixed with 4% 
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paraformaldehyde for 1 h at room temperature. Worms were removed, rinsed with fresh 
PBS and mounted carefully onto glass slides using Prolong Gold with DAPI (Life 
Technologies). Slides were then stored in the dark at 4˚C prior to imaging. Imaging was 
performed using an Olympus IX-71 laser-scanning confocal microscope (Fluoview 2000, 
v2.0) equipped with 405 nm, 488 nm, 559 nm and 635 nm lasers, spectral photomultiplier 
detection and a piezo-controlled stage. Laser power and exposure settings were set 
according to the negative (worms with no rhodamine) and positive (rhodamine containing 
nanoparticles) and maintained constant over all the experiments. Image stacks were 
collected simultaneously for bright field (transmitted light - grey scale), cell nuclei (DAPI 
- blue) and nanoparticles (rhodamine - red). Bright field and cell nuclei were used to 
identify various tissues, organs and structures in the worm such as oral opening, pharynx, 
uterus, the nerve ring, extracellular secretory apparatus, esophageal track and anal pore. 
Rendering of Z-stack data in three dimensions and minimal image processing was 
performed as described previously by our laboratory [37] using ImageJ v 1.49a (NIH). 
Software parameters for image processing remained constant for all image/data sets 
presented. 
Results 
 
Encapsulation of doxycycline and ivermectin into polyanhydride nanoparticles 
provides sustained drug release 
 
After encapsulation of the anti-filarial drugs by nanoprecipitation, the particle 
morphology and size were examined using scanning electron microscopy. Surface 
morphology was found to be consistent with previous work and the scanning electron 
photomicrographs are shown in Figure 2-1 (panel B) [26, 27, 38]. Additionally, particle 
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size was also found to be consistent with previous work [37, 39]. The mean diameter of 
the drug-containing 20:80 CPTEG:CPH nanoparticles was 218 ± 56 nm. 
 
 
Figure 3-1 Release kinetics of ivermectin (IVM) and doxycycline (DOX) Panel A: Release kinet-
ics of ivermectin (IVM) and doxycycline (DOX) from 20:80 CPTEG:CPH nanoparticles quanti-
fied using HPLC. Panel B: Scanning electron photomicrograph of 20:80 CPTEG:CPH nanoparti-
cles loaded with 5% IVM, 5% DOX, and 2% rhodamine. Scale bar: 500 nm. 
 
Using a HPLC assay as described in the Methods section, the release kinetics of 
ivermectin and doxycycline from the nanoparticles was quantified, as shown in Figure 3-
1, panel A). The 20:80 CPTEG:CPH nanoparticle formulation provided sustained release 
of both drugs over one week. That data showed that the doxycycline release profile from 
the hydrophobic 20:80 CPTEG:CPH nanoparticles showed a small burst effect, which is 
consistent with previous work [40]. It was also observed that there was a much larger 
burst release of doxycycline as compared to that of ivermectin. 
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Polyanhydride nanoparticle-based drug delivery significantly increased B. malayi 
macrofilaria mortality and significantly reduced microfilarial shedding 
 
The effectiveness of the polyanhydride nanoparticle-based delivery platform was 
compared to that of the standard soluble treatment in terms of the overall percent survival 
of B. malayi over the duration of the study with a single treatment of the previously 
described groups (Figures 3-2 and 3-3, panel A). The effect of blank (i.e., no drug) 
nanoparticles containing only rhodamine was assessed with 2 mg/mL of nanoparticles, 
the amount corresponding to that of the highest drug concentration administered (i.e., 195 
µM). Similarly, untreated controls did not contain active drugs, but were supplemented 
with rhodamine and DMSO corresponding to the amounts present in the highest 
treatment group (i.e., 195 µM drug concentration). 
The motility of the worms treated with the blank nanoparticles did not vary 
significantly from that of the untreated worms for either female or male worms (Figures 
3-2 and 3-3 and Supplemental Figure 1). The results clearly demonstrate the effectiveness 
of the nanoparticle formulations for all the treatment groups when compared to the 
soluble treatment group for drug concentrations as low as 1 nM. Another parameter to 
quantify the difference between the effectiveness of the soluble dual 
ivermectin/doxycycline treatment and that of the nanoparticle-based delivery platform 
was the average number of days to death. We conducted a fourteen-day in vitro study that 
quantified the average days to death of female (Figure 3-2, panel B) and male (Figure 3-
3, panel B) B. malayi. Random testing of viability of worms exhibiting a motility score of 
0 for metabolic activity was performed using the MTT reduction assay throughout the 
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studies and for all treatment groups (data not shown) and a representative of % MTT in-
hibition analysis is shown in Supplemental Figure 3-2 for the 5 µM drug concentration. 
Inhibition of metabolic activity greater than 75% of that of untreated controls indicated 
that worms were non-viable and declared dead. In addition, separate worms with a 
motility score of 0 were subjected to reversibility testing whereby after 24 h of no 
motility, worms were removed from the test media, washed three times and placed in 
fresh media with no drugs (data not shown). Recovery of movement was interpreted as 
the worms being temporarily paralyzed and those worms were removed from the ATD, 
except where indicated† (Figures 3-2 and 3-3, panel A). We observed reversible paralysis 
only when high doses of soluble drug (49 µM - 195 µM) were used in approximately 
25% of all worms treated in these groups. Strikingly, reversible paralysis was not ob-
served in any nanoparticle-treated group of any drug concentration, showing that the na-
noparticle formulations effectively killed the worms. The data indicated that the nanopar-
ticle-based delivery platform significantly (p<0.001) lowered the overall time to death 
when compared directly to the soluble dual ivermectin/doxycycline treatment. Treatment 
of female worms with 195 µM of the soluble drugs resulted in an average time of death in 
excess of nine days and 63% of the worms were killed (Figure 3-2, panels A and B). In 
contrast, treating the worms with the nanoparticle-based delivery system with the same 
drug concentration sharply reduced the average time to death to less than 1.2 days, and 
more significantly, 100% of the worms were killed. We also performed dose titration 
studies and systematically lowered the concentration of the two drugs from 195 µM to 1 
nM.  
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Figure 3-2  Panel A. Table outlining survival of B. malayi females after treatment with 
195, 49, 10, 5, 1.95, or 0.049 µM concentrations of ivermectin (IVM) and doxycycline 
(DOX) delivered solubly or encapsulated into 20:80 CPTEG:CPH nanoparticles. Panel B. 
Average number of days to death of B. malayi females after administration of soluble or 
encapsulated IVM/DOX treatments and comparison to control worms. Significance was 
determined at p<0.05, 0.01, or 0.001 as noted using a Student’s T test. Panel C. Average 
motility scores of B. malayi females after IVM/DOX treatments scored using a 2X 
objective on a Nikon Microscope following a 0-5 scoring system, as described in the 
Methods. Panel D. Average number of microfilaria shed by B. malayi females after 
administration of soluble or encapsulated IVM/DOX treatments and comparison to 
control worms. The NP only group contains comparable amount of rhodamine and the 
total amount of particle in this group corresponds to that of the highest drug concentration 
of 195 µM. At 14 days, all worms treated with NP only with a motility score of 0 
remained viable based on the MTT assay and recovery of motility upon transferring to 
fresh medium†. Significance was determined at p<0.05, 0.01, or 0.001 as noted using a 
Student’s T test. 
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Female worms treated with the 1 nM concentration of soluble 
ivermectin/doxycycline resulted in an average time to death that was >14 days, and more 
significantly, only 33% of the worms were killed at this concentration (Figure 3-2, panel 
A).In contrast, the worms treated with the nanoparticle-based delivery system containing 
the 1 nM drug concentration had an average time to death of <6 days, and more 
significantly, 100% macrofilarial death was observed upon treatment with the low 
concentration of ivermectin/doxycycline.  
To determine if nanoparticles changed the reproductive capacity of female worms 
the shedding of MF was observed for fourteen days (Figure 3-2, panel D). Both the 
soluble ivermectin/doxycycline and the nanoparticle-based delivery groups significantly 
reduced the overall microfilariae shed at the high drug concentration of 195 µM. But as 
the concentration of ivermectin/doxycycline was systematically reduced to 5 nM, 
significant differences (p<0.01) were observed in the MF shed by the worms treated with 
the soluble ivermectin/doxycycline groups compared to the worms that were treated with 
the nanoparticle-based delivery system, with the nanoparticles being more effective at 
lower drug concentrations. The effect of the various drug treatments on the motility of B. 
malayi MF was observed for 14 days (Figure 3-4). Similar to the effects observed for 
adults, the average time to death as well as the motility of the MF treated with the soluble 
drug was significantly (p < 0.001) higher in comparison to that of the MF that were 
treated with the nanoparticle-based delivery system, especially at low drug 
concentrations. 
For the B. malayi males (Figure 3-3, panels A and B) treatment with drug-loaded 
20:80 CPTEG:CPH nanoparticles showed a significant difference (p<0.05) in terms of 
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survival when compared to the survival of worms treated with an equivalent soluble dose 
of ivermectin/doxycycline. In terms of average time to death, male worms treated with a 
195 µM concentration of soluble ivermectin/doxycycline died after seven days and more 
significantly, only 30% of them were killed at this dose (Figure 3-3, panel A). 
 
Figure 3-3 Panel A. Table outlining survival of B. malayi males after treatment with 195, 49, 10, 
5, 1.95, or 0.049 µM concentrations of ivermectin (IVM) and doxycycline (DOX) delivered 
solubly or encapsulated into 20:80 CPTEG:CPH nanoparticles. Panel B. Average number of days 
to death of B. malayi males after soluble or encapsulated IVM/DOX treatments as compared to 
control worms. Significance was determined at p<0.05, 0.01, or 0.001 as noted using a Student’s 
T test. Panel C. Average motility scores of B. malayi males after IVM/DOX treatments scored us-
ing a 2X objective on a Nikon Microscope following a 0-5 scoring system, as described in the 
methods. 
 
In sharp contrast, all the male worms treated with the nanoparticle-based delivery 
system containing the same dose of ivermectin/doxycycline died in less than one day. 
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When the treatment concentration was reduced to 0.049 µM, the average time to death of 
worms treated with soluble ivermectin/doxycycline was >14 days with a death rate of 
only 20%. On the other hand, all the male worms treated with the nanoparticle-based 
delivery system containing the 0.049 μM concentration of Ivermectin/doxycycline died 
within ten days. 
 
Figure 3-4 The motility of B. malayi MF treated with decreasing doses of either soluble or 
encapsulated ivermectin (IVM)/doxycycline (DOX) was recorded for 14 days post treatment. The 
recorded motility scores (Panel B) were used to calculate an average time to death for each 
treatment group and dose (Panel A). To calculate the average motility score for each time, dose 
and treatment group, triplicate wells containing a minimum of 200 MF in each well were treated 
as indicated. A motility score of 0 was equated with death and the average time to death was 
plotted along with standard error. Data presented are from one of two experiments with similar 
results. Significance was determined at p<0.05, 0.01, or 0.001 as noted using a Student’s T test. 
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In conjunction with the average time to death assay we also monitored the 
motility over time to characterize the overall effectiveness of the nanoparticle treatments 
(panel C of Figures 3-2 and 3-3). With both male and female B. malayi worms, an 
exponential reduction in overall motility was observed in the worms administered the 
nanoparticle-based delivery treatments in comparison to that of the worms that received 
the soluble drug treatment. system containing the 0.049 µM concentration of ivermec-
tin/doxycycline died within ten days 
Polyanhydride nanoparticle-based treatment effectively penetrated the worm cuticle  
 
To visualize the interactions of polyanhydride nanoparticles with B. malayi 
female worms, animals were treated with equivalent amounts of a cocktail containing 
rhodamine red dye with ivermectin/doxycycline either in soluble form or encapsulated 
within the 20:80 CPTEG:CPH nanoparticles. At regular intervals worms were washed 
three times in PBS to remove surface-bound nanoparticles, fixed, and then imaged using 
confocal microscopy to localize nanoparticles within tissues. Detection of focal, intense 
rhodamine staining is consistent with size and staining patterns of intact nanoparticles. In 
comparison, diffuse red staining is indicative of free rhodamine. Worms treated with 195 
µM of the soluble drug cocktail did not accumulate rhodamine within tissues over a 
period of 96 hours (Figure 3-5, panel A).  
Over this same time interval, the much lower dose of 5 µM of 
ivermectin/doxycycline encapsulated within the nanoparticles that also contained 
rhodamine, extensively labeled the interior structures of female worms (Figure 3-5, panel 
B). Diffuse red staining reveals the rapid distribution of the released dye throughout the- 
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Figure 3-5 Confocal microscopy of female B. malayi with nanoparticles. Worms were incubated 
for 96 h with either soluble controls (panel A) or 20:80 CPTEG:CPH nanoparticles containing 
ivermectin (IVM), doxycycline (DOX), and rhodamine B (panel B), fixed and imaged by LSCM.  
Controls contained 195 µM each of IVM and DOX, and 3.9 µM rhodamine B, while the 
nanoparticles contained 5 µM of each drug and 0.1 µM of rhodamine B. Left panels are DNA 
(blue), rhodamine (red) and bright field image overlays and right panels are the respective 
individual rhodamine images collected using identical image acquisition settings. Inset box within 
the nanoparticle-treated worm outlines the area selected for side view rendering (C). 
Representative images shown demonstrate the accumulation of nanoparticles (arrows) within 
tissues throughout the worm (B) as compared to the higher amount of soluble rhodamine that was 
not detected within the body of the worms. Similar results were seen throughout the body of the 
worm in both male and female worms (data not shown). 
 
-body of the worm and focal, intact 20:80 CPTEG:CPH nanoparticles are easily discerna-
ble deep within worm tissues by confocal microscopy (Figure 3-5, panels B and C). 
Three dimensional reconstruction of confocal Z-stacked images reveal the penetration of 
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nanoparticles and release of rhodamine throughout the inner tissues of the worm (Figure 
3-5, panel C). Similar rhodamine and nanoparticle staining patterns were evident 
throughout the length of the treated worms at all concentrations tested. Internal staining 
of worms treated five hours post treatment with 195 µM of the soluble drug cocktail were 
identical to the rhodamine intensity of worms treated with 5 µM of the drug cocktail en-
capsulated within the nanoparticles for 96 hours. These observations offer insights into 
why the nanoparticle-based delivery treatments of B. malayi are highly effective, espe-
cially at low doses. 
Discussion 
 
The World Health Organization global program to eliminate LF recommends 
annual dosing of albendazole with either ivermectin or diethylcarbamazine to be 
continued for at least five years. These drugs are potent antihelmintics that kill and 
reduce shedding of MF. However, they exhibit little direct activity against the adult 
filarial worms [41]. Discovery of the endosymbiotic bacteria Wolbachia and the critical 
role they play in the biology and viability of the adult worm revealed a potential target 
that could be exploited to improve therapies for RB and LF [19, 21, 42]. The addition of 
anti-bacterials (such as doxycycline or tetracycline) to the treatment regimen can reduce 
parasite embryogenesis [20, 43], improve macrofilaricidal activity, and reduce hydrocele 
pathology in the host [44, 45]. To achieve maximal benefit, daily dosing of 200 mg for 3-
5 weeks of antibacterial drug is required and can be a difficult barrier to overcome for 
Mass Drug Administration (MDA) programs [15]. In this work, we report that the use of 
a polyanhydride nanoparticle-based carrier effectively reduced the amount of drug 
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necessary for macrofilarial death by up to 4,000-fold compared to physiologically 
relevant doses.  
The unique chemistry of the polyanhydride nanoparticles helps address many of 
the challenges associated with mass drug administration against lymphatic filariasis. The 
surface erosion profile of the polyanhydride nanoparticles sustains the slow release of 
drug at different kinetics for both drugs from the same particle as shown in Figure 3-1. 
The initial burst of the doxycycline released from the 20:80 CPTEG:CPH nanoparticles is 
faster than that observed for ivermectin. Previous work has shown that this copolymer 
composition contains weakly segregated CPTEG- and CPH-rich domains [46]. This may 
indicate a preferential partitioning of the hydrophobic ivermectin to the slowly degrading 
CPH-rich domains of the copolymer, leading to the slow release profile observed [35, 
47]. In contrast, the less hydrophobic doxycycline is released faster, suggesting 
partitioning into the faster eroding CPTEG-rich domains. This controlled release profile 
of the drugs from the polyanhydride nanoparticles may explain the enhanced efficacy 
observed with the nano-carrier treatments. The payload is protected from an aqueous 
environment for longer periods of time, which may prevent degradation of the drugs, 
leading to the reduction in required dose observed in this work. Additionally, based on 
the confocal microscopy studies described in Figure 3-5, it appears that these 
nanoparticles effectively interact with the worm cuticle and behave like a Trojan horse in 
terms of transporting the drug cocktail into the worm, bypassing excretory pumps. 
Together, the encapsulation and subsequent controlled release of the drugs at high 
concentrations both internally to the worm and localized to the cuticle may account for 
the enhanced killing observed in Figures 3-2 and 3-3. 
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Reducing the effective amount of drug required would have several benefits on 
improving therapeutic treatment of filarial diseases. We predict that increasing drug 
effectiveness would likely reduce unwanted side effects by reducing amount of drug 
needed and contribute to improving patient compliance [43, 48, 49]. As discussed above, 
we hypothesize that encapsulation and subsequent controlled release of the drug and the 
ability of the polyanhydride nanoparticle carriers to localize to the worm cuticle surface, 
and even be internalized by the worms, lead to a higher microenvironment concentration 
of the drugs. In contrast, the soluble drug cocktail is a liquid, and so to create the same 
local concentration internally to the worm and at the cuticle surface, more drug must be 
administered initially. This is supported by the confocal microscopy data in Figure 3-5, 
which show that the polyanhydride nanoparticles readily localize to the worm, increasing 
the concentration of the internalized dye as compared to the soluble control. In vivo, 
while the soluble drug will be rapidly cleared from the body, the nanoparticle-
encapsulated drug will persist in different tissues for periods up to 28 days, as shown by 
our previous studies [50, 51]. Another difficulty in treating filarial infections is that 
individuals are continually being exposed to new parasites even after successful 
completion of antiparasitic regimen [52]. It was reported by Walker et al. that while 
standard doxycycline therapy was able to reduce the majority of macrofilaria in human 
subjects, reinfection with drug-naïve parasites occurred [19]. In this scenario, we would 
predict that the delayed release capacity of the nanoparticles would be able to extend the 
effective range beyond the time frame afforded by standard dosing. 
The polyanhydride nanoparticle drug delivery platform decreased the average 
time to death of B. malayi females and facilitated a rapid decrease in the motility of 
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treated worms as shown in Figure 3-2, even at nanomolar concentrations of the drugs. 
Similar trends were also observed in the B. malayi males to a slightly lesser extent, 
possibly reflecting the comparatively lower number of Wolbachia in male compared to 
female macrofilariae (Figure 3-3). Rapid killing would likely contribute to the dramatic 
reduction in shedding by female worms at low nanoparticle concentrations (Figure 3-2, 
panel D). Effectiveness at the lower concentrations may prove to be more beneficial as 
rapid killing of MF is known to induce severe side-effects within the host [53]. It is also 
likely that the nanoparticles increased the rate of delivery of ivermectin and rapidly 
paralyzed the muscles within the body of the worm and the vagina, which are needed to 
expel the MF. A similar in vitro observation was made by Tompkins et al. with Brugia 
treated with either moxidectin or ivermectin [41]. 
Finally, the confocal microscopy data in Figure 3-5 provides an initial explanation 
of the strong interactions between polyanhydride nanoparticles and the cuticle surface, 
which is hypothesized to lead to the efficacy profile of this nano-carrier platform. 
Tracking the fluorescent rhodamine B co-loaded into the nanoparticles demonstrated a 
greater increased influx of payload into the worm compared to drug and dye delivered 
solubly. As previously stated, in addition to providing sustained release of drug, with 
implications for dose sparing and patient compliance, the drug-loaded polyanhydride 
nanoparticles demonstrated enhanced internalization by the B. malayi worms. One of the 
benefits of this type of Trojan horse behavior of the nanoparticles is the ability to create 
microenvironments with high drug concentrations, in contrast to soluble drug cocktail 
treatments, which diffuse in an aqueous solution [54]. To achieve the benefit of an 
increased local drug concentration, the nanoparticles must interact with the target cell, or, 
74 
 
 
in this case, the B. malayi adult worm or microfilaria. The data in Figure 3-5 clearly 
showed that the nanoparticles are interacting with the worms in a way not previously 
described, improving the rapid delivery of drugs. We speculate that the nanoparticles 
undergo facilitated diffusion into the worm, by crossing the cuticle, penetrating the 
hypodermis membrane barriers and accessing deeper tissues within the worm [55, 56]. 
Preliminary assessment of treated worms by dissection corroborates cuticular penetration 
because far fewer nanoparticles were observed in the gut and pharynx of worms, while 
they did accumulate in deeper tissues including the hypodermis. More detailed studies are 
underway in our laboratories to further delineate the mechanisms of nanoparticle 
transport across the cuticle of the worms. 
Resistance to anthelmintic drugs is on the rise due in part to the over-expression 
of ABC-transporters that act as multi-drug resistant (MDR) efflux pumps in many 
parasites, including Onchocerca and Brugia [57]. Our success with delivery of drug 
cocktails within nanoparticles needs to be analyzed in the context of previous work, 
wherein the approach of delivering drug combinations was shown to reduce the 
development of resistance in parasites [18]. However, adoption of cocktail therapy into 
MDA programs remains problematic due to the need to maintain high levels of 
doxycycline [18]. We posit that encapsulating low doses of these drugs into the Trojan 
horse polyanhydride nanoparticles address the difficulties in maintaining prolonged 
delivery of antiparasitic drugs. The activity of the efflux pumps would normally reduce 
effective drug concentrations within the worm by preventing absorption through the 
esophagus as well as reducing intracellular concentration within cells. We speculate 
based on our results that the efficient and rapid direct penetration of the polyanhydride 
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nanoparticles through the surface of the worm would bypass poor esophageal absorption. 
We hypothesize that accessing the worm through this unique mechanism would be a 
selective pressure that would be difficult for the parasite to overcome and provide a 
paradigm-changing technology to combat filarial disease. 
Conclusions 
 
Filarial diseases represent a significant social and economic burden in areas that 
are endemic with the filarial endoparasite B. malayi, and its symbiotic bacteria 
Wolbachia. We report the use of a polyanhydride nanoparticle-based drug delivery 
platform for the co-delivery of the antiparasitic drug, ivermectin, to reduce macro and 
microfilarial burden and the antimicrobial, doxycycline, to eliminate the symbiotic 
Wolbachia. The co-delivery of doxycycline and ivermectin in the context of 
polyanhydride nanoparticles effectively killed adult female and male B. malayi filarial 
worms with up to a 4,000-fold reduction in the amount of drug used. Further, the time to 
death of the macrofilaria was significantly reduced when the anti-filarial drug cocktail 
was delivered in the context of the polyanhydride nanoparticles. Confocal microscopy 
experiments suggest that the polyanhydride nanoparticles behave like a Trojan horse and 
penetrate the outer membrane of the worm cuticle. The nanoparticles effectively deliver 
the drugs at high enough microenvironment concentrations to vital areas within the 
worm, thus significantly enhancing their effectiveness at killing the worms. These 
findings may have significant consequences for the reduction in the amount of drug and 
the length of treatment required for filarial infections and provide a paradigm-changing 
technology to combat filarial disease. 
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Figure 3-6  Synergism of ivermectin (IVM) and doxycycline (DOX) in reducing motility of adult 
B. malayi females following encapsulation of drugs into nanoparticles. Average time to death of 
three worms treated in separate wells is shown in Panel B. Average motility scores of B. malayi 
females (Panel C) after treatments where visually scored with the 0-5 scoring system, as 
described in the methods. Panel D Indicates the use of the “Worminator”, a computer motion 
screening program utilized for motility scoring in B. malayi (Marcellino C, Gut J, Lim KC, Singh 
R, McKerrow J, & Sakanari J (2012). WormAssay: a novel computer application for whole-plate 
motion-based screening of macroscopic parasites. PLoS Negl Trop Dis 6(1): e1494). The percent 
dead were worms with a motility score of 0 (Panel A) and confirmed by MTT to show inhibition 
greater than 80% of untreated control 
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Figure 3-7 Enzymatic reduction of MTT reagent by adult B. malayi females following incubation 
with various treatments for 9 days. Motility of worms tested by the MTT assay is shown in Figure 
3-6. Inhibition was calculated using optical density values of reduction of MTT reagent for un-
treated worms to represent maximum metabolic activity (Panel B). Changes in reduction of MTT 
recorded values for soluble and nanoparticle-based drug treatment groups as compared to un-
treated worms were calculated as percent inhibition (Panel A). Three individually treated worms 
were used for each treatment group and individual MTT percent inhibition was used to calculate 
the average and standard error. Significance difference of p<0.01 was calculated between the 
soluble IVM/DOX and the nanoparticle-encapsulated IVM/DOX. Inhibition greater than 75% 
was interpreted as loss in viability. 
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Abstract 
 
Amphiphilic polyanhydride nanoparticles (NP) are chemically and structurally 
distinct from other polymer or lipid-based particle delivery systems. These NPs are solid, 
surface eroding particles, which encapsulate small molecules or proteins that become an 
integral component of the particle. Their variable hydrophobicity imparts a unique, native 
cellular affinity leading to a high degree of internalization by mononuclear phagocytes 
(MP). The reticular endothelial system consisting of dendritic cells, blood monocytes, 
and tissue-resident macrophages found in the liver, spleen, and lymph nodes that are 
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responsible for clearing, processing, and degrading foreign materials from circulation. 
We sought to capitalize on two of the unique characteristics of NPs: extending intracellu-
lar persistence where the particles slowly erode and release the cargo molecule in a con-
trolled manner. As well as, through the delivery of a co-encapsulated antiparasitic therapy 
consisting of albendazole, diethylcarbamazine or ivermectin along with the antibacterial 
drug doxycycline. In vitro studies with B. pahangi demonstrate an increase in antipara-
sitic activity, as measured by recording worm motility following exposure to soluble or 
encapsulated drugs. The combination of doxycycline with ivermectin for the average time 
of death (TOD) observed in B. pahangi females was reduced from 6.5 days for the solu-
ble to 4 at the highest concentration shown (25 μg) of NPs. To achieve matched drug 
efficacy to that of the soluble drug, the overall NP concentration was reduced 500 times 
to achieve match antiparasitic activity. The use of NPs with the drug combination dieth-
ylcarbamazine/albendazole/doxycycline showed an even greater impact on parasitic kill-
ing when comparing the highest concentration (25 μg) from 9 days with soluble to 2 days 
for encapsulated drugs. As well as similar reductions in the necessary overall drug con-
centration as with the ivermectin groups. When comparing the lowest concentration of 
NPs (0.05 µg) against the highest concentration (25 μg), the NPs were able to kill an ad-
ditional three days faster against adult female worms. Similar results were obtained with 
adult B. pahangi male worms. We envision that encapsulation of drugs into NP will serve 
to repurpose current anti-filarial treatment methods into more potent and targeted thera-
pies by offering increased patient compliance and increasing efficacy of the drugs.  
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Introduction 
 
The parasitic helminth Wuchereria bancrofti, Brugia malayi, and B. timori are the 
causative agents of Lymphatic Filariasis (LF). Currently, over 120 million people are at 
risk of contracting Lymphatic Filariasis, with an average of 38.5 million people showing 
clinically active filariasis. While efforts to mitigate the effect of these diseases have been 
successful in some regions, current medications are insufficient to reach elimination by 
2020 [1-3].The disease is characterized by fever, lymphangitis, hydrocele, lymphoedema, 
and elephantiasis, and is one of the most common causes of arthropod-mediated disability 
[3, 4]. The unique parasitic life cycle begins when the larval microfilariae (MF) are 
aquired up during a blood meal from an infected host by the insect vector. The MF (L1) 
undergoes two larval molting’s stages L2, and the infective L3 stage, this takes around 
10-14 days to occur [5]. When the infected mosquito feeds on another human host, the 
infective larvae (L3) are deposited within host tissue at the bite site and migrate to the 
lymphatics. One of the unique characteristics of the L3 stage is its ability to modulate and 
suppress the host immune response via secretion of proteins and microRNAs [6, 7]. 
These proteins and microRNAs allow for the initial suppression of the innate immune re-
sponse which gives the opportunity for the L3 stage to mature into the adult worms 
(macrofilaria). A single female macrofilaria can produce over a billion MF during this 
time [8, 9]. The host’s innate immune response to the MF involves many different cell 
populations, which include granulocytes such as eosinophils, mast cells and polymorpho-
nuclear leukocytes (PMNs), as well as monocytes. These immune cell populations can 
recognize, trap and kill the blood circulation MF in the human filarial parasitic nematode 
Brugia malayi [10, 11].  For the majority of the day, MF sequester within the lungs of the 
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host and only appear in the peripheral blood circulation for a few hours each night, which 
coincides with maximal mosquito feeding [12].  
This parasitic nematode harbors an obligate intracellular bacteria of the Rickettsi-
alaes order of α-proteobacteria called Wolbachia [13]. Wolbachia, are a vital component 
of larval development and adult-worm fertility and viability. Typically, Wolbachia is 
found within hypodermal cells of both sexes. However, vertical transmission of the 
bacteria to MF is facilitated by the presence of bacteria in the ovaries, oocytes, and 
embryos during development in females. Because of their long lifespan, mass drug treat-
ment protocols must be maintained for between 4-5 years if the transmission is to be in-
terrupted [13].  
Current treatment protocols primarily focused on interrupting the spread of LF by 
targeting the MF larvae with combinations of anti-helminthic medications. The drugs 
most frequently used to manage LF include albendazole (ABZ), a benzimidazole 
derivative; diethylcarbamazine (DEC), a derivative of piperazine; which is involved in 
modulation of the host immune response to be effective [14] and ivermectin (IVM), 
which is believed to be a broad-spectrum antiparasitic agent [15-19]. Ivermectin has been 
shown in animal parasites to modulate the activity of PMNs as well as monocytes [11, 
20]. These drug combinations are used primarily for long-term, community-directed 
treatments aimed at interrupting transmission. Some of the possible side effects of these 
drugs include fever, itching, and possibly oedema, arthritis, and lymphadenopathy [21]. 
These side effects are primarily due to the extensive paralysis and killing of the MF. 
These medications have minimal activity against the causative organism, adult Wuchere-
ria bancrofti, Brugia malayi and B. timori, and have thus far, failed to deliver a radical 
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curative treatment. This failure is due to the unique composition of the outer cuticle and 
the specificity of infected tissue limits, and the permeability of these compounds. These 
treatments form the foundation of the global eradication program used for LF.  Current 
research has highlighted the use of drugs with macrofilaricidal activity [15], use of these 
drugs or combinations could greatly improve the probability of a curative treatment.  
Attempts to develop treatments for macrofilaria have focused on the use of anti-
microbials of the tetracycline class, primarily doxycycline (DOX). Use of this drug as 
well as the combinations of the previously mentioned anti-filarial regimens may provide 
adequate targeting of the symbiotic intracellular bacteria Wolbachia [17, 22]. These anti-
microbials have been shown to reduce the number of resident Wolbachia, although the 
exact symbiotic role within the nematode is not directly known. Research has shown that 
the use of DOX can cause long-term sterilization and death of adult female worms in 6 to 
12 months with a 3-6 week treatment course [13, 23-25]. However, limitations associated 
with the use of the above drugs is four-fold: specific restrictions on patient age and health 
status due to cytotoxicity; the inability to reach broad tissues where the adult filarial 
nematodes reside; as well as counter-indications in areas endemic for the Loa loa (Loi-
asis) parasite; and poor patient compliance. [26]. The use of ivermectin can cause severe 
kill off of Loa loa MF resulting in post-ivermectin effects causing coma, irreversible neu-
rologic complications and death [27]. An alternative antibiotic which has been tested and 
has shown effectiveness against Rickettsiae is rifampicin, which is better tolerated in chil-
dren and pregnant patients and has been shown to be effective against Wolbachia in On-
chocerca parasites in vitro [28]. However, rifampicin has been shown to be less effective 
than doxycycline in vivo [29, 30]. Additional therapeutic options for doxycycline could 
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be useful when combined with current antiparasitic drugs; however, combination thera-
pies present difficulties for drugs that have different systemic half-lives, similar toxicity 
profiles, low aqueous solubility, and reduced shelf life properties. These equilibrium sol-
ubility issues can be exascebated by the differing comprehensive drug administration pro-
grams that already suffer from poor patient compliance, and multi-year therapy regimes 
[31].  These issues have spurred the need for alternative drugs and rational design of de-
livery vehicles.  
Because of the diversity of disease, location and therapies, utilization of a na-
noscale delivery systems can be designed to facilitate delivery of small molecules and 
proteins [32-34]. Use of these delivery systems can be further enhanced through their 
ability to cross multiple physiological barriers readily, to targeted disease sites, all while 
minimizing toxicities. Most polyester nanoparticle formulations are rapidly sequestered 
by phagocyte cells (MPS) [32, 35-37]. Nanoparticles have also been shown to offer better 
pharmacokinetic properties such as controlled and sustained release, and targeting of spe-
cific tissues or organs [38]. All these features provide successful strategies for the devel-
opment and utilization of amphiphilic polyanhydride nanoparticles (NP) for targeted de-
livery of antimicrobial drugs, against multiple diseases. Previous research has highlighted 
there use as a delivery vehicle for both drugs and vaccines for other diseases [15, 34, 39-
46].  Polyanhydride’s possess excellent biocompatibility and drug delivery potential, hav-
ing hydrophilic properties with highly hydrophobic backbones [47]. These materials con-
fer surface erosion properties that can be tailored by increasing the degree of hydrophobi-
city of the backbone chemistry. By tailoring the degree of hydrophobicity, 
polyanhydride’s can be modified to possess rapidly degrading properties (over a period of 
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hours to days) to very slow degradation (greater than a month) [48]. Such release profiles 
can enable single-dose therapies, whereby extending the in situ drug concentration, re-
duce potential drug toxicity, enhance tissue specificity and increase patient compliance. 
The tailorability of the polyanhydride nanoparticles to slowly erode and release the cargo 
molecule in a controlled manner will increase the pharmacodynamics properties against 
both the adult nematode and Wolbachia.  
In this work, we demonstrate the use of paired combinations of doxycycline with 
albendazole, diethylcarbamazine, or ivermectin through encapsulation into three different 
polyanhydride nanoparticle formulations, to determine a leading antiparasitic platform for 
efficacy testing against adult B. pahangi filarial worms. Our previous research on Brugia 
malayi highlighted the use of the drug combination ivermectin and doxycycline [15]. To 
determine the effectiveness of these drugs combined with the use of NPs against Brugia 
pahangi. B. pahangi is a primary parasite used in the Brugia-gerbil Meriones unguicula-
tus animal model. Meriones unguiculatus is used extensively for testing of drug compo-
nents, and immune responses against Brugia species.  
The PANs ability to penetrate the outer cuticle of the Brugia worm and 
effectively deliver drugs directly to the worm and its symbiotic bacteria Wolbachia at a 
maintained pharmacokinetic concentrations causes death. The work described herein pro-
vides insight into the use of NPs to reduce the morbidity of the filarial disease, by reduc-
ing the MF shed and improving macrofilaricidal activity.  
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Materials and methods 
 
Acquisition and storage of macrofilaria and microfilariae 
 
Live adult B. pahangi females, males, and microfilariae were acquired from the 
NIH/NIAID Infectious Disease Filariasis Research Reagent Repository Center (FR3) at 
the University of Georgia (Athens, GA). Adult worms were maintained in non-phenol red 
Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 10% heat-in-
activated fetal bovine serum (FBS) and 1% penicillin-streptomycin. The macrofilaria 
were held in an incubator at a temperature of 37°C supplemented with 5% carbon dioxide 
(CO2). Female and male worms were stored individually in 48 well microtiter plates con-
taining 1 mL of RPMI-1640. Previously shed MF were housed in 50 mL conical tubes 
containing 25 mL of RPMI-1640. Upon arrival of the filarial worms, they were separated 
and placed into individual 48 well microtiter plates that contained the previously de-
scribed media. 
Motility evaluation 
 
Ocular scoring 
 
The motility of the adult worms treated with various formulations was observed 
for 30 seconds by utilizing a 2X objective on a Nikon Microscope and scored utilizing 
the following 0–5 scoring system: zero percent motility reduction, head and tail 
uninhibited as well as mid-section unaffected = 5; 1 to 25% motility reduction, ability to 
visualize both the head and tail movements quickly as well as midsection = 4; 26 to 49% 
motility reduction, showing a partial mid-section paralysis = 3; 50 to 74% motility 
reduction, showing full mid-section paralysis followed by a substantial reduced 
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movement in the head and tail = 2; 75 to 99% motility reduction, showing full mid-
section paralysis followed by either head and or tail paralysis but not limited to 
occasional movement over a 30 second time period = 1; and a score of 0 represented 
100% death (i.e., non-motile). The loss of motility of the adult worms was compared with 
that of respective untreated controls. 
“Worminator” motility system 
 
The open source computer application “WormAssay” as described by [49, 50] is a 
qualitative computer analysis program built to assist in large scale motility assays. The 
WormAssay application (v1.4) utilized an Apple iMac computer running (v10.9.5).  A 
Sony (HDR-CX220) video camera (Sony, Inc.) was used as the HD video capture input 
for macrofilaria assays. Macroscopic, full plate assays were accomplished using a dark 
field illuminator and plate holder constructed similarly to the one built and described by 
[49].  Worminator “Assay Analyzer” option was set to “Lucas-Kanade Optical Flow (Ve-
locity, one organism per well)” with the “Plate Orientation” set to “Bottom-Read” for the 
Brugia adult parasites. Filarial worms where recorded for one minute thirty seconds 
hourly for the first 6 hours and then daily for fifteen days thereafter. The assays were de-
veloped to have high efficiency and reproducibility and yielded objective data that is not 
subject to scorer bias. 
Nanoparticles 
 
For the synthesis of the CPH and CPTEG monomers, the polyanhydride 
polymers, 20:80 CPH:SA , 20:80 CPTEG:CPH, and 50:50 CPTEG:CPH and the 
ivermectin/doxycycline (IVM/DOX) and diethylcarbamazine, albendazole and 
doxycycline (DEC/ALB/DOX) loaded polyanhydride nanoparticles, acetic acid, acetic 
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anhydride, acetone, acetonitrile, chloroform, dimethyl formamide, ethyl ether, hexane, 
methylene chloride, pentane, petroleum ether, potassium carbonate, sodium hydroxide, 
sulfuric acid, and toluene were purchased from Fisher Scientific (Fairlawn, NJ). The 
chemicals 1,6-dibromohexane, 1-methyl-2-pyrrolidinone, hydroxybenzoic acid, N,N-
dimethylacetamide, sebacic acid, and tri-ethylene glycol were obtained from Sigma 
Aldrich (St. Louis, MO). The chemical 4-p-fluorobenzonitrile was purchased from 
Apollo Scientific (Cheshire, UK). For 1H NMR analysis deuterated chloroform and 
deuterated dimethyl sulfoxide were purchased Cambridge Isotope Laboratories (Andover, 
MA). A fluorescent dye, Rhodamine B, was purchased from Sigma Life Science (St. 
Louis, MO). Ivermectin, doxycycline, diethylcarbamazine, albendazole and doxycycline 
were also purchased from Sigma Life Science (St. Louis, MO). 
Polymer Synthesis 
Synthesis of the monomers used, 1,6-bis(p-carboxyphenoxyhexane) (CPH) and 
1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) was performed as described else-
where [47]. 20:80 molar copolymers of CPTEG and CPH and CPH and SA were synthe-
sized through melt condensation polymerization, as previously described in detail [51-53] 
. Molecular weight was confirmed using 1H NMR. 
Nanoparticle Fabrication 
Doxycycline/ivermectin and diethylcarbamazine, albendazole and doxycycline - 
loaded nanoparticles of 20:80 CPH:SA , 28:80 CPTEG:CPH and 50:50 CPTEG:CPH 
were fabricated through solid/oil/oil nanoprecipitation, as previously described [54-56]. 
Drug combinations doxycycline and ivermectin, each at 5% (w/w), with Rhodamine B at 
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2% (w/w) were added to the polymer. Drug combinations, diethylcarbamazine, albend-
azole and doxycycline each at 5% (w/w), with Rhodamine B at 2% (w/w) were added to 
the polymer. The solid drug and polymer mixture was then dissolved in methylene chlo-
ride at a concentration of 20 mg/mL followed by rapid precipitation into the antisolvent, 
pentane. The polyanhydride nanoparticles were then collected using vacuum filtration. 
The drug-loaded particles were characterized for size and morphology by scanning elec-
tron microscopy (SEM, FEI Quanta SEM, Hillsboro, OR). 
Drug release kinetics Drug treatments of B. pahangi  
Ivermectin (22,23-dihydroavermectin B1), doxycycline hyclate (C22H24N2O8  
HCl 0.5H2O  0.5C2H6O), albendazole (C12H15N3O2S), diethylcarbamazine 
(C10H21N3O), were dissolved in DMSO at a final concentration of 0.02% v/v. RPMI 
1640 medium was prepared such that the final concentrations of each drug group tested in 
nanoparticles and soluble were 100, 25, 12.5, 5, 2.5, 1, .0.05, 0.05, 0.005, and 0.005 
μg/ml, respectively. Control medium contained nanoparticles with 2% rhodamine B with 
0.02% DMSO and rhodamine B, but no drug. Individual worms that were previously 
placed into 48 well flat bottom culture plates upon arrival had new fresh medium that 
contained 1 mL of RPMI-1640, 0.01% streptomycin and penicillin and 10% heat-
inactivated fetal calf serum. B. pahangi were incubated at 37° C and 5% CO2 for 1–2 
hours for acclimatization to evaluate baseline motility before the experiment began. The 
nanoparticle-encapsulated drugs and standard antifilarials (i.e., free drug with no nano-
particle encapsulation) were added as previously described above. For example, a dose of 
25 μg of encapsulated drug contained 0.125 mg of nanoparticles w/w. Nanoparticles were 
added to each well, and correspondingly lower amounts of nanoparticles were added as 
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the drug concentrations decreased. Controls received equal amounts of medium but 
lacked the nanoparticles and standard antifilarials. Filariae were incubated at 37°C and 
5% CO2 and monitored for 15 days post-treatment. 
Viability assessment 
 
Reversibility assays where conducted 24 h following a motility score of 0, 
throughout the treatment. Individual worms were transferred to a new 48 well microtiter 
plate, washed 3 times with 37° C PBS, and then 1 mL of the previously described media 
was added. Worms were placed in an incubator at a temperature of 37°C supplemented 
with 5% carbon dioxide (CO2). After 48 h an ocular and “worminator” motility score was 
recorded. Upon completion of reversibility adult female worm viability was assessed 
utilizing a standard 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
(MTT)-formazan colorimetric assay. The same female worms used in the motility assay 
were gently blotted and transferred to a 96 well microtiter plate that contained 0.2 mL of 
1mg/mL MTT in phosphate-buffered saline (pH 7.2) and incubated for 2 h at 37°C. The 
formazan formed was extracted in 0.15 mL of DMSO for 4 h at 23°C, and the absorbance 
was measured at 570 nm using a spectrophotometer (FLUOstar Omega version 1.01). 
The mean absorbance of the formazan from the treated worms was compared with that of 
the controls. The viability of the treated worms was assessed by calculating the percent 
inhibition in motility and MTT reduction over the DMSO-treated control worms. 
MF shedding and motility  
 
The effect of treatments on MF shedding and subsequent motility was assessed 
using two experimental approaches. The direct effect on MF was performed by collecting 
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MF from the spent media of healthy untreated female worms. Spent media was 
centrifuged for 10 min at 200 rcf; the MF were re-suspended in fresh media and 
enumerated by counting using a 14.80 mm² grid plate. Aliquots containing at least 250 
MF were dispensed into wells of a 96 well plate and treated in triplicate with either 
soluble drug, blank nanoparticles or nanoparticles containing drugs as indicated. Wells 
were then monitored and scored daily for MF movement. Motility of MF scoring was 
carried out using a 10X Nikon microscope, and individual scores from five separate fields 
of view (FOV) were averaged to yield a motility score for each well. Scoring was adapted 
from a previously reported method by observing the movements of the anterior and 
posterior body over one min [36]. Data were analyzed by ANOVA and graphs were 
assembled using GraphPad Prism (v6.05). In separate experiments, the effect of treating 
adult female Brugia and their ability to release MF was monitored and recorded for 14 
days. The motility of the shed MF was also recorded. Each experiment, the various 
treatment groups, and the differing concentrations of the drugs were repeated for a 
minimum of three times. 
Nanoparticle uptake by B. pahangi 
 
To understand the interaction between the nanoparticles and the filarial worms, 
recently deceased adult worms (motility score of “0”) from treated and untreated 
experimental groups were fixed and prepared for confocal microscopy. Worms were 
removed from treatment wells, washed twice in pH 7.4 PBS and fixed with 4% 
paraformaldehyde for 1 h at room temperature. Worms were removed, rinsed with fresh 
PBS and mounted carefully onto glass slides using Prolong Gold with DAPI (Life 
Technologies). Slides were then stored in the dark at 4°C before imaging. Imaging was 
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performed using an Olympus IX-71 laser-scanning confocal microscope (Fluoview 2000, 
v2.0) equipped with 405 nm, 488 nm, 559 nm and 635 nm lasers, spectral photomultiplier 
detection and a piezo-controlled stage. Laser power and exposure settings were set 
according to the negative (worms with no rhodamine) and positive (rhodamine containing 
nanoparticles) and maintained constant over all the experiments. Image stacks were 
collected simultaneously for bright field (transmitted light—grey scale), cell nuclei 
(DAPI— blue) and nanoparticles (rhodamine—red). Bright field and cell nuclei were 
used to identify various tissues, organs, and structures in the worm such as oral opening, 
pharynx, uterus, the nerve ring, extracellular secretory apparatus, esophageal track and 
anal pore. Rendering of Z-stack data in three dimensions and minimal image processing 
was performed as described previously by our laboratory [36]using ImageJ v 1.49a 
(NIH). Software parameters for image processing remained constant for all image/data 
sets presented. 
Results  
 
Influence of nanoparticle formulations on the fate of B. pahangi 
 
Prior experiments assessed the benefit of NP encapsulation of IVM/DOX on B. 
malayi filariae revealed a benefit of co-encapsulation into nanoparticles formulated with 
20:80 CPTEG:CPH chemistry. Differences in drug sensitivities for the different antipara-
sitic drugs, thus repeating the NP IVM/DOX in vitro experiments with B. pahangi macro-
filaria to determine if a similar NP benefit exists. Female worms were incubated with de-
creasing amounts of drug concentration and worm motility was observed as previously 
described to quantify the antiparasitic activity (Figue 3-1). NP of the following polymer 
combinations 20:80 CPTEG:CPH, 50:50 CPTEG:CPH, and 20:80 CPH:SA were used to 
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encapsulate IVM/DOX and the fluorescent molecule rhodamine B (Rho). The only sig-
nificant concentration between the nanoparticle formulations shown was the 25 μg/ml 
compared to the soluble. Testing of the effects of blank (i.e., no drug) and 2% Rho nano-
particles and showed no significant differences between the untreated controls. 
Nanoparticle-based drug delivery increased synergism of first-line anti-filarial drug 
activity against B. pahangi female macrofilaria. 
 
The effectiveness of the polyanhydride nanoparticle-based delivery platform was 
compared to that of the standard soluble treatment for the first line anti-filarial and anti-
microbial drugs ivermectin/doxycycline. Single-drug titrations of (Figure 4-2) IVM/DOX 
was administered to female B. pahangi. Through ocular motility scoring the reduced mo-
tility over time was reported to average days to death (A). There were no significant dif-
ferences between the nanoparticle-based delivery and soluble ivermectin/doxycycline 
above 25 μg/ml (not shown). The lower concentrations of NP, provided a ≤ 50% reduc-
tion in the (Fig. 3-2, A) overall time to death when compared to the soluble treated 
worms. The minimum effective concentrations found in the soluble group that reduced 
the overall days to death by <50% was observed at the 25 μg/ml concentration. Worms 
that did not receive either soluble or NP treatment died between 13 and 15 days.  
In conjunction with the average days to death assay, females were monitored for 
motility with the worm assay software. A representative graph is shown at seven days 
post-treatment. Drug concentration responses were calculated using the worms mean 
motility units and percent change, compared to the untreated controls vs. drug 
concentration (Figure 4-2, B). 
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Figure 4-1 Comparison of Polyanhydride nanoparticle formulations on B. pahangi females. An 
average number of days to death of B. pahangi females, utilizing either soluble or encapsulated 
equivalent amounts of IVM/DOX and the Rho dye into three different nanoparticle 
formulation.Significance was determined at p<0.05, 0.01, or 0.001 as noted using a Two-Way 
ANOVA test. 
Hyper-motility was observed, where the motility of the treated parasites increased 
relative to the untreated controls was evident at the lower treatment concentrations in the 
soluble groups. The data indicated that the use of nanoparticle-based delivery 
significantly (p < 0.05) increased the percent inhibition when compared directly to the 
soluble ivermectin/doxycycline. 
Reversibility and viability assays were conducted when the motility score of the 
worm reaches 0. Worms with a motility score of 0 were subjected to reversibility testing 
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whereby after 24 h of no motility, worms were removed from the test media, washed 
three times and placed in fresh media with no drugs. Reversibility of ≥ 20% paralysis was 
found within all soluble concentration groups. The nanoparticle-based platform had one 
female within the 1 μg/ml group reach a motility score of 0 and reverse, but died within 
48 h. These same females were also tested for overall worm viability (as measured by the 
MTT test). Testing of the viability of females (Figure 4-2, C) after 24hrs of reversibility 
testing, was consistent with observed average days to death and changes in motility. A 
representative graph of % MTT inhibition is shown for the 5 and 0.05 μg/ml drug 
concentrations. Inhibition of metabolic activity greater than 75% of that of untreated 
controls indicated that worms were non-viable and declared dead. 
Soluble and nanoparticle-delivered ivermectin/doxycycline cocktail inhibit MF 
production in a time and concentration-dependent manner (Figure 4-2, D). Shedding in 
soluble treated female worms averaged ~70% of untreated at and above 5 g/ml. In con-
trast, NP reduced MF shedding by ~90% over the same at and above 5 μg/ml and ~70% 
at the lowest concentration of 0.05 ug/ml. The effect of NP on MF shedding paralleled 
similar activity on motility of parent female worms. The soluble ivermectin/doxycycline 
at concentrations above 5 μg/ml showed a relatively stable-release of MF for over the 
fourteen days. The minimum effective concentrations that reduced MF shedding by 
higher than 50% for the soluble groups was 5 μg/ml. There's the 
nanoparticle-based delivery system decreased overall shedding ≤ 60% at the lowest 
concentrations of 0.05 μg/ml. 
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NP increases antifilarial activity of diethylcarbamazine, albendazole, and doxycy-
cline 
 
The second-line (Figure 4-3) antifilarials drugs diethylcarbamazine and 
albendazole replaced ivermectin in nanoformulations and combined with doxycycline as 
an anti-Wolbachia agent.  Following synthesis of NP with dec/abz/dox, NP and soluble 
drug suspensions were incubated with female and male B. pahangi worms. Results from 
our independent experiments for observational motility scoring, calculated average time 
to death (ATD), metabolic activity and MF shedding are shown in Figure 4-3. A 
significant (P <0.01) reduction in the average days to death when comparing the NP 
formulations against the soluble controls (Figure 4-3, A). NP formulations at all 
concentrations ranging from 25 ug/ml down to 0.05 ug/ml significantly shortened the 
ATD of female worms compared to soluble controls. Soluble delivery of second-line 
drugs only improved killing over untreated at higher concentrations, while ≥ 1 ug/ml did 
not improve ATD compared to untreated. At the lowest concentration 0.05 μg/ml, the 
ATD of 6.2 days for NP was half the time of both untreated controls and soluble (~13 
days ATD for both). A dramatic result observed was that the lowest concentration of NP 
(0.05 ug/ml) was equivalent to ATD score obtained for the highest soluble concentration 
of 25 ug/ml, demonstrating antiparasitic equivalent activity in NP with 100x less active 
drug.  The soluble dec/abx/dox achieved a similar time to death, in the 5 μg/ml group (8.7 
days) but required 100x more drug then the nanoparticle-based delivery. Automated 
worm motility scoring was also recorded for these experiments, and selected results for 
5.0 and 0.05 ug/ml are shown for day 7 post-treatment in Panels B and C (Figure 4). 
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Figure 4-2 Effects of antibiotics on B. pahangi female worms. Female worms were incubated 
with a single concentration of soluble or encapsulated ivm/dox.  (A) Average days to death (B) 
Percent inhibition MF motility based on Worm Assay Software. (C) Reversibility Assay-Percent 
Metabolic Inhibition. Dash line denoted if a tested group is considered effective if there is a 75% 
or greater inhibition of formazan formation compared to untreated controls. (D) Total viable MF 
shed by B. pahangi worms relative to control worms.  
 
Concentration-responses were calculated using the previously mentioned parameters and 
compared to the untreated controls (Figure 4-3, B). Automated scoring results confirmed all 
significant findings that employed observational scoring. Interestingly, motility in the lower 
concentration 0.05 μg/ml for the soluble group consistently exceeded motility of untreated. At 
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the higher concentrations reported 5 μg/ml, there was no significance found between the 
two groups.   
 
 
 
Figure 4-3 Effects of second-line antibiotics diethylcarbamazine/albendazole/doxycycline on B. 
pahangi female worms. Four independent experiments were conducted against Brugia female and 
males (not shown) worms. A total of at least five worms were incubated with a single dose titra-
tion of soluble or encapsulated DEC/ABZ/DOX. (A) Average time to death (B) Percent inhibition 
of motility based on Worm Assay Software. (C) Reversibility Assay-Percent Metabolic Inhibi-
tion. (D) Total MF Shed by B. pahangi worms relative to control worms 
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Reversibility and viability (Figure 4-3, D) assessment was conducted as previously 
described. Reversibility was similar to that of the IVM/DOX groups of ≥ 27% reversibility 
occurred within the soluble groups. The nanoparticle-based platform had one female within the 
1μg/ml group reach a motility score of 0, and upon transferring into the control media, reversed 
but died within 24 h. In addition to motility, worm viability was also assessed using an MTT 
assay (Figure 4-3, C). The nanoparticle-based delivery platform provided the most significant 
metabolic inhibition for the 5 and 0.05 μg/ml drug concentration. Inhibition of metabolic activity 
higher than 75% of that of untreated controls indicated that worms were non-viable and declared 
dead. 
Monitoring for the total number of (i.e, viable and dead) MF shed by the female 
worms (Figure 4 panel D) was also conducted. The use of dec/abz/dox inhibited total MF 
shedd of viable Brugia females in a concentration-dependent manner. The soluble 
dec/abz/dox at concentrations above ≤ 5 μg/ml showed minimal effectiveness against MF 
shedding in Brugia females.  The minimum effective concentrations that reduced MF 
shedding by higher than 50% for the soluble groups was 5 μg/ml. Where'as the 
nanoparticle-based delivery system decreased overall viable MF shed ≤ 90% at all 
concentrations tested.  
Similar to the effects observed for adults, the average time to death of the MF 
treated (Figure 4-1) with the soluble drugs was significantly (p < 0.001) higher in 
comparison to that of the MF that were treated with the nanoparticle-based delivery 
system, especially at low drug concentration in the dual ivm/dox ( Figure 4-4, A) group. 
The nanoparticle-based delivery system achieved a < 50% reduction in the time to death 
when compared to control cultures of ivermectin/doxycycline. All of the motility reduc-
tions at these concentrations are statistically significant (p < 0.01). However, the decrease 
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in time to death for the nanoparticle-based delivery of dec/abz/dox (Figure 4-4, B) the 
was only statistically significant (p < 0.05) at the 5 μg/ml concentration. The soluble 
diethylcarbamazine/albendazole/doxycycline had only minor effects on MF motility. 
Confocal microscopy     
 
To visualize the interactions of polyanhydride nanoparticles with B. pahangi fe-
male worms were treated with a cocktail of ivermectin/doxycycline with equivalent 
amounts rhodamine red dye either in soluble form or encapsulated within the 20:80 
CPTEG:CPH nanoparticles. Detection of focal, intense rhodamine staining is consistent 
with the size and staining patterns of intact nanoparticles. In comparison, diffuse red 
staining is indicative of free rhodamine. Worms were treated for 24 h with 25 µg of the 
soluble drug cocktail and 20:80 CPTEG:CPH nanoparticle cocktail to determine accumu-
lated rhodamine within tissues (Figure 4-5).  
Images demonstrate the accumulation of nanoparticles within tissues throughout 
the worm (Figure 4-5, B) as compared to the soluble rhodamine (Figure 4-5, A) showing 
minimal accumulation within the body of the worm. Diffused red staining was quantified 
through mean intensity fluorescence (MIF) in both the soluble and nanoparticle treated 
worms (Figure 4-5, C). The MFI revealed the presence of rhodamine throughout the inner 
tissues of the worms. The total accumulated rhodamine showed increased internal stain-
ing of worms treated with 20:80 CPTEG:CPH nanoparticles. Additionally, over a period 
of 72 hours (Figure 4-6), a lower dose of 12.5 µg of diethylcarbamazine/albend-
azole/doxycycline encapsulated within the 20:80 CPTEG:CPH nanoparticles also con-
taining the rhodamine red dye, extensively labeled the interior structures of female 
worms (Figure 4-6, B). 
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Figure 4-4 Effects of antibiotics on B. pahangi MF motility. MF where cultured with soluble or 
encapsulated antibiotics, and motility was observed over fourteen days. Results shown are aver-
age days to death.  
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Figure 4-5 Confocal microscopy of female B. pahangi with nanoparticles and soluble controls. 
Worms were incubated for 72 h with either soluble controls (A) or 20:80 CPTEG:CPH nanoparti-
cles containing ivermectin (IVM), doxycycline (DOX), and rhodamine B (B) fixed and imaged 
by LSCM. Controls contained 25 μg each of IVM and DOX, and 0.25 μg rhodamine B, while the 
nanoparticles contained 25 μg of each drug and 0.25 μg of rhodamine B.  Colors represent bright 
field image composite, DNA-Dapi (blue), rhodamine (red) and right panels are the respective 
bright field only. Images were collected using identical image acquisition settings. Representative 
images shown demonstrate the accumulation of nanoparticles within tissues throughout the worm 
(B) as compared to the higher amount of soluble rhodamine (A) showed minimal accumulation 
within the body of the worms. Mean fluorescence intensity (MFI) (C) of B. pahangi female 
worms shown in the relative distribution of rhodamine B comparing (A) soubly treated and (B) 
NP treated worms. Bar graphs represent mean ± SD (paired T-test) of relative MFI from ten 
equal-sized regions of interest quantified by Image J Software.       
 
Three-dimensional reconstruction of confocal Z-stacked images shows the pres-
ence of nanoparticles and release of rhodamine within inner tissues of the worm (Figure 
4-6, C). The presence of intact nanoparticles was found distributed throughout the inter-
nal reproductive organs of the worm (Figure 4-6, D).  
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Figure 4-6 Confocal microscopy of female B. pahangi with nanoparticles. (A) A schematic 
drawing is representing a female B. pahangi. Females range in length from 45-55 mm by 130-170 
μm in width. Worms were incubated for 72 h with (B) 20:80 CPTEG:CPH nanoparticles contain-
ing DEC/ABZ/DOX, and rhodamine B, fixed and imaged by LSCM. Nanoparticles contained 
12.5 μg of each drug and 0.125 of rhodamine. B Panel A is bright field image composite, rhoda-
mine (red), DNA-Dapi (blue), and far right panel are the respective individual bright field. Inset 
box within the nanoparticle-treated worm outlines the area selected for side view rendering. Rep-
resentative images are shown (C) demonstrate the accumulation of nanoparticles (arrows) within 
tissues throughout the worm. Panel D a composite image of dapi (blue) and rhodamine B (red) 
outlining the accumulation of nanoparticles within specific reproductive organs of the female 
worm. Similar results were seen throughout the body of the worm in both male and female worms 
(data not shown). 
 
Discussion 
 
The most significant barrier to the implementation of antibiotic chemotherapy for 
Lymphatic filariasis has been the duration of the regimen required for permanent 
sterilization of female worms, or potent macrofilaricides [22]. The pathology of 
lymphatic filariasis is thought to be dependent on the presence of the adult worm and 
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interruption can bring direct relief to individual patients. The use of antifilarials such as 
Diethylcarbamazine is primarily useful as a microfilaricide and partially effective 
macrofilaricide. Ivermectin and albendazole are broad-spectrum anthelmintics that have 
been shown to decrease the prevalence through interruption and transmission of MF [57]. 
Currently, the use of doxycycline or tetracyclines as a safe and effective drug for adult 
macrofilaria sterilization has been shown to be effective at targeting the symbiont 
Wolbachia. The incorporation of doxycycline has also been shown to have long-term 
embryostatic effects [24, 58, 59]. However, previously published doxycycline regimens 
are lengthy, and a shorter regimen is desirable to complement classical anti-filarial drugs. 
Such studies have highlighted the use of other drugs active against rickettsia-like 
organisms such as rifampicin. These studies have found that short course, high 
concentration therapies provide comparable depletion of the symbiont Wolbachia thereby 
reducing the embryogenic capacity within macrofilariae [59]. However, Rifampicin is a 
known potent inhibitor of cytochrome P450 enzymes (CYPs) which are clinically 
relevant in the metabolism and elimination of drugs.  
The present studies have confirmed our previous research that focused on the effects of 
encapsulated antibacterial antibiotics on Brugia malayi and extended our understanding 
of this topic in several ways [15]. In this study, we report the use of a polyanhydride 
nanoparticle-based carrier to efficiently reduce the amount of drug necessary for 
macrofilariae death by up to 200-fold compared to physiologically relevant doses. The 
three polymer combinations (Figure 4-1)  20:80 CPTEG:CPH, 50:50 CPTEG:CPH, and 
20:80 CPH:SA each containing encapsulated Ivermectin and Doxycycline at various 
concentrations. The use of a nanoparticle only formulation(i.e., no drug) and found 
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minimal activity against Brugia. The nanoparticle formulations (Figure 4-1) were 
relatively similar in their effectiveness in the delivering of drugs to Brugia adults. There 
were slight differences in the higher concentrations tested, this small decrease in killing 
time for the 20:80 CPH:SA group is due to the increased amounts of SA and decreased 
relative quantities CPH content. This polymer combination results in a more rapid release 
of the encapsulated drug, which is consistent with previous work. The 20:80 
CPTEG:CPH group provided the most systematic killing between the formulations. 
Previous work has shown that this copolymer composition contains weakly segregated 
CPTEG- and CPH-rich domains [60]. This composition may indicate a preferential 
partitioning of the hydrophobic ivermectin to the slowly degrading CPH-rich domains of 
the copolymer; this may explain the slight differences between the killing time of the 
nanoparticles tested. 
Both soluble ivermectin/doxycycline and diethylcarbamazine/albend-
azole/doxycycline (Figure 4-2) provided a minimal macrofilaricidal activity for the con-
centration ranges tested. The polyanhydride nanoparticle drug delivery platform de-
creased the average time to death of B. pahangi females and facilitated a reduction in the 
total number of the MF shed as shown in Figure 4-2. Rapid killing would likely 
contribute to the dramatic reduction in shedding by female worms at low nanoparticle 
concentrations (Figure 4-2, C and D).  The use of diethylcarbamazine/albend-
azole/doxycycline was most effective as a microfilaricide (Figure 4-4). It is also likely 
that the nanoparticles increased the rate of delivery of ivermectin and rapidly paralyzed 
the muscles within the body of the worm as well as the vulva, which is needed to expel 
the MF.  Similar trends were also observed in the MF to a slightly lesser extent in the 
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ivermectin/doxycycline groups possibly reflecting the comparatively lower number of 
Wolbachia in MF compared to female macrofilariae (Figure 4-4).The diethylcarbamaz-
ine/albendazole/doxycycline nanoparticle groups a significant reduction in viability of the 
MF over the course of treatment.  
As discussed above, the encapsulation and subsequent controlled release of the 
drug and the ability of the polyanhydride nanoparticle carriers to localize to the worm cu-
ticle surface, and even be internalized by the worms, lead to a higher microenvironment 
concentration of the drugs. In contrast, the soluble drug cocktail is in an aqueous form, 
and so to create the same concentrations internally to the worm, more drug must be 
administered initially to cross the complex cuticle surface. This is supported by the 
confocal microscopy data in Figure 4-5 and 4-6, which show that the polyanhydride 
nanoparticles readily localize to the worm, increasing the concentration of the 
internalized dye as compared to the soluble control.  The confocal microscopy data in 
Figure 4-6 provides an initial observation of the strong interactions between polyanhy-
dride nanoparticles and the cuticle surface, which is hypothesized to lead to the efficacy 
profile of this nano-carrier platform. Tracking (Figure 4-5, C) the fluorescent rhodamine 
B co-loaded into the nanoparticles demonstrated a more significant increased influx of 
payload into the worm compared to drug and dye delivered solubly. In addition to 
providing sustained release of the drug, the drug-loaded polyanhydride nanoparticles 
demonstrated enhanced internalization by Brugia worms. The enhanced internalization 
properties are evident based on the exposure amount and total retained dye. We speculate 
that the nanoparticles undergo facilitated diffusion into the worm, by crossing the cuticle, 
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penetrating the hypodermis membrane barriers and accessing deeper tissues within the 
worm [61, 62].  
This data taken together provides us the necessary tools and understanding to 
incorporate the use of a nanoparticle-based delivery platform. This platform can 
efficiently target the symbiont Wolbachia through use of encapsulated antimicrobials 
thereby interrupting embryogenesis.  It is also evident that utilization of this type of 
delivery system can directly target and eliminate the macrofilaria. This can be achieved 
through interrupting the spread of disease and reducing the drug concentrations necessary 
to eliminate and effectively clearing the disease.    
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Abstract 
 
Mycobacterium marinum is a waterborne pathogen responsible for tuberculosis-
like infections in ectotherms and is an occasional opportunistic human pathogen. M. 
marinum is the closest genetic relative of the M. tuberculosis complex and as such is the 
most reliable in testing for drug susceptibility. The use of a multi-drug therapy has be-
come the standard treatment for tuberculosis. The Mycobacterium species show a high 
degree of inherent resistance to most antibiotics and chemotherapeutic agents due to their 
unique cellular membrane. The cell walls high lipid content, and unusual structure forms 
an impenetrable barrier that inhibits the entry of hydrophilic/hydrophobic antitubercular 
drugs. Herein, we describe a method utilizing amphiphilic polyanhydride nanoparticles as 
a drug delivery system against Mycobacterium, in developing a new drug delivery 
platform that can overcome the multi-facilitated inherent resistant nature of the bacteria. 
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Results showed that the use of the polyanhydride nanoparticle increased internalized by 
macrophages, efficiently trafficked to lysosomes, and release antituberculosis drugs 
intracellularly. Our results are consistent with nanoparticles improving the elimination of 
intracellular Mycobacteria by increasing intracellular targetting of the antimicrobial drug 
cocktail. Combined with previously published results illustrating the capacity of NP to 
enhance soluble delivery of antibiotics against intracellular pathogens,, these data support 
the use of polyanhydride nanoparticles as a versatile platform that can dramatically 
improve intracellular targetting with potential use as a treatment against Mycobacteria 
infections. 
Introduction 
 
The world health organization (WHO) has reported that in 2016, 6.3 million new 
cases of Mycobacterium tuberculosis were reported and nearly 1.3 million individuals 
died as a result [1]. M. tuberculosis is the ninth leading cause of death worldwide and the 
leading cause of death from a single infectious agent [1, 2]. Of these individuals infected 
almost 10% of the new cases reported were found to be resistance to the first line drugs, 
rifampicin and an additional 5% of new cases reported multi-drug resistance (MDR-TB) 
strains. These strains are reported to be resistant to at least rifampicin (RIF) and isoniazid 
(INH) [3-5]. Individuals that succumb to this disease could be prevented with appropriate 
treatment and diagnosis. The clinical features of tuberculosis (TB) infection include mul-
tistage processes of primary infection, latency, and reactivation. Years of efforts have 
been made to reduce the adverse treatment and develop an understanding of the patho-
genesis of the organism [6-8]. Researchers have used multiple mycobacteria species to 
study the pathogenesis and resistance mechanisms of tuberculosis, including M. 
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smegmatis, M. bovis, and M. marinum.  Of these models, the nontuberculous M. marinum 
is the closest genetic relative of the M. tuberculosis complex [9] and causes TB-like gran-
uloma formation in ectotherms [10]. Eighty-five percent of M. marinum loci encoding 
recognized virulence genes have homologous genes in M. tuberculosis [11]. Thus, due to 
its similar pathogenicity, granuloma formation, as well as latency profile M. marinum, is 
widely used as a model to study infections, and drug screening has been evaluated [11-
14]. 
 Nontuberculous mycobacteria (NTM) are responsible for a multiplicity of differ-
ent types of infections, including respiratory, cutaneous, and systemic [15], of which 
many of the species of NTM are multidrug-resistant [16], including M. marinum. M. 
marinum is an atypical bacilli’s that are reported to be resistant to the anti-tuberculosis 
medications isoniazid, pyrazinamide, and para-aminosalicylic acid and shows intermedi-
ate sensitivity to streptomycin [17, 18].  Unlike M. tuberculosis slow growth rate of 3-6 
weeks, M. marinum grows within 1-2 weeks. This faster growth rate allows for a model 
that can be correlated to effective drug susceptibility in vitro. 
 Another hurdle in the testing of Mycobacterium is there complex cellular wall 
[19, 20] and the use of antibiotics with a hydrophilic/hydrophobic nature [21, 22], as well 
as the use of prodrugs (metabolically activated) in the treatment of TB [23, 24]. Most sol-
uble free drugs have been found to be internalized within macrophages [25, 26] and 
stored within the lysosomes, where the bioactivity of the drug is low [27]. Mycobacte-
rium’s ability to prevent the enzymatic conversion of these prodrug antibiotics [28] inter-
feres with the capacity to act efficiently upon the bacteria due to their slow growth rate 
[29] and failure to co-localize efficiently within Mycobacteria containing endosomes.  
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Therefore, limited intracellular activity against non-replicating bacteria is often found. 
Because the therapeutic efficacy of most drugs has been well recognized, inefficient de-
livery could result in an insufficient therapeutic index, causing persistent and latent infec-
tion.  
One approach to improving the efficacy of single drug therapy has been to design 
treatment regimens based on the pharmacodynamics of antibiotics over time. Current 
treatment for M. marinum infections includes the use of the antibiotics streptomycin and 
gentamicin, with doxycycline as an emerging alternative therapy. Although fluoroquin-
olones such as ciprofloxacin have demonstrated success in research settings, these drugs 
are not widely used on humans. Additionally, treatment must be administered rapidly af-
ter the onset of symptoms for optimal efficacy [30].   
Previous research has demonstrated the increased drug efficacy, distribution, and 
sustained antiparasitic effects of co-encapsulating the antimicrobials doxycycline along 
with multiple antifilarials overextend time points (i.e., up to 14 days) with polyanhydride 
nanoparticles [31]. These nanoparticles were based on 1,6-bis(pcarboxyphenoxy)hexane 
(CPH) and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG). With the use of these 
polymer and copolymer combinations, synergism was observed between drug and encap-
sulation into nanoparticles resulting in increased antimicrobial activity through the sus-
tained release of sub-inhibitory concentrations. Varying polymer and copolymer chemis-
try combinations of the nanoparticle contributed to the antimicrobial activity of different 
drug combinations. In this work, the effect of nanoparticle chemistry was analyzed 
against the intracellular pathogen M. marinum. The use of the agar dilution method is 
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considered the most accurate reference method for Mycobacterium marinum drug suscep-
tibility testing [32]. The development, effectiveness and increased susceptibility of a pol-
yanhydride nanoparticle delivery system were explored using the first line antitubercular 
drugs rifampicin, isoniazid, pyrazinamide and ethambutol against M. marinum.  
Materials and methods 
Nanoparticles 
For the synthesis of the CPH and CPTEG monomers, the polyanhydride 
polymers, 20:80 CPH:SA , 20:80 CPTEG:CPH, and 50:50 CPTEG:CPH and the 
rifampicin, isoniazid, pyrazinamide and ethambutol-loaded polyanhydride nanoparticles, 
acetic acid, acetic anhydride, acetone, acetonitrile, chloroform, dimethyl formamide, 
ethyl ether, hexane, methylene chloride, pentane, petroleum ether, potassium carbonate, 
sodium hydroxide, sulfuric acid, and toluene were purchased from Fisher Scientific 
(Fairlawn, NJ). The chemicals 1,6-dibromohexane, 1-methyl-2-pyrrolidinone, hy-
droxybenzoic acid, N,N-dimethylacetamide, sebacic acid, and tri-ethylene glycol were 
obtained from Sigma Aldrich (St. Louis, MO). The chemical 4-p-fluorobenzonitrile was 
purchased from Apollo Scientific (Cheshire, UK). For 1H NMR analysis deuterated chlo-
roform and deuterated dimethyl sulfoxide were purchased Cambridge Isotope Laborato-
ries (Andover, MA). A fluorescent dye, Rhodamine B, was purchased from Sigma Life 
Science (St. Louis, MO).  Rifampicin, isoniazid, pyrazinamide, and ethambutol were also 
purchased from Sigma Life Science (St. Louis, MO). 
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Polymer Synthesis 
Synthesis of the monomers used, 1,6-bis(p-carboxyphenoxyhexane) (CPH) and 
1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) was performed as described else-
where [33]. 20:80 molar copolymers of CPTEG and CPH and CPH and SA were synthe-
sized through melt condensation polymerization, as previously described in detail [34-36] 
. The molecular weight was confirmed using 1H NMR. 
Nanoparticle Fabrication 
Rifampicin, isoniazid, pyrazinamide, and ethambutol -loaded nanoparticles of 20:80 
CPH:SA and  28:80 CPTEG:CPH were fabricated through solid/oil/oil nanoprecipitation, 
as previously described [37-39]. Drug combinations Rifampicin and pyrazinamide, each 
at 5% (w/w), with Rhodamine B at 2% (w/w) were added to the polymer. Drug combina-
tions, isoniazid and ethambutol each at 5% (w/w), with Rhodamine B at 2% (w/w) were 
added to the polymer. The solid drug and polymer mixture was then dissolved in meth-
ylene chloride at a concentration of 20 mg/mL followed by rapid precipitation into the 
antisolvent, pentane. The polyanhydride nanoparticles were then collected using vacuum 
filtration. The drug-loaded particles were characterized for size and morphology by scan-
ning electron microscopy (SEM, FEI Quanta SEM, Hillsboro, OR). 
Bacterial strains and growth conditions 
M.marinum (ATCC 927)  was propagated at 30°C either in Middlebrook 7H9 
broth (Difco) containing 10% oleic acid-albumin-dextrose-catalase (Difco) and 0.05% 
Tween 80 (Sigma) or on Middlebrook 7H10 agar containing 10% oleic acid-albumin-
dextrose-catalase. Frozen stocks were prepared by growing bacteria in 7H9 broth to mid-
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log phase (optical density at 600 nm [OD600], ∼0.5), collecting cells by centrifugation, 
washing once with phosphate-buffered saline containing 0.05% Tween 80 (PBST), add-
ing glycerol to 15%, and storing in aliquots at −80°C. Bacterial stocks were titered by 
plating PBST-diluted bacterial suspensions on 7H10 agar and scoring colonies after 1 
week at 30°C.The recombinant strain of M. marinum expressing the green fluorescent 
protein (M. marinum- GFP) bears an integrative plasmid (pGFPHYG2). The pGFPHYG2 
was a gift from Lalita Ramakrishnan (Addgene plasmid # 30173), and electroporation 
and selection of transformants were carried out as previously described [40]. 
Drug solutions were prepared at concentrations of 20 mg/ml (PZA; Sigma-Al-
drich) and 2 mg/ml in distilled water (INH, and EMB; Sigma-Aldrich) or dimethyl sul-
foxide (RIF; Sigma-Aldrich), filter sterilized and frozen until used.  
Cells and culture conditions 
The human monocytic cell line THP-1 was cultured in RPMI 1640 medium 10% 
(v/v) heat-inactivated fetal bovine serum. Suspension cultures of THP-1 cells were main-
tained at a cell density between 5 x 105 and 1 x 106 cells/ml of cell culture medium and 
split twice per week. THP-1 cells growing in suspension were harvested at a density of 1 
× 106 cells/ml, resuspended in fresh medium supplemented with 5 nM phorbol myristic 
acid (PMA) to differentiate the cells into adherent monocytes, and placed into 96 well 
tissue culture plates or 24-well tissue (Costar) culture plate containing sterile #1 glass 
coverslips in each well. After overnight culture in the presence of PMA, adherent cells 
were washed three times gently with phosphate-buffered saline (PBS; pH 7.4) and 
incubated for an additional 24 h in complete RPMI 1640 medium with no PMA.  
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Broth microdilution method 
Antibiotic testing against M. marinum was determined in 7H9 broth by the stand-
ard microdilution method. Briefly, 0.1-ml of a 0.1 mg ml-1 dilution of previously men-
tioned drugs were added to a 96-well plate. Control wells included medium and culture 
controls. One hundred microliters of culture (at 0.5 x 106 CFU/ml) was added to all the 
wells except the medium control wells. The plates were incubated at 30°C for up to 72 h. 
Following each incubation time intervals, twenty microlitres of each bacterial suspension 
were serially diluted in PBS and aliquots of triplicate were plated onto Middlebrook 
7H10 or 7H11 media. The plates were sealed and incubated for 1-2 weeks at 30°C. Ex-
periments were conducted in triplicate and the standard deviation is depicted on graphs 
unless otherwise stated. 
Intracellular survival of Mycobacterium  
  THP-1 cells used for evaluation of the intracellular survival of M. marinum were 
treated similarly as previously described in 96-well flat-bottom tissue culture plates. Bac-
terial suspensions were prepared and generated by scraping 14 d cultures of the M. mari-
num grown on Middlebrook 7H10 agar into screw-cap microfuge tubes containing 7H9 
media and incubated for 96 h. Pellets of bacteria were resuspended through mechanical 
disruption and numbers of bacteria present in the suspensions were determined by optical 
density at 600 nm measurements[41]. These suspensions were used to generate dilute my-
cobacteria using complete RPMI 1640 medium whereby the bacterial density was ad-
justed to desired levels to account for variations in the numbers of target monocytes. Sus-
pensions of bacteria were added to monocyte monolayers at a multiplicity of infection 
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(bacteria/monocyte ratio) of 1:1 and 10:1. Tissue culture plates were gently agitated by 
hand and then centrifuged at 4°C for 10 min at 270 x g. Moreover, transferred to an incu-
bator for 90 min 37°C with 5% CO2 to allow for phagocytosis of bacteria. Monolayers 
were washed three times with PBS to remove any remaining nonadherent bacteria. Fresh 
RPMI-1640 with 10 ug/ml gentamicin complete media was added following the last 
washing. The viability of intracellular Mycobacterium was determined by lysing mono-
cytes with 0.1% deoxycholate, diluting suspensions in PBS, and plating aliquots in tripli-
cate on Middlebrook 7H10 medium. The plates were sealed and incubated for up to 14 
days at 30°C. Total cfu/ml of bacterial survival at 24, 48 and 72 h were calculated based 
on the number of internalized bacteria detected at 2 h postinfection which represents 
100% of internalized bacteria.  All minimum inhibitory concentration testing and presen-
tation was conducted under the Clinical and Laboratory Standards Institute (CLSI) rec-
ommendations (CLSI., 2015). Experiments were performed in triplicate and the standard 
deviation is depicted on graphs unless otherwise stated 
Immunofluorescence microscopy. 
Coverslips harboring the adherent and infected monocytes were fixed with freshly 
prepared 4% paraformaldehyde in PBS (pH 7.4) at room temperature for a minimum of 
20 min. Following fixation, differential staining was initiated by washing monolayers 
with cold PBS, followed by incubating coverslips in PBS at 1 h at 4°C successively with 
mouse Lamp-1 antibody (1/200), followed with IgG-specific anti-rabbit secondary anti-
bodies conjugated with Alexa 647 fluorochromes (1/200) [42]. Monolayers were 
routinely permeabilized with bovine serum albumin-PBS solution containing a final con-
centration of 0.1% saponin (BSP). Incubations with primary and secondary antibodies (at 
127 
 
 
concentrations indicated above) were at room temperature 4 h, at which time coverslips 
were washed three times with cold BSP and affixed to a glass slide with Pro-long mount-
ing solutions. Immunofluorescence microscopy was performed using an Olympus IX-81 
laser-scanning confocal microscope (Fluoview 2014, v4.2) equipped with 405 nm, 488 
nm, 559 nm and 635 nm lasers, spectral photomultiplier detection and a piezo-controlled 
stage. Inverted Olympus IX-71 fluorescence microscope equipped with environment 
control chamber, vibration table. 4 filter sets for imaging DAPI, GFP/FITC and 
TRITC/Texas Red equipped with zenon Arc lamp, Nipkow-Confocal Module, high 
resolution-Hamamatsu CCD, and Metamorph Imaging Suite for microscope automation 
and image capture/analysis software (v. 4.12) . Fields of view were imaged using 40x 
apochromatic objective, and all image exposure conditions were maintained throughout 
the experiment. Minimal image processing was performed as described previously by our 
laboratory using ImageJ v 1.51n (NIH) [31]. Software parameters for image processing 
remained constant for all image/data sets presented. 
Results 
 
 Antimicrobial activity of single-drugs in broth cultures 
To assess the benefits of encapsulating antitubercular drugs into NP, we began by 
examining the antimicrobial activity of first-line drugs individually against broth cultures 
of M. marinum. Early log phase M. marinum cultures were exposed to rifampin, pyra-
zinamide, isoniazid and ethambutol in a single soluble concentration or encapsulated into 
nanoparticles. Following 48 hours of incubation, aliquots of cultures were serially diluted 
and plated on a solid agar medium to enumerate viable bacteria. Individual drug sensitiv-
ity results for single drugs tested against M. marinum are presented in detail in Figure 5-1. 
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Bacterial counts from untreated were used to set the limit representing inhibition of 90% of M. 
marinum (MIC90). The calculated MIC90 concentrations for the 4 soluble drugs fell within ex-
pected ranges for rifampicin at 2 μg/ml, ethambutol at 20 μg/ml, isoniazid at 5 μg/ml and greater 
than < 32μg of pyrazinamide. M. marinum is inherently resistant to pyrazinamide due to poor 
membrane diffusion owed to unique membrane permeability for this species. NP formulations 
containing rifampicin with 20:80 CPTEG:CPH chemistry reduced the MIC90 to 0.09 μg/ml, and 
20:80 CPH:SA (1.25 μg/ml). MICs for isoniazid in the 20:80 CPTEG:CHA group (5 μg/ml), 
MIC50 for ethambutol and pyrazinamide (20 μg/ml).  MICs for 20:80 CPH:SA for ethambutol, 
isoniazid, and pyrazinamide all exceeded CSLI breakpoints. There appears to be a linear growth 
trend that is neither drug nor concentration-dependent. 
The effectiveness of multi-tubercular drugs  
Results from the single drug assay provided the necessary information for con-
struction of a dual-encapsulated nanoparticle Figure 5-2. Encapsulation of first-line drugs 
rifampicin and pyrazinamide, into either 20:80 CPTEG:CPH or 20:80 CPH:SA. A single 
concentration of either soluble and or encapsulated rifampicin/pyrazinamide in nanoparti-
cles appears to improve the pyrazinamide’s mode of action against M. marinum. Use of 
NP with encapsulated rifampicin/pyrazinamide reduced the bacterial concentration 1.45 
logs CFU (± 0.05) when compared to the single PZA drug. This 10 % reduction in viable 
bacteria was found at the 0.05μg/ml concentration for (A) 20:80 CPTEG:CPH. The 20:80 
CPH”SA NP (C) provided a 1.59 log CFU (± 0.10) reduction. This is in stark contrast to 
the soluble groups.  
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Figure 5-1 M. marinum drug sensitivity profiles for rifampicin and other antibiotics in broth cul-
ture model. Drug susceptibility of M. marinum in broth culture media after 48 h exposure to (A) 
rifampicin, (B) pyrazinamide, (C) isoniazid, and (D) ethambutol as a single treatment dose of sol-
uble or encapsulated in 20:80 CPTEG:CPH nanoparticle. All data are represented as Colony 
forming units/ml (CFU). 
 
Interestingly, the addition of rifampicin with pyrazinamide reduced the antimicro-
bial activity measured for rifampicin alone, suggesting an antagonistic relationship be-
tween the administration of these drugs. This reduction in antimicrobial activity was 
observed in both soluble and NP delivered groups while less dramatic for the 20:80 
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CPTEG:CPH formulation improve upon rifampicin alone in NP. In contrast, the combi-
nation of ethambutol with isoniazid improved bacterial killing at higher concentrations 
and NP treated cultures had significantly lower CFU at both 32 µg/ml and 8 µg/ml. Inef-
fectiveness of ethambutol was improved with the addition of isoniazid when used in the 
(B) 20:80 CPTEG:CPH nanoparticle. The concentration of 0.125 μg/ ml a 1.28 log CFU 
(± 0.29) reduction in bacteria which resulted in a 9 % decrease of viable bacteria com-
pared to the single drugs. The continued trend for either 20:80 CPH:SA (D) or the soluble 
groups. Also, there appears to be a biphasic growth trend emerging that may be both time 
and concentration-dependent, this was not observed for the single drug experiments.  
Antimicrobial delivery of RIPE in broth cultures 
The combinations of rifampicin/pyrazinamide and isoniazid/ethambutol exhibited 
time-and concentration-dependent anti-tubercular activity against M. marinum (Figure 5-
2). Currently recommended therapy for active tuberculosis infections is the co-admin-
istration of all for drugs. Since the dual delivered drugs yielded combinations that were 
either antagonistic (RIF/PYR) and synergistic (INH/ETH), all subsequent experiments 
examined the benefits of NP delivery with the 4 drug cocktail of rifampicin, isoniazid, 
pyrazinamide, and ethambutol (RIPE). The use of 20:80 CPTEG:CPH with the drug 
cocktail RIPE (Figure 5-3) provided the most significant benefits of all groups tested.  
Initial results revealed that a more extended incubation period was needed for 
RIPE drug testing than that used for single or paired combination. The use of the 20:80 
CPTEG:CPH nanoparticle provided us a tenfold reduction in MIC when compared to the 
soluble group (20:80 CPH:SA not shown). A time and concentration-dependent reduction 
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of bacterial viability were observed that maximized killing for the nanoparticle delivery 
of drugs after an initial lag period of 24–48 h.  
 
 
 
Figure 5-2 The killing of M. marinum is enhanced by using nanoparticles loaded with either ri-
fampicin/pyrazinamide or isoniazid/ethambutol in broth. (A) 20:80 CPTEG:CPH RIF/PZA, (B) 
20:80 CPTEG:CPH IHN/EMB, (C) 20:80 CPH:SA RIF/PZA, and (D) 20:80 CPH:SA INH/EMB. 
Colony forming units/ml were enumerated at 48 hrs post-infection and compared with the 
CFU/ml values for soluble treated bacteria. (Student’s T-test p values * < 0.1, ** < 0.01). 
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Figure 5-3 The effectiveness of four drug cocktail against M. marinum. * indicates a significant 
reduction in bacterial CFU compared to monocyte cultures treated with soluble drug cocktail at p 
< 0.01. 
 
Intracellular fate of Mycobacterium and NP-RIPE  
 
To test the effectiveness of the nanoparticles on intercellular viability M. marinum 
was tested with the human monocyte model (THP-1) which has been used (Figure 5-4.) 
to examine intracellular growth rates of Mycobacterium. Established intracellular infec-
tion procedures with Mycobacterium avium subspecies paratuberculosis, employed a 
multiplicity of infection (MOI) consisting of a bacteria to macrophage ratio low MOI of 
1:1 with a single time point of 48 h. A single concentration of either soluble or encapsu-
lated RIPE with either 20:80 CPTEG:CPH or 20:0 CPH:SA. Mycobacteria remain viable 
(CFU/ml determination) after 48 h with single soluble drug treatment. Our results showed 
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that at least during the 48 h, THP-1 macrophages in combination with soluble drug cock-
tail RIPE were only able to provide a 1.69 log CFU (± 1.30) reduction in bacterial counts 
compared to untreated. In contrast, the nanoparticle 20:80 CPTEG:CPH provided a 6.10 
log CFU (± 0) reduction and showed no viable mycobacterium after 48 h. 
 
Figure 5-4 The killing of intracellular M. marinum is enhanced by using nanoparticles loaded 
with an antibiotic. THP-1 monocytes were infected with M. marinum at an MOI 1:1 to establish a 
productive intracellular infection. At 24 h, infected cultures were supplemented with 10 μg/mL of 
either soluble RIPE or encapsulated into polyanhydride particles. Following additional 48 h 
incubation, nontreated and drug-treated cells were washed and lysed to release intracellular 
bacteria. The lysate was subsequently serially diluted and plated on solid agar medium. Mean 
counts of bacteria for untreated cells were 1.1 x 104 CFU/mL. * indicates a significant reduction 
in bacterial CFU compared to monocyte cultures treated with soluble drug cocktail at (student t-
test) p < 0.1.  
 
The 20:80 CPH:SA NP group had variability in the total number of viable bacte-
ria but was still significantly reduced when compared to the soluble group. With the 
higher MOI concentration of 10:1 an increase in survivability of Mycobacterium within 
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macrophages is was present. Comparing the untreated to the 20:80 CPTEG:CPH NP for-
mulation at 72 h provided a 6.23 log (± 1.74) CFU reduction in bacteria at 48h and 3.40 
log CFU (± 0.24) at 72 h. The 20:80 CPH:SA NP formulation provided a 2.86 log CFU 
(± 0.11) at 48 h and 3.09 log CFU (± 0.33) at 72 h. At all-time points recovered Myco-
bacteria from the soluble treated groups where not statistically significant compared to 
the untreated.  
Intracellular localization of Mycobacterium within THP-1 macrophage 
THP-1 macrophages infected with a GFP-expressing M. marinum (GFP) at an MOI of 
10:1 where treated with either soluble or NP encapsulated drugs and followed over 72 h. 
Field of view (FOV) data provided evidence showing 35% of the macrophage did not in-
ternalize mycobacterium-GFP.   
There was also evidence of increased cellular death of THP-1 macrophages at the 
72 h time points in the untreated and soluble treatment groups, as well as an increased ex-
tracellular growth of Mycobacterium. Due to the constitutively expressed GFP in M. 
marinum, the accurately by which the total number (Figure 4-6) of extracellular and intra-
cellular bacteria counts to determine viability could not be determined. However, the na-
noparticle-treated macrophages did show a decrease in the total number of bacteria per 
cell, and a total reduced number of infected macrophages < 60% was found at 72 h.  
Lysosomal localization of M. marinum with polyanhydride nanoparticles particles 
is essential for delivery of antitubercular. To evaluate the intracellular burden of  M. 
marinum and nanoparticles in THP-1 lysosomal compartments, M. marinum expressing 
the green fluorescent protein (GFP) residing in THP-1 cells were given NP containing 
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2% Rho 20:80 CPTEG:CPH nanoparticles (Figure 5-7) for 48 h and assessed for localiza-
tion with the lysosomal with LAMP-1 marker. 
 
Figure 5-5 Intracellular targeting of NP in M. marinum infected cells. Monolayers of human mon-
ocyte THP-1 cells were infected with M. marinum 10:1 ratio. A) Colony forming units (CFU) 
were enumerated beginning with a treatment at 48 h postinfection with either soluble drug cock-
tail (RIF, PYR, EMB, and INH) or equivalent amount encapsulated within 20:80 CPTEG:CPH 
NP. Intracellular bacterial viability was determined up to 72 hours post-treatment (*p ≤ 0.05, **p 
≤ 0.01 Student's t-Test vs. Soluble). (B) Immunofluorescence microscopy of concurrent infected 
and treated macrophages at 48hrs cultures was imaged to visualize M. marinum (green) with NP 
(red) and in macrophages (cell nuclei-DNA blue).  
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Figure 5-6 Internalization and intracellular viability of mycobacteria with the 20:80 CPH:SA na-
noparticle. Monolayers of human monocyte THP-1 cells were infected with M. marinum 10:1 ra-
tio. Colony forming units (CFU) were enumerated at 48 h and 72 h post-infection, survival was 
calculated compared to CFU/ml soluble drug groups. Susceptibility to 10 μg of Isoniazid, Pyra-
zinamide, Ethambutol and Rifampicin compared to formulations of nanoparticles (*p ≤ 0.05 Stu-
dent's t-Test vs. Soluble drug groups).  
Discussion 
 
In the in vitro Mycobacterium broth assays, demonstrated the challenges 
researchers encounter in development of antitubercular treatments. The use of a single 
drug of either rifampicin, isoniazid, pyrazinamide or ethambutol in an of themselves are 
ineffective in killing mycobacteria. The 20:80 CPTEG:CPH provided enhance drug activ-
ity when directly compared to the 20:80 CPH:SA formulation. These differences in the 
killing of M. marinum by the two nanoparticle formulations support the awareness of a 
tailorable treatment. This tailorability could be adapted for use against multiple pathogens 
of interest. The 20:80 CPTEG:CPH and 20:80 CPH:SA formulation showed time and 
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concentration-dependent killing as well biphasic killing curve with the used of two antibi-
otics. The soluble drug treatment group’s had a similar outcome of drug effectiveness as 
was seen in the single drug treatment. The utilization of a four-drug cocktail of rifam-
picin, isoniazid, pyrazinamide, and ethambutol in the 20:80 CPTEG:CPH formulation 
provided superior benefits in drug delivery against M. marinum. The internalization and 
intracellular viability of M. marinum were significantly reduced with the incorporation of 
the four drug cocktail encapsulated into the two nanoparticle formulations 20:80 
CPTEG:CPH and 20:80 CPH:SA. The unique nature of mycobacteria as an intracellular 
organism is further enhanced when looking at the survivability in the presence of soluble 
drugs.We observed a noticeable reduction in the bacterial population of THP-1 infected 
cells when compared to soluble for both the 20:80 CPTEH:CPH and 20:80 CPH:SA 
formulation and a time-concentration dependent effect. This effect could be useful in 
overcoming the natural resistance mechanisms of Mycobacterium through colocalization 
and increasing the drug cocktail efficacy.   
To observe interactions of NP with the host macrophage as well as 
Mycobacterium, we performed immunofluorescence staining on infected and treated cell 
cultures and visualized them by laser scanning confocal microscopy. M. marinum in 
macrophages treated with nanoparticles were frequently observed to have a substantially 
reduced GFP expression with an aberrant bacterial morphology typically found in 
stressed and compromised bacterial membranes. These observations coincide with a 4 
fold reduction in intracellular viability measured by CFU enumeration suggesting that 
internalization of NP reduced intracellular bacterial viability. However, reduced GFP 
expression and haggard appearance of intracellular bacteria is also observed within 
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macrophages that do not have visible NP within the cell while they can be seen in close 
proximity outside the cell (Figure 5-7). This suggests that the NP can act from within but 
also nearby in a paracrine-like fashion. 
A caveat to these studies is that it cannot be determined if in fact, the reduced 
GFP expressing M. marinum are dead or dying, only that the reduction in CFU coincides 
with the aberrant bacterial morphology of M. marinum. To this point, not all bacteria 
within NP treated cells are found associated with lysosomes (Figure 5-7). Normal cellular 
processing for phagocytosed particles, including nonpathogenic or dead pathogenic 
bacteria, dictates that the internalized phagosome fuse with Lamp1+ lysosomes to initiate 
degradation of internalized material. Damaged and dead M. marinum would be more 
likely to be localized within lysosomes to degrade and process bacterial antigen.  The 
20:80 CPTEG:CPH nanoparticle provided a reduction in the total infected macrophages 
over the 48 h but not with the 20:80 CPH:SA or soluble drug-treated cultures. The 
absence of NP co-localization with all intracellular bacteria could be investigated by 
incubating M. marinum infected macrophages with 20:80 CPTEG:CPH NP loaded only 
with rhodamine as we predict drug loaded NP would eliminate bacteria if they did 
colocalize to the same intracellular compartment. To this end, we observed M. marinum 
in infected monocytes treated with 20:80 CPTEH:CPH nanoparticles were more likely to 
be within intracellular compartments that were associated with lysosomes (LAMP1+). 
Together, results from this study suggest a promising nanotherapeutic intervention 
against Mycobacterium is possible through a synergism afforded by encapsulating 
frontline anti-TB drugs into amphiphilic nanoparticles. 
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Figure 5-7  Intracellular growth of M. marinum-GFP within THP-1 macrophages during a 
2-day infection period, macrophages were treated with 3.2 μg/ml of the drug as either sol-
uble or encapsulated into nanoparticles.THP-1 macrophages were plated on to glass- 
cover slips in a 24 well tissue culture plate and infected at an MOI of 10:1 with M. mari-
num pGFPHYG2. 2% Rho B-loaded CPTEG:CPH nanoparticles (RED), M. marinum 
GFPHYG2 (green) at an infectious dose of 10:1 for 48 h, THP-1 were stained with the 
anti-LAMP-1 antibody (magenta), Nucleus staining DAPI (blue). (A) Soluble 24 h,(B)  
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Figure 5-7 (continued) NP 24 h, (C) Soluble 48 h, and (D) NP 48. Scale bar indicates 
10μm. White arrowheads note intracellular bacteria based on proximity to intracellular 
features and location of plasma membrane from brightfield analysis (not shown). Yellow 
arrowheads point out extracellular bacteria. The intensity of GFP from M. marinum was 
consistently observed to be lower in NP-treated at 48 hours (panel D) than soluble (panel 
C). 
Conclusion 
 
This work is the first reported use of a polyanhydride nanoparticle against 
Mycobacterium. We observed through this study the importance of developing a delivery 
platform that can overcome the natural resistance mechanisms of Mycobacteria. We did 
not observe significant killing of M. marinum at the higher concentrations with the use of 
the soluble drugs rifampicin, isoniazid, pyrazinamide and ethambutol. This deficiency 
strengthens the hypothesis that use of the polyanhydride nanoparticle delivery vehicle 
increases the efficacy of the antitubercular drugs. The encapsulation of the four drugs into 
polyanhydride nanoparticles significantly improved intracellular delivery targetting 
established Mycobacterium infections in vitro resulting in improved drug efficacy with 
dose sparing benefits. 
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Abstract 
 
The causative agent of Johne's disease and Crohn’s is a facultative intracellular 
enteric bacteria known as Mycobacterium avium subspecies paratuberculosis. As with 
Mycobacterium species, the cause chronic and persistent infections facilitated by intracel-
lular survival in host cells that prevent exposure to soluble antimicrobial agents used to 
treat the disease. Formulation of antimicrobial agents within bioerodable nanoparticles is 
a means to target infected cells to eliminate intracellular resident bacterial pathogens in-
cluding Mycobacterium species. The antitubercular drug cocktail containing rifampicin, 
isoniazid pyrazinamide and ethambutol were successfully encapsulated into amphiphilic 
nanoparticles synthesized with varying amounts of the hydrophobic 
carboxyphenoxyhexane polymer. Results showed that polyanhydride nanoparticles are 
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internalized efficiently by macrophages, traffic to endosomes, and release high concentra-
tions of antituberculosis drugs intracellularly. We demonstrated that drugs delivered by 
polyanhydrides killed Mycobacteria within macrophages significantly more effectively 
than standard administration of soluble drugs. This data indicates that polyanhydride na-
noparticles provide a versatile platform that can be optimized through alternating poly-
mer formulation, changing the loading percentile of each drug and intracellular release of 
specific drugs for the treatment of Mycobacteria. 
Introduction 
 
Mycobacterium avium subspecies paratuberculosis is the causative agent of 
chronic granulomatous enteritis in ruminants called Johne's disease (JD) [1] as well as 
suspected in the human inflammatory bowel diseases Crohn’s (CD) and Ulcerative Coli-
tis (UC) [2-6]. Mycobacterium avium subspecies paratuberculosis (MAP) is a nontuber-
culosis mycobacterium, of the Mycobacterium avium complex most often associated with 
the small intestinal lamina propria that is eventually fatal in many cases [7, 8]. The infec-
tion in ruminants is most commonly transmitted through the fecal-oral route due to con-
taminated closed confinement, pasture, soil, and water, as well as vertical intrauterine 
transfer [9]. The effects of JD on the U .S. dairy industry accounts for upwards of $220 
million per year, with 2 out of every three farms being seropositive [10]. Like most my-
cobacterium infection symptomology does not occur until many months after initial ex-
pose and treatment in ruminates is not suggested. 
Source of human contamination is believed to be a direct result of bacterial shed-
ding into drinking water, milk and in even meat [11-13]. The unique thick lipid cell wall 
allows the bacteria to survive pasteurization [14].The occurrences of the MAP being 
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found in individual testing positive for CD has been shown to exceed 59% [5, 6] but test-
ing is limited and can be unreliable [11]. Individuals testing seropositive for the MAP 
may undergo extensive extended drug therapy (<5 weeks) [15] using the standard 
antituberculous rifampicin, isoniazid, ethambutol, and pyrazinamide [16] as well as 
clythromycin [17].  Treatment of infected individuals caused by Mycobacterium avium 
complex remains a challenge since these organisms are resistant to the majority of an-
tituberculous drugs [16, 18].  
Poly anhydride nanoparticles improve the antimicrobial activity of anti-
tuberculocidal drugs against Mycobacterium marinum in broth as well as co-localize with 
the bacteria inside of host phagocytes. Polyanhydrides nanoparticles are solid, surface 
eroding particles that encapsulate small molecules and proteins which have been shown 
to become an integral component of the particles [19, 20]. This next-generation platform 
has demonstrated the capabilities in vitro to become a multiple drug delivery system with 
the ability to increase the efficacy of drugs against M. marinum. The ability of the nano-
particles to slowly erode and release the cargo molecule in a controlled manner allows for 
targeted antimicrobial activity. Factors that contribute to the difficulty in treating MAP 
infections are the hydrophobic mycolic acids of the outer membrane, slow growth, and 
establishing unique intracellular niche are shared by all pathogenic Mycobacterial spe-
cies. In this study, we will demonstrate the antimicrobial activity of polyanhydride nano-
particles in delivering rifampicin, isoniazid, pyrazinamide, and ethambutol. 
 We tested the growth rate of M. paratuberculosis ATCC 19698 with turbidly 
testing and looked at the effectiveness of polyanhydride nanoparticles in co-localization 
assays in the human macrophage THP-1 and the murine macrophage RAW 264.7. We 
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will look at survivability of MAP and nanoparticle interactions with both cell lines. We 
will also look at the polymers and copolymers based on CPTEG, CPH, and SA formula-
tion in their effectiveness in drug delivery and interaction with the MAP. Through this 
and previous work, we have come to recognize the enormous potential in the use of poly-
anhydride in medicine, through their unique ability in encapsulating small molecules and 
as well as increasing the efficacy of drugs.    
Materials and methods 
Nanoparticles 
For the synthesis of the CPH and CPTEG monomers, the polyanhydride 
polymers, 20:80 CPH:SA , 20:80 CPTEG:CPH, and 50:50 CPTEG:CPH and the 
rifampicin, isoniazid, pyrazinamide and ethambutol-loaded polyanhydride nanoparticles, 
acetic acid, acetic anhydride, acetone, acetonitrile, chloroform, dimethyl formamide, 
ethyl ether, hexane, methylene chloride, pentane, petroleum ether, potassium carbonate, 
sodium hydroxide, sulfuric acid, and toluene were purchased from Fisher Scientific 
(Fairlawn, NJ). The chemicals 1,6-dibromohexane, 1-methyl-2-pyrrolidinone, hy-
droxybenzoic acid, N,N-dimethylacetamide, sebacic acid, and tri-ethylene glycol were 
obtained from Sigma Aldrich (St. Louis, MO). The chemical 4-p-fluorobenzonitrile was 
purchased from Apollo Scientific (Cheshire, UK). For 1H NMR analysis deuterated chlo-
roform and deuterated dimethyl sulfoxide were purchased Cambridge Isotope Laborato-
ries (Andover, MA). A fluorescent dye, Rhodamine B, was purchased from Sigma Life 
Science (St. Louis, MO).  Rifampicin, isoniazid, pyrazinamide and ethambutol were also 
purchased from Sigma Life Science (St. Louis, MO). 
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Polymer Synthesis 
Synthesis of the monomers used, 1,6-bis(p-carboxyphenoxyhexane) (CPH) and 
1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) was performed as described else-
where [21]. 20:80 molar copolymers of CPTEG and CPH and CPH and SA were synthe-
sized through melt condensation polymerization, as previously described in detail [22-24] 
. Molecular weight was confirmed using 1H NMR. 
Nanoparticle Fabrication 
Rifampicin, isoniazid, pyrazinamide and ethambutol-loaded nanoparticles of 
20:80 CPH:SA and  28:80 CPTEG:CPH were fabricated through solid/oil/oil nanoprecip-
itation, as previously described [25-27]. Drug combinations Rifampicin and pyra-
zinamide, each at 5% (w/w), with Rhodamine B at 2% (w/w) were added to the polymer. 
Drug combinations, isoniazid and ethambutol each at 5% (w/w), with Rhodamine B at 
2% (w/w) were added to the polymer. The solid drug and polymer mixture was then dis-
solved in methylene chloride at a concentration of 20 mg/mL followed by rapid precipita-
tion into the antisolvent, pentane. The polyanhydride nanoparticles were then collected 
using vacuum filtration. The drug-loaded particles were characterized for size and mor-
phology by scanning electron microscopy (SEM, FEI Quanta SEM, Hillsboro, OR). 
Bacterial strains and growth conditions 
Mycobacterium avium paratuberculosis (ATCC 19698)  was propagated at 37°C 
either in Middlebrook 7H9 broth, containing 10% oleic acid-albumin-dextrose-catalase, 
0.05% Tween 80 (Sigma), ferric mycobactin J (Allied Monitor) and amphotericin B 
(Sigma), or on Middlebrook 7H10 agar containing 10% oleic acid-albumin-dextrose-
catalase, ferric mycobactin J (Allied Monitor) and amphotericin B (Sigma) . Frozen 
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stocks were prepared by growing bacteria in 7H9 broth to mid-log phase approximately 
3.5 weeks or until optical density at 600 nm [OD600], ∼1, collecting cells by 
centrifugation, washing once with phosphate-buffered saline containing 0.05% Tween 80 
(PBST), adding glycerol to 20%, and storing in aliquots at −80°C. Bacterial stocks were 
titered by plating PBST-diluted bacterial suspensions on 7H10 agar and scoring colonies 
after eight weeks at 37°C  5%CO2 humidified chamber. 
 Drug solutions were prepared at concentrations of 20 mg/ml (PZA; Sigma-Al-
drich) and 2 mg/ml in distilled water (INH, and EMB; Sigma-Aldrich) or dimethyl sul-
foxide (RIF; Sigma-Aldrich), filter sterilized and frozen until used.  
Cells and culture conditions 
The human monocytic cell line THP-1 was cultured in RPMI 1640 medium 10% 
(v/v) heat-inactivated fetal bovine serum. Suspension cultures of THP-1 cells were main-
tained at a cell density between 5 x 105 and 1 x 106 cells/ml of cell culture medium and 
split twice per week. THP-1 cells growing in suspension were harvested at a density of 1 
× 106 cells/ml, resuspended in fresh medium supplemented with 5 nM phorbol myristic 
acid (PMA) [28] to differentiate the cells into adherent monocytes, and placed into 96 
well tissue culture plates. After overnight culture in the presence of PMA, adherent cells 
were washed three times gently with phosphate-buffered saline (PBS; pH 7.4) and 
incubated for an additional 24 h in complete RPMI 1640 medium with no PMA. The 
monocytic adherent murine macrophage cell line RAWs 264.7 was cultured in DMEM 
medium with 10% (v/v) heat-inactivated fetal bovine serum. Cultures where maintain at 
similar cell density as described above. 
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Bacterial turbidity growth curve 
At each time point (3d), an aliquot of 1 ml of a 15 ml conical tube was disrupted 
mechanically with sterile 2mm stainless steel beads by vortexing. 900 microliters of the 
bacterial suspension were added to 8.1 ml of phosphate-buffered saline (PBS) (pH 7.2) 
was added slowly and vortexed to obtain a homogeneous cell suspension. One milliliter 
was transferred to polystyrene cuvette, and three separate values were recorded via a 
spectrometer (Bio-Rad), and OD 600 values were recorded over 28 days.  
Broth microdilution antimicrobial assay 
Antibiotic testing against M. marinum was determined in 7H9 broth by the stand-
ard microdilution method. Briefly, 0.1-ml of a 0.1 mg ml-1 dilution of previously men-
tioned drugs were added to a 96-well plate. Control wells included medium and culture 
controls. One hundred microliters of culture (at 0.5 x 106 CFU/ml) were added to wells 
except for the medium control wells. The plates were incubated at 37°C for up to 72 h. 
Following each incubation time intervals, twenty microlitres of each bacterial suspension 
were serially diluted in PBS and aliquots of triplicate were plated onto supplemented 
Middlebrook 7H10. The plates were sealed and incubated for 6-10 weeks at 37°C 
5%CO2. Experiments were conducted in triplicate and the standard deviation is reported 
on graphs unless otherwise stated.  
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Intracellular survival of Mycobacterium  
  THP-1 cells and Raw264.7 used for evaluation of the intracellular survival of M. 
avium paratuberculosis were treated similarly as previously described in 96-well flat-bot-
tom tissue culture plates. Bacterial suspensions were prepared and generated by scraping 
36 d cultures of the M. avium paratuberculosis grown on supplemented Middlebrook 
7H10 agar into screw-cap microfuge tubes containing supplemented 7H9 media and incu-
bated for seven days. Pellets of bacteria were resuspended through mechanical disruption 
and numbers of bacteria present in the suspensions were determined by optical density 
OD 600 nm measurements [29]. The suspensions were diluted to desired amounts using 
complete RPMI 1640 or DMEM medium to maintain a constant multiplicity of infection 
with slight variations in numbers of target monocytes. Suspensions of bacteria were 
added to monocyte monolayers at a multiplicity of infection (bacteria/monocyte ratio) of 
10:1. Tissue culture plates were gently agitated by hand and then centrifuged at 4°C for 
10 min at 270 x g. Moreover, transferred to an incubator for 90 min 37°C with 5% CO2 
to allow for phagocytosis of bacteria. Monolayers were washed three times with PBS to 
remove any remaining nonadherent bacteria. Fresh RPMI-1640 or DMEM complete me-
dia was added following the last washing. The viability of intracellular Mycobacterium 
was determined by lysing monocytes with 0.1% deoxycholate, diluting suspensions in 
PBS, and plating aliquots in triplicate on supplemented Middlebrook 7H10 medium. The 
plates were sealed and incubated for 6-10 weeks at 37°C 5%CO2. Total cfu/ml of bacte-
rial survival at 24, 48 and 72 h were calculated based on the number of internalized 
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bacteria detected at 2 h postinfection which represents 100% of internalized bacteria. Ex-
periments were conducted in triplicate and the standard deviation is reported on graphs 
unless otherwise stated. 
Statistical Analysis 
The statistical software GraphPad Prism (v. 7.04) was used to analyze the data. 
Student’s t-test was used to determine statistical significance among treatments and p< 
0.05 was considered significant.  
Results 
The in vitro susceptibility of human and bovine origin M. paratuberculosis is 
regulated by initial bacterial concentration and is a critical factor in drug susceptibility 
testing of slow-growing mycobacteria.  The growth of M. paratuberculosis ATCC 19698 
was recorded by measuring changes in the optical density of broth cultures. The initial 
bacterial concentrations test began with a 104, 105, and 106 CFU/ML. We followed the 
growth curve over 28 days by optical density and observed an average replication rate of 
<8 days (data not shown). The ability to accurately determine a correct replication rate 
was inherently flawed due to the natural clumping of MAP over the course of the assay. 
Other assays corroborate this same issue and have demonstrated that the method is not re-
liable [30]. In total, we performed 12 culture inhibition experiments that included the use 
of soluble and or encapsulated rifampicin, isoniazid, ethambutol, and pyrazinamide. In 
every case where antibiotics were studied for its effect on MAP, time and delivery 
method where the dependent variables.  
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Cultures treated with a drug combination of rifampicin/pyrazinamide (Figure 5-1), 
where cultures contained 10 μg of each drug per ml of MAP culture. Equivalent amounts 
of the drug cocktail were given in either soluble form or encapsulated into nanoparticles 
to assess antimicrobial activity measured by direct plating of cultures to quantify bacterial 
viability.   
At 48 hours, untreated MAP grew to 3.44 log CFU while soluble reduced 
bacterial viability to 1.55 log CFU (± 0.35) demonstrating a significant difference 
(p<0.001). Cultures treated with either NP formulation containing RIF/PZA produced no 
viable bacteria demonstrating a significant reduction from soluble antimicrobial activity 
(p<0.01). 
 
Figure 6-1 Antimicrobial activity of RIF/PZA NP against MAP.  Mycobacterium avium subspe-
cies paratuberculosis was tested for susceptibility to 10 μg of Pyrazinamide and Rifampicin. The 
graph depicts the comparison between two soluble drugs to 20:80 CPTEG:CPH and 20:80 
CPH:SA dual loaded nanoparticles. Significance being *p ≤ 0.05 Student's t-Test vs. Soluble drug 
groups. 
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In contrast to the RIF/PZA combination, soluble INH/EMB treatment at the same 
10 µg concentration, did not have antimicrobial activity (Figure 6-2). The 20:80 
CPTEG:CPH group had a total 3.22 log CFU (± 0) reduction in bacterial population with 
no viable growth detected. Whereas the 20:80 CPH:SA group also had a (p < 0.05) sig-
nificant total 1.45 log CFU (± 0.90)  FOR ALL OF THESE NUMBERS  reduction in 
bacterial population but growth was evident.  
 
Figure 6-2 Antimicrobial activity of INH/EMB NP against MAP.  Mycobacterium avium subspe-
cies paratuberculosis was tested for susceptibility to 10 μg of Isoniazid and Ethambutol. The 
graph depicts the comparison between two soluble drugs to 20:80 CPTEG:CPH and 20:80 
CPH:SA dual loaded nanoparticles. Significance being *p ≤ 0.05 Student's t-Test vs. Soluble drug 
groups. 
The combined therapeutic approach of rifampicin/pyrazinamide and isoniazid/eth-
ambutol (Figure 6-3) was tested with the four-drug combination at a single dose concen-
tration and monitored over 48 h. The 20:80 CPTEG:CPH nanoparticle group displayed 
the most significant bactericidal activity against Mycobacteria with a total 3.50 log 
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CFU/mL reduction in bacterial population. The bactericidal activity was not observed 
with the 20:80 CPH:SA nanoparticles which provided only a bacteriostatic effect of 1.16 
log CFU (± 1.10) reduction in bacterial population compared to untreated. Both nanopar-
ticle groups where significantly different than the soluble group which had only minimal 
inhibition of 0.652 log CFU (± 0.12) of the bacterial population.  
 
Figure 6-3 Antimicrobial activity of RIP/PZA/INH/EMB NP against MAP.   Mycobacterium 
avium subspecies paratuberculosis was tested for susceptibility to 10 μg to Isoniazid, Pyra-
zinamide, Ethambutol, and Rifampicin. (*p ≤ 0.05 Student's t-Test vs. Soluble drug groups). 
 
Several macrophage models have been used to study mycobacteria infections. 
These include primary macrophages, mainly human monocyte-derived macrophage 
(THP-1) or murine J774 and RAW 264.7. We conducted a short course therapy against 
THP-1 and RAW 264.7 macrophages to determine an adequate infectious model for use 
in slow-growing mycobacteria. Concurrently, we also tested a single dose of the four-
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drug combination RIPE in soluble or encapsulated in nanoparticles. We observed that the 
THP-1 was simultaneously effective in conjunction with the 20:80 CPTEG:CPH nano-
particle within 48 h. The 20:80 CPTEG:CPH nanoparticle group (Figure 6-4) provided a 
3.792 log CFU (± 0) inhibition within the bacterial population over the 48 h and the 
20:80 CPH:SA 2.062 logs CFU (± 1.09) compared to the soluble.  
  
Figure 6-4 Internalization and intracellular viability. Monolayers of human monocyte THP-1 cells 
were infected with Mycobacterium avium subspecies paratuberculosis 10:1 ratio. Colony forming 
units (CFU) were enumerated at 48 h postinfection, survival was calculated compared to CFU/ml 
soluble drug groups. Susceptibility to 10 μg of Isoniazid, Pyrazinamide, Ethambutol, and Rifam-
picin compared to formulations of PANs. (*p ≤ 0.05 Student's t-Test vs. Soluble drug groups) 
The use of the murine macrophage RAW 264.7 showed a more robust bacterial 
population in direct comparison to the THP-1 macrophages. We observed the natural 
wean in growth at 24 h and subsequently observed exponential growth. This is consistent 
with what is reported with the use of murine macrophages. The 20:80 CPTEG:CPH NPs 
(Figure 6-5) reduced the bacterial burden by 1.674 log CFU (± 0.08) at 48 h and 3.515 
log CFU (± 1.69) at 72 h compared to the non-treated. The solubly treated MAP at 48 h 
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0.054 log CFU (± 0.18) and 0.609 log CFU (± 0.14) at 72 h. The CPH:SA NPs 1.368 log 
CFU (± 0.15) at 48 h and 2.007 log CFU (± 0.33) at 72 h (Figure 5-6). The use of the 
four-drug combination RIPE for the soluble treated macrophages did not provide addition 
bactericidal activity against M. paratuberculosis.  
 
Figure 6-5 Intracellular viability MAP within murine macrohpages following treatment with 
RIF/PZA/INH/EMB CPTEG:CPH NP. Monolayers of murine macrophage 267.4 cells were in-
fected with Mycobacterium avium subspecies paratuberculosis 10:1 ratio. Colony forming units 
(CFU) were enumerated at 24,48 and 72 h postinfection, survival was calculated compared to 
CFU/ml soluble drug groups. Susceptibility to 10 μg of Isoniazid, Pyrazinamide, Ethambutol, and 
Rifampicin compared to 20:80 CPTEG:CPH polyanhydride nanoparticle. Standard error is 
denoted on graphs (*p ≤ 0.05 Student's t-Test vs. Soluble drug groups.  
 
 
 
159 
 
 
Discussion 
We demonstrated the ability of polyanhydride nanoparticles to improve killing of 
intracellular M. paratuberculosis. We also demonstrated that use of polyanhydride nano-
particles provides greater internalized efficacy by macrophages, increased trafficking to 
endosomes, and releases higher concentrations of antituberculosis drugs intracellularly. 
We have shown that the four-drug combination rifampicin, isoniazid, pyrazinamide and 
ethambutol drugs delivered by polyanhydride nanoparticles killed Mycobacteria within 
 
 
Figure 6-6 Intracellular viability MAP within murine macrohpages following treatment with 
RIF/PZA/INH/EMB CPH:SA NP Monolayers of murine macrophage 267.4 cells were infected 
with Mycobacterium avium subspecies paratuberculosis 10:1 ratio. Colony forming units (CFU) 
were enumerated at 24, 48 and 72 h postinfection, survival was calculated compared to CFU/ml 
soluble drug groups. Susceptibility to 10 μg of Isoniazid, Pyrazinamide, Ethambutol, and Rifam-
picin compared to 20:80 CPH:SA polyanhydride nanoparticle. Standard error is denoted on 
graphs (*p ≤ 0.05 Student's t-Test vs. Soluble drug groups) 
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macrophages significantly more effectively than an equivalent amount of free drug. We 
also demonstrated the importance of utilizing an appropriate macrophage cell line in test-
ing against slow vs. fast-growing mycobacteria. Our observation was consistent with 
what is reported [31] with the use of murine macrophages vs. human macrophages. We 
found that the THP-1 macrophage responded very strongly to infection whereas the re-
sponse of RAW 267.4 to M. paratuberculosis infection is weaker in the magnitude of 
suppression, at least regarding the overall length of our study. This data demonstrates that 
there may be a more suitable carrier for drug delivery to treat slow-growing intracellular 
Mycobacterium pathogens. This study outlines an approach that allows for a multiple 
drug delivery platform showing increased efficacy and intracellular pathogen targeting. 
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Abstract 
 
Inadequate dosing and incomplete treatment regimens, coupled with the ability of 
the tuberculosis bacilli to cause latent infections that are tolerant of currently used drugs, 
have fueled the rise of multidrug-resistant (MDR-TB) and extensively drug-resistant 
(XDR-TB) tuberculosis. Treatment of both MDR-TB and XDR-TB infections is a 
significant clinical challenge that has few viable or effective solutions; therefore patients 
face a poor prognosis and years of therapy. This research focuses on the development of a 
new drug delivery platform utilizing polyanhydride nanoparticles in combination with the 
anti-tubercular drugs rifampicin (RIF), isoniazid (INH), pyrazinamide (PZA) and 
ethambutol (EMB) as a drug cocktail (RIPE) that have the potential for treating MDR-TB 
and XDR-TB. This research highlights the use of the use of the nanoparticle platforms 
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strengths to as it pertains to, in vitro and in vivo efficacy.  Herein, we demonstrate the 
current challenges in the treatment of tuberculosis and how the use of a nanoparticle-
based drug delivery platform can adapt to these difficulties, with an emphasis on 
Mycobacterium susceptibility to first-line drugs. 
Introduction 
 
Many intracellular pathogens gain initial entry through the host mucosal surfaces, 
especially those of the respiratory tracts. Transmission can be primarily a result of 
person-to-person contact and aerosolization of droplets containing bacteria that are small 
enough to enter the alveoli [1]. Most facultative intracellular bacteria cause chronic or re-
current infections, as is the case with Mycobacterium tuberculosis. M. tuberculosis 
(MTB) have developed several strategies to prevent their killing by phagocytosis through 
inhibition of phagosomal acidification, and inhibition of phagolysosome formation. Fol-
lowing uptake into macrophages, MTB resides within a modified lysosomal compart-
ment, thereby avoiding the primary destructive mechanisms of the cell [2-4]. Modifica-
tion of the lysosomal compartment provides an environment that facilitates replication 
and protection from antimicrobials [4-6]. 
Frequent failures of the treatment of tuberculosis (TB) are due to the insufficient 
dosing, incomplete treatment regimens caused by poor patient compliance, and latency 
profile of the bacilli [7, 8]. Initial treatment requires a two-step process; the first involves 
an “intensive phase” of a four-drug high dose cocktail containing the antibiotics 
rifampicin (RIF), isoniazid (INH), pyrazinamide (PZA) and ethambutol (EMB). The 
“intensive phase”  is limited to two-months to avoid the high toxicity issues found with 
this therapy regime.  Following the “intensive phase” a longer “continuation phase” 
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occurs with RIF and INH and can last for up to two years [9-11]. This secondary treat-
ment is necessary for the eradication of remaining bacilli that enter a dormant or latent 
phase during the early stages of infection. The lenghtly requirement of treatment 
highlights the unique pathogenesis of Mycobacterium, this remaining population of non-
replicating “persistent state”  is seen within the caseous core of lung granulomas [12]. 
These “persister” bacilli are genetically drug-susceptible but exhibit a phenotypic toler-
ance to currenty available first-line drugs [13, 14].  
Although the incidence and mortality rates of TB have significantly declined 
within the last ten years, the advances in TB control remain hindered by the increase in 
reports of drug-resistance [14, 15]. Multidrug-resistant TB (MDR-TB), is defined as re-
sistant to at least two antibiotics such as rifampicin and isoniazid [16, 17]. Extensively 
drug-resistant TB (XDR-TB) is a phenotypically adapted MDR which shows resistant to 
isoniazid and rifampin, plus fluoroquinolones and at least one of the injectable second-
line drugs, such as amikacin [18, 19]. Furthermore, cases of totally drug-resistant 
tuberculosis (TDR-TB) have recently been reported in Asia, Africa, India and Europe. 
TDR-TB is reported to be resistant to all available drug chemotherapy’s [20]. Most drug 
resistance is due to inadequate therapy regimes and pre-existing illnesses such as human 
immunodeficiency virus (HIV). There are two types of mycobacterial resistance; 
acquired resistance (i.e., environmental) or by infection with a drug-resistant strain (i.e., 
primary resistance) [21]. 
These intrinsic resistance mechanisms of MTB are thought to be the crucial link 
between a therapeutic cure and persistent infection [9, 22]. Because virtually all classes 
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of antibiotics require bacterial replication for their primary mode of action, the non-repli-
cating state of the bacilli is believed to render MTB resistant to otherwise bactericidal an-
tibiotics. This unique nature of the disease, specificity of location, and development of 
the unique granuloma structure contains and provides protection to persistent bacilli [23, 
24], increasing the necessity for an antimicrobial treatment that provides continuous in-
tracellular drug concentrations within these specialized sites. Therefore, there is a need to 
design novel antimicrobial delivery systems that effectively inhibit the growth and 
protect against multiple strains of M. tuberculosis whereby enhancing patient compliance 
by utilizing a condensed dose regimen. 
This study demonstrates that the use of biodegradable polyanhydride 
nanoparticles can successfully encapsulate and release the small molecules rifampicin, 
isoniazid, pyrazinamide and ethambutol (RIPE) against M. tuberculosis.  Polyanhydride’s 
have multiple benefits compared to other delivery systems [25]. These nanoparticles have 
shown sustained release profiles through bulk and surface erosion. The erosion profile 
provides a sustained release of cargo while maintaining the polymer reliability and func-
tion [26]. The use of polyanhydride nanoparticles comprised of 1,6-bis(p-
carboxyphenoxy)hexane (CPH), 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG), 
have been shown to be well suited for the delivery of small molecules and proteins 
through the pulmonary, subcutaneous and intraperitoneal administration. This delivery is 
further favorable based on the safety profile, mild inflammatory response, and their 
ability to enhance immunity [27, 28].  Additionally, polyanhydride nanoparticles have 
been shown to provide pathogen-mimicking capabilities that improve the internalization 
activity through functionalization and tailorable polymer combinations which have been 
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demonstrated to increase cellular uptake, particle persistence and accumulation within 
macrophages [25, 29, 30].  
This work demonstrates a significant decrease in viable bacilli when tested within 
the human macrophage THP-1 in vitro. As well as, in vivo experiments will highlight the 
use of the nanoparticle-based delivery platform consisting of the RIPE drugs adminis-
tered intraperitoneal to mice, reducing the prevalence of “persistor bacilli” when com-
pared to soluble drugs. These studies provide a fundamental foundation for future work 
for the rational design of an anti-tuberculosis treatment based off of polyanhydride nano-
particles containing the RIPE drug cocktail.  
Materials and methods 
Nanoparticles 
For the synthesis of the CPH and CPTEG monomers, the polyanhydride polymer, 
20:80 CPTEG:CPH and the rifampicin, isoniazid, pyrazinamide and ethambutol-loaded 
polyanhydride nanoparticles, acetic acid, acetic anhydride, acetone, acetonitrile, 
chloroform, dimethyl formamide, ethyl ether, hexane, methylene chloride, pentane, 
petroleum ether, potassium carbonate, sodium hydroxide, sulfuric acid, and toluene were 
purchased from Fisher Scientific (Fairlawn, NJ).1-methyl-2-pyrrolidinone, 
hydroxybenzoic acid, N,N-dimethylacetamide, and tri-ethylene glycol were obtained 
from Sigma Aldrich (St. Louis, MO). The chemical 4-p-fluorobenzonitrile was purchased 
from Apollo Scientific (Cheshire, UK). For 1H NMR analysis deuterated chloroform and 
deuterated dimethyl sulfoxide were purchased Cambridge Isotope Laboratories (Andover, 
MA). A fluorescent dye, Rhodamine B, was purchased from Sigma Life Science (St. 
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Louis, MO).  Rifampicin, isoniazid, pyrazinamide, and ethambutol were also purchased 
from Sigma Life Science (St. Louis, MO). 
Polymer Synthesis 
Synthesis of the monomers used, 1,6-bis(p-carboxyphenoxyhexane) (CPH) and 
1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) was performed as described else-
where [31]. 20:80 molar copolymers of CPTEG and CPH were synthesized through melt 
condensation polymerization, as previously described in detail [26, 32, 33]. The 
molecular weight was confirmed using 1H NMR. 
 
Nanoparticle Fabrication 
Rifampicin, isoniazid, pyrazinamide and ethambutol-loaded nanoparticles of 
28:80 CPTEG:CPH were fabricated through solid/oil/oil nanoprecipitation, as previously 
described [34-36]. Drug combinations Rifampicin and pyrazinamide, each at 5% (w/w), 
were added to the polymer. Drug combinations, isoniazid, and ethambutol each at 5% 
(w/w) were added to the polymer. The solid drug and polymer mixture was then 
dissolved in methylene chloride at a concentration of 20 mg/mL followed by rapid pre-
cipitation into the antisolvent, pentane. The polyanhydride nanoparticles were then col-
lected using vacuum filtration. The drug-loaded particles were characterized  for size and 
morphology by scanning electron microscopy (SEM, FEI Quanta SEM, Hillsboro, OR). 
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Drug release kinetics 
Rifampicin, pyrazinamide, and isoniazid were quantified by RP-HPLC. RIF and 
PZA release samples in PBS were separated using a Phenomenex Kinetex 2.6-micron 
C18 100Å 100x4.6mm column and a mobile phase consisting of a 73:20:7 volume ratio 
of water: acetonitrile : methanol. The flow rate was set to 0.4 mL/min, and rifampicin and 
pyrazinamide eluted at 4.8 min and 2.8 min, respectively. Rifampicin and pyrazinamide 
were detected by absorbance at 262 nm and 326 nm. Rifampicin and pyrazinamide base 
extraction samples in 40 mM NaOH were separated using a Zorbax SB-C8 5-micron 
4.6x150mm column. A mobile phase gradient was used, ramping from 83:2:15 to 
55:30:15 water : acetonitrile : tetrahydrofuran. The flow rate was 1 mL/min, and rifam-
picin and pyrazinamide eluted at 14.1 min and 1.4 min, respectively. RIF and PZA were 
detected by absorbance at 262 nm and 333 nm, respectively. Isoniazid release samples in 
PBS were separated using a Phenomenex Kinetex 2.6-micron C18 100Å 100x4.6mm 
column and a mobile phase consisting of a 95:5 volume ratio of water : acetonitrile. The 
flow rate was set to 0.4 mL/min, and isoniazid eluted at 4.3 min. IZD base extraction 
samples in 40 mM NaOH were separated using a Zorbax Eclipse XDB-C8 5-micron 
4.6x150mm column. A mobile phase gradient was used, ramping from 98:2 to 90:10 
water : acetonitrile. The flow rate was set to1 mL/min, and isoniazid eluted at 1.1 min. 
Isoniazid PBS release and base extraction samples were detected. Stocks of each drug in 
PBS and 40 mM NaOH were prepared. Dilution series of these stocks in PBS and NaOH 
were used to quantify drug concentration in each sample by absorbance at 260 nm. 
 
171 
 
  
Mycobacteria and culture conditions. 
M. tuberculosis strains (H37Rv, HN563 and NR49360) were propagated at 37°C 
either in Middlebrook 7H9 broth (Difco) containing 10% oleic acid-albumin-dextrose-
catalase (Difco) and 0.05% Tween 80 (Sigma) or on Middlebrook 7H10 or 7H11 agar 
containing 10% oleic acid-albumin-dextrose-catalase. Cycloheximide (50 μg ml−1), am-
photericin B (50μg ml -1) and carbenicillin (15 μg ml-1) was included in the media to 
prevent fungal and as a selective agent. Frozen stocks were prepared by growing bacteria 
in 7H9 broth to mid-log phase (optical density at 600 nm [OD600], ∼0.5), collecting cells 
by centrifugation, washing once with phosphate-buffered saline containing 0.05% Tween 
80 (PBST), adding glycerol to 15%, and storing in aliquots at −80°C. Bacterial stocks 
were titered by plating PBST-diluted bacterial suspensions on 7H10 agar and scoring col-
onies after 3 to 4 weeks at 37°C. 
Drug solutions were prepared at concentrations of 20 mg/ml (PZA; Sigma-Al-
drich) and 2 mg/ml in distilled water (INH, and EMB; Sigma-Aldrich) or dimethyl sul-
foxide (RIF; Sigma-Aldrich), filter sterilized and frozen until used. 
THP-1 cell cultures 
The human monocytic cell line THP-1 was cultured in RPMI 1640 medium with 10% 
fetal bovine serum (FBS). Suspension cultures of THP-1 cells were maintained at a cell 
density of 2 × 106 cells/ml of cells in culture medium and split two times per week. THP-
1 cells growing in suspension were harvested at a density of 1 × 106 cells/ml, and 
hemocytometer and trypan blue dye assessed cell viability. 
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Table 7-1 Level of DNA relatedness among strains of Mycobacterium species 
Level of DNA relatedness among strains of mycobacterial species[37, 38] 
Level of relatedness % to guanine and cytosine: 
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M. tuberculosis 
H37Rv 
____ N/A 99 <.1 86 
M. tuberculosis 
HN563 
N/A* N/A* N/A* N/A* N/A* 
M. tuberculosis NR 
49360 
99 N/A* ____ 45 85.4 
M. paratuberculosis <.1 N/A* <.1 ____ 45 
M. marinum 
 
86 N/A* 85.4 45 ____ 
N/A* The complete genome of M. tuberculosis, strain HN563 is currently being 
sequenced. 
---- Non-applicable 
Cells were resuspended in fresh medium supplemented with 5 nM phorbol 
myristic acid (PMA) to terminally differentiate the cells into adherent monocytes. 
Suspensions were adjusted to a concentration of 0.5 x105 cells/ml in warm supplemented 
RPMI, seeded in 96-well plates adding 200 [micro]l of suspension per well, and cells 
were allowed to adhere and differentiate, at 37°C in 5% CO2 atmosphere for 24 h. 
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Table 7-2 Mycobacterial drug susceptibility 
Mycobacterial drug susceptibility 
MIC (mg/L)[39] 
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Broth microdilution method. 
Antibiotic testing against M. tuberculosis HN563 and NR49360 were determined 
in 7H9 broth by the standard microdilution method. Briefly, 0.1-ml of a 0.1 mg ml-1 dilu-
tion of RIPE drugs were added to a 96-well plate. Control wells included medium and 
culture controls. One hundred microliters of culture (at 0.5 x 106 CFU/ml) was added to 
all the wells except the medium control wells. The plates were incubated at 37°C for up 
to 7 days. Following each incubation time intervals, twenty microlitres of each bacterial 
suspension were serially diluted in PBS and aliquots of triplicate were plated onto Mid-
dlebrook 7H10 or 7H11 media. The plates were sealed and incubated for 18–26 days at 
37°C. Experiments were performed in duplicate and the standard deviation is depicted on 
graphs unless otherwise stated.   
Intracellular viability and replication of the M. tuberculosis in THP-1 cells. 
THP-1 cells used for evaluation of the intracellular survival of M. tuberculosis 
strains were treated similarly as previously described in 96-well flat-bottom tissue culture 
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plates. Bacterial suspensions were prepared and generated by scraping 14 d cultures of 
the M. tuberculosis strains grown on Middlebrook 7H10 agar into screw-cap microfuge 
tubes containing 7H9 media and incubated for 96 h. Pellets of bacteria were resuspended 
through mechanical disruption and numbers of bacteria present in the suspensions were 
determined by optical density at 600 nm measurements[40]. These suspensions were used 
to generate dilute M. tuberculosis using complete RPMI 1640 medium whereby the bac-
terial density was adjusted to desired levels to account for variations in the numbers of 
target monocytes. Suspensions of bacteria were added to monocyte monolayers at a mul-
tiplicity of infection (bacteria/monocyte ratio) of 10:1 for M. tuberculosis H37Rv, 
NR49360, and HN563. Tissue culture plates were gently agitated by hand and then cen-
trifuged at 4°C for 10 min at 270 x g. Moreover, transferred to an incubator for 90 min 
37°C with 5% CO2 to allow for phagocytosis of bacteria. Monolayers were washed three 
times with PBS to remove any remaining nonadherent bacteria. Fresh RPMI-1640 with 
10 ug/ml gentamicin complete media was added following the last washing. The viability 
of intracellular Mycobacterium was determined by lysing monocytes with 0.1% deoxy-
cholate, diluting suspensions in PBS, and plating aliquots in triplicate on Middlebrook 
7H10 and 7H11 medium. The plates were sealed and incubated for 18–26 days at 37°C. 
Total cfu/ml of bacterial survival at 24, 48 and 72 h were calculated based on the number 
of internalized bacteria detected at 1.5 h postinfection which represents 100% of internal-
ized bacteria. Experiments were performed in duplicate and the standard deviation is de-
picted on graphs unless otherwise stated.   
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Acute Mycobacterium infection in animals 
Male C3H/HeNCrl mice (6–8 weeks old) was purchased from Charles River 
(Wilmington, MA, USA). All animals were housed in a biosafety level 3 facility and pro-
cedures related to mice followed protocols approved by the Institutional Animal Care and 
Use Committee at Iowa State University. This species of mice was chosen for the ability 
to model both the systemic/acute phase of tuberculosis ( < 2 weeks post i.p. infection) 
and the chronic/granulomatous phase infection ( > 6 weeks post i.p. infection)[41]. Paren-
teral administration of infectious doses were through intraperitoneal injection of thawed 
aliquots that were prepared by dilution to ∼0.4 104 CFU ml−1 in PBST, vortexed (15 s) 
to disperse clumps, and injection of 0.5 ml (∼2000 CFU)  
Animal chemotherapy 
Chemotherapy was initiated 14 days after intraperitoneal infection. Mice received 
intraperitoneal administration the RIPE drugs as either soluble or encapsulated into 20:80 
CPTEG:CPH. Dosing was once daily for seven consecutive days with 12 mice per treat-
ment group. The soluble RIPE treatment group received 0.15 mg/kg soluble rifampicin, 
isoniazid, pyrazinamide, and ethambutol in 500 μl PBS. NP-RIPE group received five mg 
of encapsulated 20:80 CPTEG:CPH nanoparticle containing a total drug concentration of 
0.15 mg/kg rifampicin, isoniazid, pyrazinamide, and ethambutol in 500 μl PBS. During 
the study period, mice were weighed weekly to monitor the mean animal body weights. 
Bacterial burden present within target tissues of spleen, liver, and lungs were 
quantified by harvesting tissues 2 days following the week of treatment. Mice were 
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euthanized by CO2 overdose, right lungs, left liver lobe, and whole spleens were 
aseptically removed and these organs were transferred into 2 ml tubes each containing 1 
ml sterile distilled water and 0.2 mm diameter stainless steel beads for homogenization 
for 30 seconds of 30,000 rpm with a tissue homogenizer (1-3 times)  (BioSpec Products 
Inc., Bartlesville, OK) CFU counts of the organs were performed using the diluted 
homogenate in PBS, and plating of aliquots in triplicate on Middlebrook 7H10 and 7H11 
plates (Becton Dickinson, Sparks, MD, USA) for cfu enumeration, as previously 
described. Data are derived from 12 mice per treatment group and 8 mice for the un-
treated controls. The remaining left lung and liver from each animal were fixed in 10% 
buffered formaldehyde for histopathology.  
The screening of an independent, drug-sensitive persister population 
Presence of a persister population was tested in a 96-well plate adding 100 μl of 
tissue homogenate suspension (liver, spleen, lung) per well.  Briefly, 0.1-ml of a 0.01 mg 
ml-1 dilution of rifampicin drug was suspended into 7H9 culture broth and added to tissue 
homogenates and incubated at 37C 5% CO2 for 96 h.  Following incubation, twenty mi-
crolitres of each bacterial suspension were serially diluted in PBS and aliquots of tripli-
cate were plated onto Middlebrook 7H10 or 7H11 media. The plates were sealed and in-
cubated for 18–26 days at 37°C.  
Statistical analysis 
The statistical software GraphPad Prism (v.7.04) was used to analyze the data. 
Two-way ANOVA and Student t-test were used to determine statistical significance 
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among treatments and p< 0.05 was considered significant. Standard deviation is depicted 
unless otherwise stated. 
Results 
 
Mycobacterium tuberculosis strains H37Rv (WT-TB), HN563 (MDR-TB) and 
NR49360 (XDR-TB) was tested for (Figure 7-1, 2, and 3) susceptibility and sensitivity to 
the four drug cocktail rifampicin, pyrazinamide, isoniazid, and ethambutol (RIPE) either 
as soluble or encapsulated into 20:80 CPTEG:CPH nanoparticle. Mycobacterium cultures 
were incubated with a single dose of decreasing amounts of drug conducted over seven 
days with subsequent plating of bacterial enumerations. RIPE concentrations above 0.32 
ug/ml were inhibitory for both soluble and NP treated cultures. The XDR-TB exhibited 
increased sensitivity to the nanoparticles at the highest and mid-range (64 and 10 μg/ml) 
concentration. NP encapsulation showed 2.01 log CFU (± 0.83) killing activity over solu-
ble at the 64 μg/ml. The ability of the XDR-TB strain to survive within the highest con-
centration tested of the 4 drug RIPE cocktail demonstrates the “extensive” nature of re-
sistance of this isolate and is consistent with published reports for this and other XDR 
strains.  
The MDR-TB (Figure 7-2) was also susceptible to the nanoparticle and soluble 
drugs for all concentrations tested. However, the 20:80 CPTEG:CPH nanoparticle group 
provided the highest inhibition of MDR-TB. An almost 200 fold decrease in the drug was 
observed to achieve an 8.32 log CFU (± 0.83) difference within the bacterial population. 
The H37Rv strain showed similar sensitivity to the drug cocktail as was seen in the 
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MDR-TB. These results provide the opportunity to further examine the intracellular 
events of bacterial infection and effectiveness of the drug cocktail. 
 
Figure 7-1 Antimicrobial activity of NP-RIPE against XDR-TB M. tuberculosis NR49360   Enu-
meration of MTB CFU from the 48hr treatment of broth cultures with decreasing concentrations 
of soluble and NP-RIPE formulations. (Student’s T-test p values * < 0.05, ** < 0.01). 
 
To examine the intracellular fate of Mycobacteria three strains H37Rv, MDR-TB, 
and XDR-TB we (Figure 7-4) tested at an MOI of 10:1 in the human macrophage cell 
line THP-1. Infectious bacteria where allowed 24 h to reach their ecological niche before 
a single application of the previously mentioned drug cocktail was applied and monitored 
over 48 h. For the H37RV (Figure 7-3) strain at the at the 10 μg/ml concentration the NPs 
decreased the survivability of mycobacterium nearly  5.23 log CFU (± 0.59) and the solu-
ble drug group also provided a  ⁓ 4.5 log CFU (± 0.54)  reduction in the bacterial popula-
tion. The MDR-TB showed susceptibility to the drug cocktail. 
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Figure 7-2 The killing of M. tuberculosis MDR-TB enhanced by using nanoparticles loaded with 
rifampicin, pyrazinamide, isoniazid and ethambutol in broth. Colony forming units/ml were enu-
merated at 48 hrs post-infection and compared with the CFU/ml values for soluble treated bacte-
ria. (Student’s T-test p values * < 0.05, ** < 0.01). 
 
 Intracellular MDR-TB (B) was more sensitive to RIPE encapsulated in NP 
group than soluble reflected in reducing the bacterial population an averaged 4.90 log 
CFU ( ± 0.61) and nearly a 3.04 log CFU (± 0.56 ). There were significant differences 
found between the total log CFU when we directly compared the nanoparticle and soluble 
group (p <0.05). The XDR-TB showed limited sensitivity to the drugs, which was to be 
expected due to the natural resistance mechanisms. Although, the nanoparticle group did 
provide a 1.64 log CFU (± 0.13) reduction in the bacterial population and had insufficient 
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variability. Whereas, the soluble group provided a 1.01 log CFU (± 0.67) bacterial 
population reduction but had considerable variability between each replicate.  
 
 
Figure 7-3 Killing of M. tuberculosis H37Rv enhanced by using nanoparticles loaded with rifam-
picin, pyrazinamide, isoniazid and ethambutol in broth. CFU units/ml were enumerated at 48 hrs 
post-infection and compared with the CFU/ml values for soluble treated bacteria. (Student’s T-
test p values * < 0.05, ** < 0.01). 
The in vivo activity of the four drug cocktail as either soluble or encapsulated into 
20:80 CPTEG:CPH nanoparticle using the C3H mouse model. An early acute phase My-
cobacterium infection model was employed by infecting mice with one the following M. 
tuberculosis strains H37Rv, MDR-TB, and XDR-TB. Mice were infected intraperitoneal, 
and treatment began fourteen days post infection with daily 0.15mg/kg doses of drug 
cocktail given over seven consecutive days. Tissues from the spleen, liver, and luge were 
collected for either homogenization or histopathology and mean change is weight was 
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also accessed. The total bacterial population was lower than expected for all excised tis-
sues, but due to the constraints of the experiment, this was to be expected. 
The Mycobacterium H37Rv (Figure 7-5) strain, was actively establishing an acute 
infection within the tissues collected. Inhibition of Mycobacterium was seen in the spleen 
and lung in the nanoparticle (P < 0.05) treated mice. The nanoparticle formulation low-
ered the 0.815 log CFU (± 1.20) for the spleen and 2.56 log CFU (± 1.31) for the lung, 
respectively.  The solubly treated groups did not reduce the total CFU within any tissues 
sampled, and overall development of a resister bacterial population was not evident. 
The MDR-TB strain was actively establishing infection in the liver, spleen and 
lung (Figure 7-6). The soluble group and the nanoparticle group showed an increased in 
bactericidal (p<0.05) activity in the spleen. Soluble presented a 1.21 log CFU (±1.24) and 
NP 1.18 log CFU (±1.20) reduction in the bacterial population compared to untreated. 
MDR-TB did not appear affected by soluble or encapsulated drug in the liver or 
lung tissue. The development of a statistically significant (P<0.05) set of persister bacte-
ria emerge within the spleen and lungs and no bacteria were recovered from the liver. ob-
served considerable variability in the total recovered bacteria between the tissues and ob-
served an increase in the bacterial burden was found in the spleen (p< 0.05) for the nano-
particle group 0.31 log CFU (± 0.35) compared to the untreated. 
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Figure 7-4 Continued on next page. 
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Figure 7-4  Intracellular viability of Mycobacterium tuberculosis in the Human macrophage THP-
1 (continued from previous page). Three strains of Mycobacteria where infected at an MOI of 
10:1 and monitored over 24 h. (A) WT-TB H37Rv, (B) MDR-TB HN563, and (C) XDR-TB 
NR49360. Before treatment of the drug cocktail, RIPE was applied as a single dose for 48 h. The 
cell lysate was serially diluted and was plated onto 7H10 agar plates for CFU bacterial survival. 
Student t-test was performed for significance between the nanoparticle and soluble group (<0.01). 
 
The Mycobacterium XDR-TB strain (Figure 7-7) was active in the spleen, liver, 
and lung for both the soluble and nanoparticle treatment groups. Unlike the H37Rv and 
MDR-TB, the XDR-TB was the most actively established of the three strains. The XDR-
TB was most active in the liver and lung (P < 0.05), the average CFU recovered for the 
nanoparticle group for the liver was 4.35 log CFU (±0.69) and lung 2.80 log CFU (± 
1.43). The soluble group also had minimal effects against XDR-TB, CFUs recovered 
from the spleen 4.63 log CFU (± 0.47), liver 5.05 log CFU (± 1.77), and lung 2.99 log 
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CFU (± 1.53). Development of a persister population was evident with the solublly 
treated mice having the largest population of bacteria was recovered from the spleen 3.37 
log CFU (± 1.76) and lung of 3.65 log CFU (± 1.71), this is in sharp contrasts to the na-
noparticle and untreated. We did not recover any viable persister bacterial from the liver 
for all groups tested.
 
Figure 7-5 The use of the drugs against H37Rv in vivo. Use of the four drugs RIPE following a 
acute infection in C3H mice with Mycobacterium tuberculosis H37Rv. The graph is a 
representation of dose-response and development of a persister bacterial population in mice. Stu-
dent t-test was performed for significance between the nanoparticle and soluble group (<0.05). 
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Figure 7-6 The use of drugs against HN563 (MDR) in vivo. Development of an acute infection in 
C3H mice with Mycobacterium tuberculosis HN563 (MDR). The graph is a representation of 
dose-response and development of a persister bacterial population in mice. Student t-test was 
performed for significance between the nanoparticle and soluble group (<0.05). 
 
The C3H mice’s weights (Figure 7-8) over the course of the experiment were 
monitored and did found no ill effect was found for all groups. Results from 
histopathology (N=3) did not show any evidence of a lesions in the liver, spleen or 
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granuloma formation in the lung. Further, acid-fast histochemical stains for organisms 
were negative.  
 
Figure 7-7 The use of the drugs against XDR-TB in vivo. Mycobacterium tuberculosis NR49360 
(XDR) presented as an acute infection in C3H mice over a 22 d infection. The graph is a repre-
sentation of dose-response and development of a persister bacterial population in mice. Student t-
test was performed for significance between the nanoparticle and soluble group (<0.05). 
 
Using an HPLC assay as described in the methods section, the release kinetics of 
rifampicin, pyrazinamide, and isoniazid from nanoparticles was quantified, as shown in 
Figure 7-9. The 20:80 CPTEG:CPH nanoparticle formulation for the three drugs shown-
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indicate an initial burst release profile, followed by sustained release is shown in the iso-
niazid nanoparticles. It was also observed that there was a much larger burst release of 
pyrazinamide as compared to that of rifampicin within the first 24 h. 
 
Figure 7-8 C3H mice weights where collected once every seven days over twenty-two days. (A) 
WT-TB , (B) MDR-TB, and (C) XDR-TB. There were no significant differences found between 
the untreated and those that were either treated with soluble or encapsulated rifampicin, isoniazid, 
pyrazinamide or ethambutol. Significance was determined using a student t-test.   
 
Encapsulation efficiency was also quantified, and revealed in the dual encapsula-
tion of pyrazinamide with rifampicin the total drug encapsulated was significantly less 
188 
 
  
than expected. The pyrazinamide encapsulated at 60 ± 0.97 % and rifampicin 80 ± 0.87 
%. The nanoparticles containing the isoniazid and ethambutol showed a 58.08 ± 0.52 % 
encapsulation efficiency for isoniazid, respectively. Ethambutol was not quantified.  
 
 
Figure 7-9 The in vitro release profiles of pyrazinamide, rifampicin, and isoniazid. Total fraction 
release of drug over time quantified by HPLC. Total released drug over 48 h, 20:80 CPTEG:CPH 
nanoparticles. Dash line indicated 100% drug release.    
  
Nanoparticles used in the in vivo and HPLC assay where evaluated against M. 
marinum towards bacterial susceptibility of the released free four drug cocktail drugs 
from 20:80 CPTEG:CPH nanoparticles. Released drugs were tested in comparison to a 
known volume and concentration of soluble drug cocktail and applied to a bacterial popu-
lation and monitored over time (Figure 7-10). The solubly treated group of 10 μg did not 
demonstrate an inhibitory effect over the treatment duration. The released drugs from the 
189 
 
  
24 h time point also showed an initial burst of drugs was released as seen in the HPLC as-
say. The majority of the total drug was released from the nanoparticles within the first 72 
h and provided minimal effects against M. marinum at later time points (data not shown).  
 
 
Figure 7-10 Inhibitory activity of the released drug against M. marinum. 20:80 CPTEG:CPH NPs 
used in the in vitro assay were examined for total drug encapsulation and released drug over time. 
Supernatants collected at specified time points from the NPs were applied at equivalent volumes 
relative to the solubly treated groups and monitored over nine days. At determined time points, 
bacterial enumerations were plated onto select media and monitored for CFU/ml. Student t-test 
was performed for significance between the nanoparticle and soluble group (<0.05) 
 
Discussion 
 
This current work demonstrates the importance of rationally designing delivery 
vehicles for drug optimization. Because of the known differences in drug sensitivity 
among Mycobacterium, the need for the development of an innovative drug delivery 
platform that can overcome these factors must be considered for treatment of the chronic 
phase. The encapsulation of the drugs rifampicin, isoniazid, pyrazinamide and 
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ethambutol into polyanhydride nanoparticles provided benefits over the use of soluble 
drugs including; colocalization, increased drug efficacy, and dose sparing. 
 In the in vitro Mycobacterium broth assay, polyanhydride nanoparticles improved 
upon the antimicrobial activity of soluble drugs against MDR-TB and XDR-TB. We 
found that an increased concentration range of drug was minimally active against the 
MDR-TB and XDR-TB  without encapsulation. The soluble inhibition breakpoint for the 
MDR-TB was found to be <64μg/ml which is higher than previously published for this 
strain. The most significant effect of the drug cocktail was seen with the use of the 
nanoparticles as a delivery vehicle. A susceptible breakpoint of 1.6μg/ml, and resistance 
was not evident at the lowest concentration tested of 0.032 μg/ml. The XDR-TB the 
inhibition breakpoint for the soluble and nanoparticle groups was <64 μg/ml, with 
resistance observed at > 1.6μg/ml. There where minor differenced in the soluble groups 
total CFU/ ml for the MDR-TB and XDR-TB when comparing the two assays to each 
other.  
The Human macrophages THP-1 was infected with Mycobacterium at an MOI of 
10:1. The decrease in the bacterial population suggests colocalization of the nanoparticle 
occurred with both the MDR-TB and XDR-TB. We previously have shown that the 
highly virulent intracellular pathogen Brucella co-localizes with the nanoparticles within 
infected cells and this observation correlates with increased intracellular bacterial killing 
[29, 30, 42].  Similar experiments assessing changes in MTB intracellular survival in the 
presence of the NP-RIPE drug cocktail on MTB survival were described in this work 
whereby a single 10 μg/ml dose of either soluble or encapsulated RIPE was given to 
MTB infected human macrophages. While NP-RIPE and soluble RIPE treatment equally 
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reduced intracellular viability in WT MTB strain H37Rv, NP-RIPE reduced bacterial 
counts to an amount significantly lower than soluble demonstrating the increased efficacy 
of NP delivery of the four drug cocktail. It is of note that soluble groups in this 
intracellular infection study consistently produced higher amounts of variability in CFU 
recovered than either NP-RIPE or untreated groups. Within the treatment group, 
increases in the variability (1-2 log) for the soluble group whereas in the nanoparticle 
group this was not observed.  
Microbial drug persistence is a widespread phenomenon in which a sub-popula-
tion of microorganisms can survive antimicrobial treatment without the development of 
extrinsic resistance. This small sub-population of Mycobacterium that survives the lethal 
effects of the antibiotic drug is referred to as “persister” [43]. Persistence is distinct from 
resistance in that, unlike resistant mutants, persister populations do not undergo active 
replication in the presence of the antibiotics (“stressor”), and population growth resumes 
only once the drug has been removed [44]. This stress response is a mechanism by which 
Mycobacterium is inherently known for, and provides evidence for the development of a 
latent infection.  
The presence of a persister bacterial population within the MDR-TB and XDR-
TB treatment groups was further exacerbated after treatment with both the soluble and 
NPs. It appears that the primary treatment with NP provided a large enough stress in-
duced persistence response by which Mycobacterium entered into a dormancy state ear-
lier than in the untreated groups. This may suggest that the activity of the NPs in the 
delivery of antibiotics provided a large enough stress response to arrest the cellular 
growth prematurely whereby inhibiting the action of the antibiotics. Additional studies to 
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confirm this will need to occur. The lack of a viable hepatic TB population as well as 
granuloma formation within the lungs. Studies have shown that individuals can develop 
granulomas of the lung and hepatic lesions within fourteen days of exposure and those 
that tested positive for pulmonary TB also test positive for hepatic TB 50-80% of the 
time [45, 46]. We can only attribute this lack of granuloma and hepatic lesion 
development primarily to the early acute phase.  
Conclusion 
 
We demonstrated the use of polyanhydride nanoparticle as an alternative drug 
delivery platform for the treatment of WT-TB, MDR-TB, and XDR-TB. This is the first 
reported multi-strain M. tuberculosis in vivo study conducted with the use of 
polyanhydride nanoparticles and the four drug cocktail rifampicin, pyrazinamide, 
ethambutol, and isoniazid. Our in vitro studies provided an insight into the benefits of 
encapsulating rifampicin, isoniazid, pyrazinamide, and ethambutol. We observed the use 
of encapsulated antituburculars showed an increased drug efficacy and dose sparing when 
used against WT-TB, MDR-TB, and XDR-TB in vitro. Despite the reduced sustained 
drug release profile and reduced encapsulation efficacy, the utilization of amphiphilic 
polyanhydride nanoparticles still showed benefits in vivo. Together, this data exemplify 
the physiochemical properties of polyanhydride nanoparticles against Mycobacterium. 
This work has provided the foundational framework for future studies focused on the 
interactions between Mycobacterium and use of polyanhydride nanoparticle.  
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 CHAPTER 8 . CONCLUSIONS AND FUTURE WORK 
 
The long-term goals of this research are to design an innovative nanotechnology 
delivery platform that can be utilized in multiple applications. The many challenging as-
pects of parasitic and intracellular pathogen treatment include the unique multi-stages of 
disease and location of the pathogen within a host must all be considered in developing 
novel therapies. The effectiveness of polyanhydride nanoparticles was validated through 
this research by improving the delivery of small hydrophilic/hydrophobic molecules and 
targeting of infected tissues. All these benefits highlight the use of polyanhydrides as a 
delivery platform. Beneficial aspects of drug delivery observed in this work include 
increasing drug efficacy, tailoring drug release profiles, and the ability to encapsulate 
small molecules. In this regard, examining the use of altered polymer combinations, 
surface functionalization and size could be optimized to fit these specific applications for 
future studies. 
In chapter two we investigated the interaction of polyanhydride nanoparticle as a 
drug delivery platform for the antibiotics ivermectin and doxycycline against one of the 
causative agents of lymphatic filariasis, B. malayi. The co-delivery of doxycycline and 
ivermectin in polyanhydrides improved killing of adult parasites with up to 4,000 fold 
less drug compared to standard, soluble drug administration. Examination of worms by 
confocal microscopy revealed the rapid penetration of polyanhydride nanoparticles inside 
the worm suggesting rapid translocation across the cuticle. The delivery of micromolar 
concentrations of ivermectin and doxycycline reduced the shedding and viability of 
microfilaria. These results support the hypothesis; enhanced killing of the macrofilaria 
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results from the nanoparticles penetrating the outer membrane of B. malayi and deliver 
the drug directly the symbiotic bacteria Wolbachia. 
As discussed above, the encapsulation and subsequent controlled release of 
ivermectin and doxycycline further enhanced our understanding of the ability of the poly-
anhydride nanoparticle carriers to localize to the worm cuticle surface and translocate 
into the worms, leading to a higher concentration of bioavailable drugs. Experiments de-
tailed in chapter three continued the investigation of NP properties by examining the 
delivery of different cocktails of approved antiparasitic drugs against another Brugia fi-
larial worm species, B. pahangi. B. malayi is a parasite of humans and does not infect ro-
dents while B. pahangi is capable of causing disease in both host types. The animal 
models of lymphatic filariasis use B. pahangi infections in gerbils. In vitro, NP delivery 
of drug combinations diethylcarbamazine, albendazole, and doxycycline along with 
ivermectin and doxycycline provided significant benefits over soluble administrations. 
The results showed that use of the NP as a delivery vehicle effectively killed adult 
worms, reduced microflorae shedding and acted as a microfilaricide. Attempts to perform 
in vivo studies were unsuccessful at demonstrating a significant difference due to the 
variability inherent in B. pahangi infections in gerbils and inability to conduct studies 
with larger numbers of animals. Additionally, future studies would need to be performed 
that focused on improving the pharmacokinetics of polyanhydride nanoparticles includ-
ing; optimization of bioavailability, route of administration, and biodistribution to match 
the efficacy of the in vitro assays.   
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The result from the Brugia chapters provides an understanding of the NPs behav-
ior against intracellular bacteria. NPs are capable of delivering the antimicrobial doxycy-
cline to the endosymbiotic bacteria Wolbachia and applied it to the intracellular bacteria 
Mycobacterium. In chapter four we assessed co-encapsulation of the first line 
antitubercular rifampicin, isoniazid, pyrazinamide, and ethambutol with polyanhydrides. 
The complexity of antimicrobial therapies directed against Mycobacterium tuberculosis 
result from the specificity of the intracellular nature of the bacteria. The innate abilities of 
the intracellular nature of Mycobacterium provide a challenging model to study the effec-
tiveness of drug delivery. We sought to exploit the flexibility of NP properties to co-de-
liver small molecules intracellularly to treat Tuberculosis infections. A synergistic effect 
of NPs was demonstrated in chapters three and four to improve the effectiveness of ap-
proved anti-TB drugs was confirmed using in vitro culture and intracellular pathogenesis 
tissue culture models. The result showed numerous benefits using the nanoparticles in en-
capsulation and delivery of the four antituberculars effectively killing Mycobacterium in 
broth culture and subsequent studies treating macrophages.  
We observed rapid and efficient internalization of NP by macrophages and intra-
cellular distribution. The reduction of intracellular Mycobacterium in the presence of the 
nanoparticle suggests a possible co-localization event occurs between the bacteria. This 
theory supported by co-localization of NP with another intracellular bacterial pathogen, 
Brucella. The most significant reduction in intracellular B. abortus and B. melitensis sur-
vival was observed in NP-treated groups that also exhibited the highest level of internali-
zation by host macrophages. Microscopic observations revealed the bacteria colocalized 
with the NP [1-3]  The macrophages treated with equivalent concentrations of the soluble 
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drug did not provide improved antimycobacterial activity. Future studies could include 
the examination of the bacterial/nanoparticle interaction by utilizing fluorescently labeled 
derivatives of selected carbohydrates that could functionalize to nanoparticles [3-5], 
providing insight into the interactions between Mycobacterium and the nanoparticles. 
Studying of the bacterial interaction of mycobacteria with the carbohydrate functional-
ized nanoparticles could be accomplished through targeting of the intermembrane trans-
porter system (ABC transporter). The intermembrane of Mycobacterium has been re-
ported to possess five recognizable carbohydrate transporters [6] and shows the favorable 
use of host lipids as carbon sources for growth and persistence during infection [7]. Also, 
Mycobacterium utilizes a substantial amount of carbohydrates as part of their unique cel-
lular membrane components, which are carbohydrate-rich providing another alternative 
[6, 7]. 
In chapter six we examined the ability of NP delivery of antitubercular drugs 
against select strains of multi-drug (MDR) and extensively drug-resistant (XDR) M. tu-
berculosis (TB).  In the in vitro broth assay, polyanhydride nanoparticles improved the 
antimicrobial activity of soluble drugs against MDR-TB and XDR-TB. In infected mac-
rophages, nanoparticles were able to enhance antimicrobial activity against intracellular 
MDR-TB and XDR-TB. Similar results with Brucella and M. marinum suggests that the 
reduction in the bacterial population results from co-localization of the nanoparticle with 
both the MDR-TB and XDR-TB. 
 As previously mentioned the failures of most therapies occur during the transition 
from an in vitro model to an in vivo model. The research acquired from the in vitro study 
was applied to an acute TB infection in C3H mice, a model that mimics systemic disease 
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[8, 9]. A component of this study quantified the number of persistent drug isolates recov-
ered from infected tissues. The presence of a population of antibiotic persistent bacterial 
within the MDR-TB and XDR-TB treatment groups were found to be more significant 
after treatment with both the soluble and NPs comparatively, against the untreated. The 
early stages of infectious mycobacteria undergo constrained replication and are forced 
into a dormant state in the infected tissue by the host response. Bacteria were found to be 
rapidly replicating during early stages following infection compared to untreated. The 
stressor of antituberculars further exasperated the emergence of a persister or resistance 
population in the early infectious stages of the disease. The presence of an active persister 
population may suggest that the activity of the drug-loaded NPs provided a sufficient 
stress response to increase the cellular growth prematurely. Additional, studies are essen-
tial that focus on enhancing the pharmacokinetics including; bioavailability of the drugs, 
route of administration, and biodistribution of the polyanhydride nanoparticles. In gen-
eral, encapsulation of antimicrobials in nanoparticles to treat mycobacterial infections 
could improve efficacy, lessen toxic side effects of prolonging treatment intervals all re-
sulting in an improved patient compliance.  
In conclusion, the studies carried throughout this dissertation has extended the 
volume of information regarding the use of amphiphilic polyanhydride nanoparticles as a 
nanotherapy against several infectious diseases. These remarkable results, suggests that 
the use of tailorable polyanhydride nanoparticles as a drug delivery vehicle. These studies 
reflect the need for new therapeutic approaches and facilitate bridging the gap between 
traditional infectious disease practices and the introduction of modern nanomedicine ther-
apies.  
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